,title,geo_accession,status,submission_date,last_update_date,type,channel_count,source_name_ch1,organism_ch1,characteristics_ch1,characteristics_ch1.1,characteristics_ch1.2,characteristics_ch1.3,characteristics_ch1.4,characteristics_ch1.5,characteristics_ch1.6,characteristics_ch1.7,characteristics_ch1.8,characteristics_ch1.9,characteristics_ch1.10,characteristics_ch1.11,characteristics_ch1.12,characteristics_ch1.13,characteristics_ch1.14,characteristics_ch1.15,characteristics_ch1.16,characteristics_ch1.17,characteristics_ch1.18,characteristics_ch1.19,characteristics_ch1.20,characteristics_ch1.21,characteristics_ch1.22,characteristics_ch1.23,treatment_protocol_ch1,molecule_ch1,extract_protocol_ch1,label_ch1,label_protocol_ch1,taxid_ch1,hyb_protocol,scan_protocol,data_processing,platform_id,contact_name,contact_email,contact_phone,contact_institute,contact_address,contact_city,contact_state,contact_zip/postal_code,contact_country,contact_web_link,supplementary_file,data_row_count,age_years:ch1,chemosensitivity_prediction:ch1,clinical_ajcc_stage:ch1,clinical_nodal_status:ch1,clinical_t_stage:ch1,dlda30_prediction:ch1,drfs_1_event_0_censored:ch1,drfs_even_time_years:ch1,er_status_ihc_esr1_for indeterminate:ch1,er_status_ihc:ch1,erbb2_status:ch1,esr1_status:ch1,ggi_class:ch1,grade:ch1,her2_status:ch1,pam50_class:ch1,pathologic_response_pcr_rd:ch1,pathologic_response_rcb_class:ch1,pr_status_ihc:ch1,rcb_0_i_prediction:ch1,sample id:ch1,set_class:ch1,source:ch1,tissue:ch1,type_taxane:ch1
GSM615096,1002,GSM615096,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1002",Homo sapiens,sample id: 1002,source: ISPY,age_years: 37.8,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 1,drfs_even_time_years: 2.346,esr1_status: P,erbb2_status: N,set_class: SET-High,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615096/suppl/GSM615096_FL1790_ISPY_11.CEL.gz,22283,37.8,Rx Sensitive,IIB,N1,T2,RD,1,2.346,P,P,N,P,Low,2,N,LumA,RD,RCB-III,P,RCB-0/I,1002,SET-High,ISPY,breast cancer tumor,NA
GSM615097,1005,GSM615097,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1005",Homo sapiens,sample id: 1005,source: ISPY,age_years: 45.8,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T3,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: NA,drfs_1_event_0_censored: 0,drfs_even_time_years: 5.552,esr1_status: P,erbb2_status: N,set_class: SET-Int,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: Normal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615097/suppl/GSM615097_FL1791_ISPY_12.CEL.gz,22283,45.8,Rx Sensitive,IIIA,N1,T3,RD,0,5.552,P,P,N,P,Low,2,N,Normal,RD,NA,P,RCB-0/I,1005,SET-Int,ISPY,breast cancer tumor,NA
GSM615098,1009,GSM615098,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1009",Homo sapiens,sample id: 1009,source: ISPY,age_years: 40.7,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T3,clinical_nodal_status: N0,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 5.503,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615098/suppl/GSM615098_FL1792_ISPY_13.CEL.gz,22283,40.7,Rx Insensitive,IIB,N0,T3,pCR,0,5.503,N,N,N,N,High,3,N,Basal,RD,RCB-II,N,RCB-II/III,1009,SET-Low,ISPY,breast cancer tumor,NA
GSM615099,1011,GSM615099,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1011",Homo sapiens,sample id: 1011,source: ISPY,age_years: 40.8,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 4=Indeterminate,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 5.424,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615099/suppl/GSM615099_FL1793_ISPY_14.CEL.gz,22283,40.8,Rx Insensitive,IIB,N1,T2,pCR,0,5.424,N,N,N,N,High,4=Indeterminate,N,Basal,pCR,RCB-0/I,N,RCB-0/I,1011,SET-Low,ISPY,breast cancer tumor,NA
GSM615100,1016,GSM615100,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1016",Homo sapiens,sample id: 1016,source: ISPY,age_years: 35.5,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T3,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 1,drfs_even_time_years: 1.580,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615100/suppl/GSM615100_FL1794_ISPY_15.CEL.gz,22283,35.5,Rx Insensitive,IIIA,N1,T3,RD,1,1.58,P,P,N,P,High,2,N,LumA,RD,RCB-II,P,RCB-II/III,1016,SET-Low,ISPY,breast cancer tumor,NA
GSM615101,1019,GSM615101,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1019",Homo sapiens,sample id: 1019,source: ISPY,age_years: 52.2,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T4,clinical_nodal_status: N0,clinical_ajcc_stage: IIIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 5.205,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615101/suppl/GSM615101_FL1795_ISPY_16.CEL.gz,22283,52.2,Rx Insensitive,IIIB,N0,T4,pCR,0,5.205,N,N,N,N,High,3,N,Basal,RD,RCB-II,N,RCB-II/III,1019,SET-Low,ISPY,breast cancer tumor,NA
GSM615102,1027,GSM615102,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1027",Homo sapiens,sample id: 1027,source: ISPY,age_years: 38.2,er_status_ihc: N,pr_status_ihc: N,her2_status: I,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 4=Indeterminate,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 1,drfs_even_time_years: 2.732,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615102/suppl/GSM615102_FL1894_ISPY27.CEL.gz,22283,38.2,Rx Insensitive,IIA,N0,T2,pCR,1,2.732,N,N,N,N,High,4=Indeterminate,I,Basal,RD,RCB-II,N,RCB-II/III,1027,SET-Low,ISPY,breast cancer tumor,NA
GSM615103,1031,GSM615103,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1031",Homo sapiens,sample id: 1031,source: ISPY,age_years: 54.2,er_status_ihc: I,pr_status_ihc: I,her2_status: NA,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T3,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: NA,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: NA,drfs_1_event_0_censored: 0,drfs_even_time_years: 5.300,esr1_status: P,erbb2_status: N,set_class: SET-Int,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615103/suppl/GSM615103_FL1895_ISPY28.CEL.gz,22283,54.2,Rx Sensitive,IIIA,N1,T3,RD,0,5.3,P,I,N,P,High,NA,NA,LumA,RD,NA,I,RCB-II/III,1031,SET-Int,ISPY,breast cancer tumor,NA
GSM615104,1034,GSM615104,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1034",Homo sapiens,sample id: 1034,source: ISPY,age_years: 46.6,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T3,clinical_nodal_status: N3,clinical_ajcc_stage: IIIC,grade: 4=Indeterminate,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 1,drfs_even_time_years: 0.783,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615104/suppl/GSM615104_FL1896_ISPY29.CEL.gz,22283,46.6,Rx Insensitive,IIIC,N3,T3,pCR,1,0.783,N,N,N,N,High,4=Indeterminate,N,Basal,RD,RCB-III,N,RCB-II/III,1034,SET-Low,ISPY,breast cancer tumor,NA
GSM615105,1035,GSM615105,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1035",Homo sapiens,sample id: 1035,source: ISPY,age_years: 40.8,er_status_ihc: P,pr_status_ihc: P,her2_status: P,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T4,clinical_nodal_status: N3,clinical_ajcc_stage: IIIC,grade: 2,pathologic_response_pcr_rd: NA,pathologic_response_rcb_class: NA,drfs_1_event_0_censored: 1,drfs_even_time_years: 0.000,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615105/suppl/GSM615105_FL1897_ISPY30.CEL.gz,22283,40.8,Rx Insensitive,IIIC,N3,T4,RD,1,0,P,P,N,P,High,2,P,LumA,NA,NA,P,RCB-0/I,1035,SET-Low,ISPY,breast cancer tumor,NA
GSM615106,1037,GSM615106,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1037",Homo sapiens,sample id: 1037,source: ISPY,age_years: 51.1,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T3,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 4=Indeterminate,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.156,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615106/suppl/GSM615106_FL1898_ISPY31.CEL.gz,22283,51.1,Rx Insensitive,IIIA,N1,T3,pCR,0,4.156,N,N,N,N,High,4=Indeterminate,N,Basal,RD,RCB-II,N,RCB-II/III,1037,SET-Low,ISPY,breast cancer tumor,NA
GSM615107,1038,GSM615107,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1038",Homo sapiens,sample id: 1038,source: ISPY,age_years: 37.8,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T3,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 4=Indeterminate,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.370,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615107/suppl/GSM615107_FL1899_ISPY32.CEL.gz,22283,37.8,Rx Insensitive,IIIA,N1,T3,pCR,0,4.37,N,N,N,N,High,4=Indeterminate,N,Basal,RD,RCB-0/I,N,RCB-0/I,1038,SET-Low,ISPY,breast cancer tumor,NA
GSM615108,1041,GSM615108,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1041",Homo sapiens,sample id: 1041,source: ISPY,age_years: 46.6,er_status_ihc: P,pr_status_ihc: P,her2_status: P,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T3,clinical_nodal_status: N3,clinical_ajcc_stage: IIIC,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.597,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615108/suppl/GSM615108_FL1882_ISPY33.CEL.gz,22283,46.6,Rx Insensitive,IIIC,N3,T3,RD,0,4.597,P,P,N,P,High,3,P,LumB,RD,RCB-III,P,RCB-II/III,1041,SET-Low,ISPY,breast cancer tumor,NA
GSM615109,1044,GSM615109,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1044",Homo sapiens,sample id: 1044,source: ISPY,age_years: 58.8,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T3,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 4=Indeterminate,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 1,drfs_even_time_years: 1.248,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615109/suppl/GSM615109_FL1829_ISPY118.CEL.gz,22283,58.8,Rx Insensitive,IIIA,N1,T3,pCR,1,1.248,N,N,N,N,High,4=Indeterminate,N,Basal,RD,RCB-III,N,RCB-II/III,1044,SET-Low,ISPY,breast cancer tumor,NA
GSM615110,1045,GSM615110,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1045",Homo sapiens,sample id: 1045,source: ISPY,age_years: 49.6,er_status_ihc: I,pr_status_ihc: I,her2_status: NA,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T3,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 1,drfs_even_time_years: 0.953,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615110/suppl/GSM615110_FL1883_ISPY34.CEL.gz,22283,49.6,Rx Insensitive,IIIA,N1,T3,pCR,1,0.953,N,I,N,N,High,3,NA,Basal,pCR,RCB-0/I,I,RCB-0/I,1045,SET-Low,ISPY,breast cancer tumor,NA
GSM615111,1049,GSM615111,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1049",Homo sapiens,sample id: 1049,source: ISPY,age_years: 50.4,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T4,clinical_nodal_status: N1,clinical_ajcc_stage: Inflammatory,grade: 4=Indeterminate,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 1,drfs_even_time_years: 0.988,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615111/suppl/GSM615111_FL1799_ISPY20.CEL.gz,22283,50.4,Rx Insensitive,Inflammatory,N1,T4,pCR,1,0.988,N,N,N,N,High,4=Indeterminate,N,Basal,RD,RCB-III,N,RCB-II/III,1049,SET-Low,ISPY,breast cancer tumor,NA
GSM615112,1050,GSM615112,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1050",Homo sapiens,sample id: 1050,source: ISPY,age_years: 63.2,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T3,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 4=Indeterminate,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 1,drfs_even_time_years: 1.832,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615112/suppl/GSM615112_FL1800_ISPY21.CEL.gz,22283,63.2,Rx Insensitive,IIIA,N1,T3,pCR,1,1.832,N,N,N,N,High,4=Indeterminate,N,Basal,RD,RCB-II,N,RCB-II/III,1050,SET-Low,ISPY,breast cancer tumor,NA
GSM615113,1054,GSM615113,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1054",Homo sapiens,sample id: 1054,source: ISPY,age_years: 42.8,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 4=Indeterminate,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 1,drfs_even_time_years: 0.307,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615113/suppl/GSM615113_FL1801_ISPY22.CEL.gz,22283,42.8,Rx Insensitive,IIB,N1,T2,pCR,1,0.307,N,N,N,N,High,4=Indeterminate,N,Basal,RD,RCB-III,N,RCB-II/III,1054,SET-Low,ISPY,breast cancer tumor,NA
GSM615114,1055,GSM615114,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1055",Homo sapiens,sample id: 1055,source: ISPY,age_years: 52.8,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.104,esr1_status: P,erbb2_status: N,set_class: SET-High,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615114/suppl/GSM615114_FL1802_ISPY23.CEL.gz,22283,52.8,Rx Sensitive,IIA,N0,T2,RD,0,4.104,P,P,N,P,Low,2,N,LumA,RD,RCB-III,P,RCB-II/III,1055,SET-High,ISPY,breast cancer tumor,NA
GSM615115,1057,GSM615115,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1057",Homo sapiens,sample id: 1057,source: ISPY,age_years: 44.2,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T4,clinical_nodal_status: N1,clinical_ajcc_stage: Inflammatory,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 1,drfs_even_time_years: 0.151,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615115/suppl/GSM615115_FL1884_ISPY35.CEL.gz,22283,44.2,Rx Insensitive,Inflammatory,N1,T4,pCR,1,0.151,N,N,N,N,High,2,N,Basal,RD,RCB-II,N,RCB-II/III,1057,SET-Low,ISPY,breast cancer tumor,NA
GSM615116,1061,GSM615116,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1061",Homo sapiens,sample id: 1061,source: ISPY,age_years: 54.2,er_status_ihc: N,pr_status_ihc: N,her2_status: P,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T3,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 1,drfs_even_time_years: 0.964,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615116/suppl/GSM615116_FL1789_ISPY_10.CEL.gz,22283,54.2,Rx Insensitive,IIIA,N1,T3,RD,1,0.964,N,N,N,N,High,3,P,Basal,RD,RCB-II,N,RCB-II/III,1061,SET-Low,ISPY,breast cancer tumor,NA
GSM615117,1062,GSM615117,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1062",Homo sapiens,sample id: 1062,source: ISPY,age_years: 34.6,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T3,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 1,drfs_even_time_years: 0.115,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615117/suppl/GSM615117_FL1788_ISPY_9.CEL.gz,22283,34.6,Rx Insensitive,IIIA,N1,T3,pCR,1,0.115,P,P,N,N,High,3,N,Basal,RD,RCB-II,P,RCB-II/III,1062,SET-Low,ISPY,breast cancer tumor,NA
GSM615118,1064,GSM615118,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1064",Homo sapiens,sample id: 1064,source: ISPY,age_years: 60.1,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: NA,pathologic_response_rcb_class: NA,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.415,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615118/suppl/GSM615118_FL1679_C219411.CEL.gz,22283,60.1,Rx Insensitive,IIB,N1,T2,pCR,0,2.415,N,N,N,N,High,3,N,Basal,NA,NA,N,RCB-II/III,1064,SET-Low,ISPY,breast cancer tumor,NA
GSM615119,1067,GSM615119,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1067",Homo sapiens,sample id: 1067,source: ISPY,age_years: 58.4,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: NA,pathologic_response_rcb_class: NA,drfs_1_event_0_censored: 1,drfs_even_time_years: 2.872,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: Basal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615119/suppl/GSM615119_FL1678_C219203.CEL.gz,22283,58.4,Rx Insensitive,IIB,N1,T2,RD,1,2.872,N,N,N,P,Low,3,N,Basal,NA,NA,N,RCB-0/I,1067,SET-Low,ISPY,breast cancer tumor,NA
GSM615120,1068,GSM615120,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1068",Homo sapiens,sample id: 1068,source: ISPY,age_years: 53.2,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T3,clinical_nodal_status: N0,clinical_ajcc_stage: IIB,grade: 1,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.706,esr1_status: P,erbb2_status: N,set_class: SET-High,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615120/suppl/GSM615120_FL1680_C221152.CEL.gz,22283,53.2,Rx Sensitive,IIB,N0,T3,RD,0,4.706,P,P,N,P,Low,1,N,LumA,RD,RCB-II,P,RCB-II/III,1068,SET-High,ISPY,breast cancer tumor,NA
GSM615121,1074,GSM615121,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1074",Homo sapiens,sample id: 1074,source: ISPY,age_years: 36.5,er_status_ihc: P,pr_status_ihc: N,her2_status: NA,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T3,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.222,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615121/suppl/GSM615121_FL1854_ISPY65.CEL.gz,22283,36.5,Rx Insensitive,IIIA,N1,T3,RD,0,4.222,P,P,N,P,High,3,NA,LumB,RD,RCB-II,N,RCB-II/III,1074,SET-Low,ISPY,breast cancer tumor,NA
GSM615122,1078,GSM615122,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1078",Homo sapiens,sample id: 1078,source: ISPY,age_years: 31.3,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T3,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 2,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.822,esr1_status: P,erbb2_status: N,set_class: SET-Int,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615122/suppl/GSM615122_FL1887_ISPY38.CEL.gz,22283,31.3,Rx Sensitive,IIIA,N1,T3,RD,0,3.822,P,P,N,P,Low,2,N,LumA,pCR,RCB-0/I,P,RCB-0/I,1078,SET-Int,ISPY,breast cancer tumor,NA
GSM615123,1088,GSM615123,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1088",Homo sapiens,sample id: 1088,source: ISPY,age_years: 53.1,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.304,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615123/suppl/GSM615123_FL1816_ISPY101.CEL.gz,22283,53.1,Rx Sensitive,IIA,N0,T2,RD,0,4.304,P,P,N,P,High,3,N,LumB,pCR,RCB-0/I,P,RCB-0/I,1088,SET-Low,ISPY,breast cancer tumor,NA
GSM615124,1089,GSM615124,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1089",Homo sapiens,sample id: 1089,source: ISPY,age_years: 61.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T4,clinical_nodal_status: N2,clinical_ajcc_stage: IIIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.162,esr1_status: P,erbb2_status: N,set_class: SET-High,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615124/suppl/GSM615124_FL1817_ISPY102.CEL.gz,22283,61,Rx Sensitive,IIIB,N2,T4,RD,0,4.162,P,P,N,P,High,2,N,Basal,RD,RCB-II,P,RCB-II/III,1089,SET-High,ISPY,breast cancer tumor,NA
GSM615125,1092,GSM615125,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1092",Homo sapiens,sample id: 1092,source: ISPY,age_years: 44.1,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.074,esr1_status: P,erbb2_status: N,set_class: SET-High,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: Normal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615125/suppl/GSM615125_FL1890_ISPY41.CEL.gz,22283,44.1,Rx Sensitive,IIA,N0,T2,RD,0,4.074,P,P,N,P,Low,2,N,Normal,RD,RCB-0/I,P,RCB-0/I,1092,SET-High,ISPY,breast cancer tumor,NA
GSM615126,1095,GSM615126,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1095",Homo sapiens,sample id: 1095,source: ISPY,age_years: 43.6,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T4,clinical_nodal_status: N0,clinical_ajcc_stage: Inflammatory,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.800,esr1_status: P,erbb2_status: N,set_class: SET-High,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615126/suppl/GSM615126_FL1891_ISPY42.CEL.gz,22283,43.6,Rx Sensitive,Inflammatory,N0,T4,RD,0,3.8,P,P,N,P,High,3,N,LumA,RD,RCB-III,P,RCB-II/III,1095,SET-High,ISPY,breast cancer tumor,NA
GSM615127,1100,GSM615127,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1100",Homo sapiens,sample id: 1100,source: ISPY,age_years: 63.3,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.126,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615127/suppl/GSM615127_FL1872_ISPY43.CEL.gz,22283,63.3,Rx Insensitive,IIA,N0,T2,RD,0,4.126,P,P,N,P,High,2,N,LumA,RD,RCB-II,N,RCB-II/III,1100,SET-Low,ISPY,breast cancer tumor,NA
GSM615128,1106,GSM615128,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1106",Homo sapiens,sample id: 1106,source: ISPY,age_years: 50.4,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T4,clinical_nodal_status: N1,clinical_ajcc_stage: IIIB,grade: NA,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 1,drfs_even_time_years: 1.344,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615128/suppl/GSM615128_FL1842_ISPY83.CEL.gz,22283,50.4,Rx Insensitive,IIIB,N1,T4,RD,1,1.344,P,P,N,P,High,NA,N,LumB,RD,RCB-II,P,RCB-II/III,1106,SET-Low,ISPY,breast cancer tumor,NA
GSM615129,1113,GSM615129,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1113",Homo sapiens,sample id: 1113,source: ISPY,age_years: 53.5,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 4=Indeterminate,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.954,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615129/suppl/GSM615129_FL1843_ISPY84.CEL.gz,22283,53.5,Rx Sensitive,IIB,N1,T2,RD,0,2.954,P,P,N,P,High,4=Indeterminate,N,LumB,RD,RCB-0/I,P,RCB-0/I,1113,SET-Low,ISPY,breast cancer tumor,NA
GSM615130,1114,GSM615130,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1114",Homo sapiens,sample id: 1114,source: ISPY,age_years: 44.8,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T4,clinical_nodal_status: N1,clinical_ajcc_stage: IIIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.019,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: Her2,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615130/suppl/GSM615130_FL1844_ISPY85.CEL.gz,22283,44.8,Rx Insensitive,IIIB,N1,T4,RD,0,4.019,P,P,N,N,Low,2,N,Her2,RD,RCB-II,P,RCB-II/III,1114,SET-Low,ISPY,breast cancer tumor,NA
GSM615131,1123,GSM615131,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1123",Homo sapiens,sample id: 1123,source: ISPY,age_years: 61.9,er_status_ihc: P,pr_status_ihc: P,her2_status: I,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T3,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 4=Indeterminate,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.883,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615131/suppl/GSM615131_FL1803_ISPY24.CEL.gz,22283,61.9,Rx Insensitive,IIIA,N1,T3,RD,0,2.883,P,P,N,P,Low,4=Indeterminate,I,LumA,RD,RCB-III,P,RCB-II/III,1123,SET-Low,ISPY,breast cancer tumor,NA
GSM615132,1127,GSM615132,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1127",Homo sapiens,sample id: 1127,source: ISPY,age_years: 47.6,er_status_ihc: P,pr_status_ihc: P,her2_status: I,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.574,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615132/suppl/GSM615132_FL1858_ISPY69.CEL.gz,22283,47.6,Rx Insensitive,IIA,N0,T2,RD,0,1.574,P,P,N,P,High,2,I,LumA,RD,RCB-III,P,RCB-II/III,1127,SET-Low,ISPY,breast cancer tumor,NA
GSM615133,1132,GSM615133,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1132",Homo sapiens,sample id: 1132,source: ISPY,age_years: 51.4,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 1,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.617,esr1_status: P,erbb2_status: N,set_class: SET-High,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615133/suppl/GSM615133_FL1847_ISPY88.CEL.gz,22283,51.4,Rx Sensitive,IIA,N0,T2,RD,0,3.617,P,P,N,P,Low,1,N,LumA,RD,RCB-III,P,RCB-II/III,1132,SET-High,ISPY,breast cancer tumor,NA
GSM615134,1134,GSM615134,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1134",Homo sapiens,sample id: 1134,source: ISPY,age_years: 43.1,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 1,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.696,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: Normal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615134/suppl/GSM615134_FL1848_ISPY89.CEL.gz,22283,43.1,Rx Insensitive,IIB,N1,T2,RD,0,3.696,P,P,N,P,Low,1,N,Normal,RD,RCB-III,P,RCB-II/III,1134,SET-Low,ISPY,breast cancer tumor,NA
GSM615135,1135,GSM615135,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1135",Homo sapiens,sample id: 1135,source: ISPY,age_years: 58.9,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.841,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: Normal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615135/suppl/GSM615135_FL1849_ISPY90.CEL.gz,22283,58.9,Rx Insensitive,IIB,N1,T2,RD,0,3.841,N,N,N,N,Low,3,N,Normal,RD,RCB-III,N,RCB-II/III,1135,SET-Low,ISPY,breast cancer tumor,NA
GSM615136,1136,GSM615136,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1136",Homo sapiens,sample id: 1136,source: ISPY,age_years: 60.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T3,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 1,drfs_even_time_years: 0.545,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615136/suppl/GSM615136_FL1892_ISPY25.CEL.gz,22283,60,Rx Insensitive,IIIA,N1,T3,pCR,1,0.545,N,N,N,N,High,3,N,Basal,RD,RCB-III,N,RCB-II/III,1136,SET-Low,ISPY,breast cancer tumor,NA
GSM615137,1138,GSM615137,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1138",Homo sapiens,sample id: 1138,source: ISPY,age_years: 35.1,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T3,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 4=Indeterminate,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.464,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615137/suppl/GSM615137_FL1888_ISPY39.CEL.gz,22283,35.1,Rx Sensitive,IIIA,N1,T3,pCR,0,2.464,P,P,N,N,High,4=Indeterminate,N,Basal,pCR,RCB-0/I,N,RCB-0/I,1138,SET-Low,ISPY,breast cancer tumor,NA
GSM615138,1140,GSM615138,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1140",Homo sapiens,sample id: 1140,source: ISPY,age_years: 35.1,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T3,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.904,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615138/suppl/GSM615138_FL1851_ISPY92.CEL.gz,22283,35.1,Rx Insensitive,IIIA,N1,T3,RD,0,3.904,P,P,N,P,High,2,N,LumB,RD,RCB-II,N,RCB-II/III,1140,SET-Low,ISPY,breast cancer tumor,NA
GSM615139,1144,GSM615139,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1144",Homo sapiens,sample id: 1144,source: ISPY,age_years: 56.3,er_status_ihc: N,pr_status_ihc: N,her2_status: NA,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.360,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Her2,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615139/suppl/GSM615139_FL1874_ISPY45.CEL.gz,22283,56.3,Rx Sensitive,IIB,N1,T2,pCR,0,2.36,N,N,N,N,High,3,NA,Her2,pCR,RCB-0/I,N,RCB-0/I,1144,SET-Low,ISPY,breast cancer tumor,NA
GSM615140,1145,GSM615140,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1145",Homo sapiens,sample id: 1145,source: ISPY,age_years: 39.4,er_status_ihc: N,pr_status_ihc: N,her2_status: P,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T3,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 2,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.032,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615140/suppl/GSM615140_FL1875_ISPY46.CEL.gz,22283,39.4,Rx Insensitive,IIIA,N1,T3,pCR,0,1.032,N,N,N,N,High,2,P,Basal,pCR,RCB-0/I,N,RCB-0/I,1145,SET-Low,ISPY,breast cancer tumor,NA
GSM615141,1149,GSM615141,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1149",Homo sapiens,sample id: 1149,source: ISPY,age_years: 59.2,er_status_ihc: NA,pr_status_ihc: NA,her2_status: NA,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T3,clinical_nodal_status: N1,clinical_ajcc_stage: Inflammatory,grade: NA,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.239,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615141/suppl/GSM615141_FL1876_ISPY47.CEL.gz,22283,59.2,Rx Insensitive,Inflammatory,N1,T3,pCR,0,3.239,N,NA,N,N,High,NA,NA,Basal,RD,RCB-III,NA,RCB-II/III,1149,SET-Low,ISPY,breast cancer tumor,NA
GSM615142,1150,GSM615142,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1150",Homo sapiens,sample id: 1150,source: ISPY,age_years: 51.5,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T3,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 4=Indeterminate,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.946,esr1_status: P,erbb2_status: N,set_class: SET-Int,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615142/suppl/GSM615142_FL1877_ISPY48.CEL.gz,22283,51.5,Rx Sensitive,IIIA,N1,T3,RD,0,2.946,P,P,N,P,High,4=Indeterminate,N,LumA,RD,RCB-II,P,RCB-II/III,1150,SET-Int,ISPY,breast cancer tumor,NA
GSM615143,1155,GSM615143,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1155",Homo sapiens,sample id: 1155,source: ISPY,age_years: 42.7,er_status_ihc: N,pr_status_ihc: P,her2_status: NA,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.902,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615143/suppl/GSM615143_FL1879_ISPY50.CEL.gz,22283,42.7,Rx Insensitive,IIA,N0,T2,RD,0,2.902,N,N,N,N,High,3,NA,Basal,pCR,RCB-0/I,P,RCB-0/I,1155,SET-Low,ISPY,breast cancer tumor,NA
GSM615144,1158,GSM615144,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1158",Homo sapiens,sample id: 1158,source: ISPY,age_years: 61.8,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.261,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615144/suppl/GSM615144_FL1881_ISPY52.CEL.gz,22283,61.8,Rx Sensitive,IIA,N0,T2,RD,0,3.261,P,P,N,P,High,2,N,LumA,RD,RCB-II,P,RCB-0/I,1158,SET-Low,ISPY,breast cancer tumor,NA
GSM615145,1160,GSM615145,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1160",Homo sapiens,sample id: 1160,source: ISPY,age_years: 55.7,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T3,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: NA,drfs_1_event_0_censored: 0,drfs_even_time_years: 0.898,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615145/suppl/GSM615145_FL1862_ISPY53.CEL.gz,22283,55.7,Rx Insensitive,IIIA,N1,T3,pCR,0,0.898,N,N,N,N,High,3,N,Basal,RD,NA,N,RCB-II/III,1160,SET-Low,ISPY,breast cancer tumor,NA
GSM615146,1163,GSM615146,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1163",Homo sapiens,sample id: 1163,source: ISPY,age_years: 38.9,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.533,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615146/suppl/GSM615146_FL1809_ISPY94.CEL.gz,22283,38.9,Rx Sensitive,IIA,N0,T2,pCR,0,2.533,N,N,N,N,High,3,N,Basal,pCR,RCB-0/I,N,RCB-0/I,1163,SET-Low,ISPY,breast cancer tumor,NA
GSM615147,1164,GSM615147,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1164",Homo sapiens,sample id: 1164,source: ISPY,age_years: 60.1,er_status_ihc: P,pr_status_ihc: P,her2_status: I,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T3,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: NA,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.872,esr1_status: P,erbb2_status: N,set_class: SET-Int,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615147/suppl/GSM615147_FL1863_ISPY54.CEL.gz,22283,60.1,Rx Sensitive,IIIA,N1,T3,RD,0,2.872,P,P,N,P,High,NA,I,LumA,RD,RCB-II,P,RCB-II/III,1164,SET-Int,ISPY,breast cancer tumor,NA
GSM615148,1165,GSM615148,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1165",Homo sapiens,sample id: 1165,source: ISPY,age_years: 39.7,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T3,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.669,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615148/suppl/GSM615148_FL1810_ISPY95.CEL.gz,22283,39.7,Rx Insensitive,IIIA,N1,T3,pCR,0,2.669,N,N,N,N,High,3,N,Basal,RD,RCB-II,N,RCB-II/III,1165,SET-Low,ISPY,breast cancer tumor,NA
GSM615149,1169,GSM615149,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1169",Homo sapiens,sample id: 1169,source: ISPY,age_years: 44.2,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T3,clinical_nodal_status: N2,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 1,drfs_even_time_years: 0.715,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615149/suppl/GSM615149_FL1866_ISPY57.CEL.gz,22283,44.2,Rx Insensitive,IIIA,N2,T3,pCR,1,0.715,N,N,N,N,High,3,N,Basal,RD,RCB-III,N,RCB-II/III,1169,SET-Low,ISPY,breast cancer tumor,NA
GSM615150,1170,GSM615150,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1170",Homo sapiens,sample id: 1170,source: ISPY,age_years: 44.4,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T3,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.174,esr1_status: P,erbb2_status: N,set_class: SET-High,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615150/suppl/GSM615150_FL1827_ISPY116.CEL.gz,22283,44.4,Rx Sensitive,IIIA,N1,T3,RD,0,2.174,P,P,N,P,Low,2,N,LumA,RD,RCB-III,P,RCB-II/III,1170,SET-High,ISPY,breast cancer tumor,NA
GSM615151,1172,GSM615151,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1172",Homo sapiens,sample id: 1172,source: ISPY,age_years: 44.6,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 0.914,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615151/suppl/GSM615151_FL1867_ISPY58.CEL.gz,22283,44.6,Rx Insensitive,IIA,N0,T2,pCR,0,0.914,N,N,N,N,High,2,N,Basal,RD,RCB-II,N,RCB-II/III,1172,SET-Low,ISPY,breast cancer tumor,NA
GSM615152,1173,GSM615152,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1173",Homo sapiens,sample id: 1173,source: ISPY,age_years: 44.0,er_status_ihc: I,pr_status_ihc: I,her2_status: NA,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N2,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.798,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615152/suppl/GSM615152_FL1811_ISPY96.CEL.gz,22283,44,Rx Insensitive,IIIA,N2,T2,pCR,0,2.798,N,I,N,N,High,3,NA,Basal,RD,RCB-II,I,RCB-II/III,1173,SET-Low,ISPY,breast cancer tumor,NA
GSM615153,1175,GSM615153,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1175",Homo sapiens,sample id: 1175,source: ISPY,age_years: 64.3,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T3,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.672,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615153/suppl/GSM615153_FL1868_ISPY59.CEL.gz,22283,64.3,Rx Insensitive,IIIA,N1,T3,RD,0,2.672,P,P,N,P,High,2,N,LumB,RD,RCB-II,P,RCB-II/III,1175,SET-Low,ISPY,breast cancer tumor,NA
GSM615154,1177,GSM615154,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1177",Homo sapiens,sample id: 1177,source: ISPY,age_years: 40.8,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.530,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615154/suppl/GSM615154_FL1870_ISPY61.CEL.gz,22283,40.8,Rx Sensitive,IIB,N1,T2,pCR,0,2.53,N,N,N,N,High,3,N,Basal,pCR,RCB-0/I,N,RCB-0/I,1177,SET-Low,ISPY,breast cancer tumor,NA
GSM615155,1180,GSM615155,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1180",Homo sapiens,sample id: 1180,source: ISPY,age_years: 31.5,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T4,clinical_nodal_status: N1,clinical_ajcc_stage: IIIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.192,esr1_status: P,erbb2_status: N,set_class: SET-Int,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615155/suppl/GSM615155_FL1820_ISPY105.CEL.gz,22283,31.5,Rx Sensitive,IIIB,N1,T4,RD,0,3.192,P,P,N,P,High,3,N,Basal,RD,RCB-II,P,RCB-0/I,1180,SET-Int,ISPY,breast cancer tumor,NA
GSM615156,1188,GSM615156,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1188",Homo sapiens,sample id: 1188,source: ISPY,age_years: 38.3,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.026,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615156/suppl/GSM615156_FL1871_ISPY62.CEL.gz,22283,38.3,Rx Insensitive,IIB,N1,T2,pCR,0,2.026,N,N,N,N,High,3,N,Basal,RD,RCB-II,N,RCB-II/III,1188,SET-Low,ISPY,breast cancer tumor,NA
GSM615157,1191,GSM615157,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1191",Homo sapiens,sample id: 1191,source: ISPY,age_years: 45.9,er_status_ihc: P,pr_status_ihc: I,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.045,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Her2,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615157/suppl/GSM615157_FL1812_ISPY97.CEL.gz,22283,45.9,Rx Insensitive,IIB,N1,T2,RD,0,2.045,P,P,N,P,High,2,N,Her2,RD,RCB-II,I,RCB-II/III,1191,SET-Low,ISPY,breast cancer tumor,NA
GSM615158,1193,GSM615158,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1193",Homo sapiens,sample id: 1193,source: ISPY,age_years: 59.6,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 1,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.275,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615158/suppl/GSM615158_FL1821_ISPY106.CEL.gz,22283,59.6,Rx Insensitive,IIA,N0,T2,RD,0,2.275,P,P,N,P,Low,1,N,LumA,RD,RCB-III,P,RCB-II/III,1193,SET-Low,ISPY,breast cancer tumor,NA
GSM615159,1197,GSM615159,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1197",Homo sapiens,sample id: 1197,source: ISPY,age_years: 44.7,er_status_ihc: N,pr_status_ihc: P,her2_status: NA,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 4=Indeterminate,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.692,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Her2,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615159/suppl/GSM615159_FL1861_ISPY72.CEL.gz,22283,44.7,Rx Insensitive,IIB,N1,T2,pCR,0,1.692,N,N,N,N,High,4=Indeterminate,NA,Her2,RD,RCB-II,P,RCB-II/III,1197,SET-Low,ISPY,breast cancer tumor,NA
GSM615160,1199,GSM615160,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1199",Homo sapiens,sample id: 1199,source: ISPY,age_years: 37.7,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T3,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 1,drfs_even_time_years: 0.383,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615160/suppl/GSM615160_FL1822_ISPY107.CEL.gz,22283,37.7,Rx Insensitive,IIIA,N1,T3,pCR,1,0.383,N,N,N,N,High,3,N,Basal,RD,RCB-III,N,RCB-II/III,1199,SET-Low,ISPY,breast cancer tumor,NA
GSM615161,1200,GSM615161,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1200",Homo sapiens,sample id: 1200,source: ISPY,age_years: 43.8,er_status_ihc: I,pr_status_ihc: I,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.401,esr1_status: P,erbb2_status: N,set_class: SET-High,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615161/suppl/GSM615161_FL1823_ISPY108.CEL.gz,22283,43.8,Rx Sensitive,IIA,N0,T2,RD,0,2.401,P,I,N,P,High,2,N,LumA,RD,RCB-III,I,RCB-II/III,1200,SET-High,ISPY,breast cancer tumor,NA
GSM615162,1203,GSM615162,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1203",Homo sapiens,sample id: 1203,source: ISPY,age_years: 42.3,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T3,clinical_nodal_status: N2,clinical_ajcc_stage: IIIA,grade: 1,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: NA,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.508,esr1_status: P,erbb2_status: N,set_class: SET-Int,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615162/suppl/GSM615162_FL1824_ISPY109.CEL.gz,22283,42.3,Rx Sensitive,IIIA,N2,T3,RD,0,2.508,P,P,N,P,Low,1,N,LumA,RD,NA,P,RCB-II/III,1203,SET-Int,ISPY,breast cancer tumor,NA
GSM615163,1205,GSM615163,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1205",Homo sapiens,sample id: 1205,source: ISPY,age_years: 42.6,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T3,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: NA,pathologic_response_pcr_rd: NA,pathologic_response_rcb_class: NA,drfs_1_event_0_censored: 0,drfs_even_time_years: 0.523,esr1_status: P,erbb2_status: N,set_class: SET-High,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615163/suppl/GSM615163_FL1712_C254891.CEL.gz,22283,42.6,Rx Sensitive,IIIA,N1,T3,RD,0,0.523,P,P,N,P,High,NA,N,LumB,NA,NA,P,RCB-II/III,1205,SET-High,ISPY,breast cancer tumor,NA
GSM615164,1208,GSM615164,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1208",Homo sapiens,sample id: 1208,source: ISPY,age_years: 42.1,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T3,clinical_nodal_status: N0,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.432,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615164/suppl/GSM615164_FL1825_ISPY110.CEL.gz,22283,42.1,Rx Sensitive,IIB,N0,T3,pCR,0,1.432,N,N,N,N,High,3,N,Basal,pCR,RCB-0/I,N,RCB-0/I,1208,SET-Low,ISPY,breast cancer tumor,NA
GSM615165,1209,GSM615165,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1209",Homo sapiens,sample id: 1209,source: ISPY,age_years: 43.4,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.640,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Normal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615165/suppl/GSM615165_FL1833_ISPY74.CEL.gz,22283,43.4,Rx Insensitive,IIA,N0,T2,RD,0,1.64,P,P,N,P,High,2,N,Normal,RD,RCB-II,N,RCB-II/III,1209,SET-Low,ISPY,breast cancer tumor,NA
GSM615166,1210,GSM615166,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1210",Homo sapiens,sample id: 1210,source: ISPY,age_years: 40.6,er_status_ihc: P,pr_status_ihc: P,her2_status: NA,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T3,clinical_nodal_status: N0,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.119,esr1_status: P,erbb2_status: N,set_class: SET-High,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Normal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615166/suppl/GSM615166_FL1828_ISPY117.CEL.gz,22283,40.6,Rx Sensitive,IIB,N0,T3,RD,0,2.119,P,P,N,P,High,2,NA,Normal,RD,RCB-II,P,RCB-II/III,1210,SET-High,ISPY,breast cancer tumor,NA
GSM615167,1216,GSM615167,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1216",Homo sapiens,sample id: 1216,source: ISPY,age_years: 34.4,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N2,clinical_ajcc_stage: IIIA,grade: 2,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.133,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: Normal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615167/suppl/GSM615167_FL1834_ISPY75.CEL.gz,22283,34.4,Rx Insensitive,IIIA,N2,T2,RD,0,1.133,N,N,N,P,Low,2,N,Normal,pCR,RCB-0/I,N,RCB-0/I,1216,SET-Low,ISPY,breast cancer tumor,NA
GSM615168,1217,GSM615168,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1217",Homo sapiens,sample id: 1217,source: ISPY,age_years: 50.1,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 4=Indeterminate,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: NA,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.361,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615168/suppl/GSM615168_FL1835_ISPY76.CEL.gz,22283,50.1,Rx Insensitive,IIA,N0,T2,RD,0,1.361,P,P,N,P,Low,4=Indeterminate,N,LumA,RD,NA,P,RCB-II/III,1217,SET-Low,ISPY,breast cancer tumor,NA
GSM615169,1218,GSM615169,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1218",Homo sapiens,sample id: 1218,source: ISPY,age_years: 47.8,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T3,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.264,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615169/suppl/GSM615169_FL1805_ISPY112.CEL.gz,22283,47.8,Rx Insensitive,IIIA,N1,T3,pCR,0,2.264,N,N,N,P,High,3,N,Basal,RD,RCB-II,N,RCB-0/I,1218,SET-Low,ISPY,breast cancer tumor,NA
GSM615170,1219,GSM615170,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1219",Homo sapiens,sample id: 1219,source: ISPY,age_years: 46.0,er_status_ihc: P,pr_status_ihc: P,her2_status: NA,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T3,clinical_nodal_status: N0,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.198,esr1_status: P,erbb2_status: N,set_class: SET-High,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615170/suppl/GSM615170_FL1806_ISPY113.CEL.gz,22283,46,Rx Sensitive,IIB,N0,T3,RD,0,2.198,P,P,N,P,Low,2,NA,LumA,RD,RCB-II,P,RCB-II/III,1219,SET-High,ISPY,breast cancer tumor,NA
GSM615171,1220,GSM615171,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1220",Homo sapiens,sample id: 1220,source: ISPY,age_years: 43.1,er_status_ihc: N,pr_status_ihc: N,her2_status: NA,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: NA,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.390,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615171/suppl/GSM615171_FL1836_ISPY77.CEL.gz,22283,43.1,Rx Insensitive,IIB,N1,T2,pCR,0,2.39,N,N,N,N,High,NA,NA,Basal,pCR,RCB-0/I,N,RCB-0/I,1220,SET-Low,ISPY,breast cancer tumor,NA
GSM615172,1223,GSM615172,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1223",Homo sapiens,sample id: 1223,source: ISPY,age_years: 59.8,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.587,esr1_status: P,erbb2_status: N,set_class: SET-Int,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615172/suppl/GSM615172_FL1837_ISPY78.CEL.gz,22283,59.8,Rx Sensitive,IIA,N0,T2,RD,0,2.587,P,P,N,P,Low,2,N,LumA,RD,RCB-II,P,RCB-II/III,1223,SET-Int,ISPY,breast cancer tumor,NA
GSM615173,1225,GSM615173,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1225",Homo sapiens,sample id: 1225,source: ISPY,age_years: 47.8,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T1,clinical_nodal_status: N1,clinical_ajcc_stage: IIA,grade: NA,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.086,esr1_status: P,erbb2_status: N,set_class: SET-High,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615173/suppl/GSM615173_FL1807_ISPY114.CEL.gz,22283,47.8,Rx Sensitive,IIA,N1,T1,RD,0,2.086,P,P,N,P,Low,NA,N,LumA,RD,RCB-II,P,RCB-II/III,1225,SET-High,ISPY,breast cancer tumor,NA
GSM615174,1226,GSM615174,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1226",Homo sapiens,sample id: 1226,source: ISPY,age_years: 42.1,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N2,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.478,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615174/suppl/GSM615174_FL1838_ISPY79.CEL.gz,22283,42.1,Rx Insensitive,IIIA,N2,T2,RD,0,2.478,P,P,N,P,High,3,N,LumB,RD,RCB-II,P,RCB-II/III,1226,SET-Low,ISPY,breast cancer tumor,NA
GSM615175,1227,GSM615175,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1227",Homo sapiens,sample id: 1227,source: ISPY,age_years: 42.5,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T3,clinical_nodal_status: N0,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.527,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615175/suppl/GSM615175_FL1839_ISPY80.CEL.gz,22283,42.5,Rx Insensitive,IIB,N0,T3,pCR,0,2.527,N,N,N,N,High,3,N,Basal,pCR,RCB-0/I,N,RCB-0/I,1227,SET-Low,ISPY,breast cancer tumor,NA
GSM615176,1231,GSM615176,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1231",Homo sapiens,sample id: 1231,source: ISPY,age_years: 45.5,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T3,clinical_nodal_status: N0,clinical_ajcc_stage: IIB,grade: 1,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.453,esr1_status: P,erbb2_status: N,set_class: SET-Int,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: Normal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615176/suppl/GSM615176_FL1840_ISPY81.CEL.gz,22283,45.5,Rx Sensitive,IIB,N0,T3,RD,0,2.453,P,P,N,P,Low,1,N,Normal,RD,RCB-II,P,RCB-II/III,1231,SET-Int,ISPY,breast cancer tumor,NA
GSM615177,1232,GSM615177,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1232",Homo sapiens,sample id: 1232,source: ISPY,age_years: 50.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T3,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: NA,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.744,esr1_status: P,erbb2_status: N,set_class: SET-Int,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615177/suppl/GSM615177_FL1709_C244678.CEL.gz,22283,50,Rx Sensitive,IIIA,N1,T3,RD,0,1.744,P,P,N,P,High,NA,N,LumA,RD,RCB-II,P,RCB-II/III,1232,SET-Int,ISPY,breast cancer tumor,NA
GSM615178,1236,GSM615178,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample ISPY-1236",Homo sapiens,sample id: 1236,source: ISPY,age_years: 38.6,er_status_ihc: N,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.936,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615178/suppl/GSM615178_FL1826_ISPY115.CEL.gz,22283,38.6,Rx Insensitive,IIB,N1,T2,pCR,0,1.936,N,N,N,N,High,3,N,Basal,RD,RCB-III,P,RCB-II/III,1236,SET-Low,ISPY,breast cancer tumor,NA
GSM615179,M106,GSM615179,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M106",Homo sapiens,sample id: M106,source: MDACC,age_years: 56.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 7.083,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615179/suppl/GSM615179_20537_AB01913244_17054.CEL.gz,22283,56,Rx Insensitive,IIA,N0,T2,RD,0,7.083,P,P,N,P,Low,2,N,LumA,RD,RCB-0/I,P,RCB-0/I,M106,SET-Low,MDACC,breast cancer tumor,NA
GSM615180,M107,GSM615180,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M107",Homo sapiens,sample id: M107,source: MDACC,age_years: 47.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T3,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 5.758,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615180/suppl/GSM615180_29539_AB01833535_35695.CEL.gz,22283,47,Rx Insensitive,IIIA,N1,T3,RD,0,5.758,P,P,N,P,Low,2,N,LumA,RD,RCB-II,P,RCB-II/III,M107,SET-Low,MDACC,breast cancer tumor,NA
GSM615181,M111,GSM615181,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M111",Homo sapiens,sample id: M111,source: MDACC,age_years: 49.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T3,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 7.395,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615181/suppl/GSM615181_19893_AB01988634_17017.CEL.gz,22283,49,Rx Insensitive,IIIA,N1,T3,pCR,0,7.395,N,N,N,N,High,3,N,Basal,pCR,RCB-0/I,N,RCB-0/I,M111,SET-Low,MDACC,breast cancer tumor,NA
GSM615182,M113,GSM615182,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M113",Homo sapiens,sample id: M113,source: MDACC,age_years: 75.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 7.439,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Her2,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615182/suppl/GSM615182_19893_AB01779189_17018.CEL.gz,22283,75,Rx Insensitive,IIA,N0,T2,RD,0,7.439,N,N,N,N,High,3,N,Her2,RD,RCB-0/I,N,RCB-0/I,M113,SET-Low,MDACC,NA,NA
GSM615183,M117,GSM615183,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M117",Homo sapiens,sample id: M117,source: MDACC,age_years: 34.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 6.710,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615183/suppl/GSM615183_20537_AB01913201_17055.CEL.gz,22283,34,Rx Insensitive,IIB,N1,T2,RD,0,6.71,P,P,N,P,Low,2,N,LumA,RD,RCB-II,P,RCB-II/III,M117,SET-Low,MDACC,NA,NA
GSM615184,M120,GSM615184,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M120",Homo sapiens,sample id: M120,source: MDACC,age_years: 51.0,er_status_ihc: N,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 7.302,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615184/suppl/GSM615184_29539_AB01833504_35681.CEL.gz,22283,51,Rx Insensitive,IIA,N0,T2,pCR,0,7.302,N,N,N,N,High,3,N,Basal,RD,RCB-0/I,P,RCB-0/I,M120,SET-Low,MDACC,NA,NA
GSM615185,M121,GSM615185,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M121",Homo sapiens,sample id: M121,source: MDACC,age_years: 65.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T1,clinical_nodal_status: N0,clinical_ajcc_stage: I,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 1,drfs_even_time_years: 5.591,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615185/suppl/GSM615185_19893_AB01983888_17050.CEL.gz,22283,65,Rx Sensitive,I,N0,T1,pCR,1,5.591,N,N,N,N,High,3,N,Basal,RD,RCB-0/I,N,RCB-0/I,M121,SET-Low,MDACC,NA,NA
GSM615186,M123,GSM615186,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M123",Homo sapiens,sample id: M123,source: MDACC,age_years: 51.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T3,clinical_nodal_status: N3,clinical_ajcc_stage: IIIB,grade: 1,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 6.661,esr1_status: P,erbb2_status: N,set_class: SET-Int,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615186/suppl/GSM615186_20558_AB01711719_17202.CEL.gz,22283,51,Rx Sensitive,IIIB,N3,T3,RD,0,6.661,P,P,N,P,High,1,N,LumA,pCR,RCB-0/I,N,RCB-0/I,M123,SET-Int,MDACC,NA,NA
GSM615187,M128,GSM615187,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M128",Homo sapiens,sample id: M128,source: MDACC,age_years: 66.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 6.834,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615187/suppl/GSM615187_19893_AB01983905_17019.CEL.gz,22283,66,Rx Insensitive,IIA,N0,T2,RD,0,6.834,P,P,N,P,Low,2,N,LumA,RD,RCB-II,P,RCB-II/III,M128,SET-Low,MDACC,NA,NA
GSM615188,M129,GSM615188,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M129",Homo sapiens,sample id: M129,source: MDACC,age_years: 61.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 5.717,esr1_status: P,erbb2_status: N,set_class: SET-High,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615188/suppl/GSM615188_29539_AB01833758_35698.CEL.gz,22283,61,Rx Sensitive,IIA,N0,T2,RD,0,5.717,N,N,N,P,High,2,N,LumB,RD,RCB-II,N,RCB-II/III,M129,SET-High,MDACC,NA,NA
GSM615189,M130,GSM615189,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M130",Homo sapiens,sample id: M130,source: MDACC,age_years: 65.0,er_status_ihc: N,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 1,drfs_even_time_years: 1.144,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Her2,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615189/suppl/GSM615189_19893_AB01983478_17035.CEL.gz,22283,65,Rx Insensitive,IIB,N1,T2,pCR,1,1.144,N,N,N,N,High,3,N,Her2,RD,RCB-II,P,RCB-II/III,M130,SET-Low,MDACC,NA,NA
GSM615190,M133,GSM615190,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M133",Homo sapiens,sample id: M133,source: MDACC,age_years: 37.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 7.127,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615190/suppl/GSM615190_20979_AB01913684_16983.CEL.gz,22283,37,Rx Sensitive,IIA,N0,T2,pCR,0,7.127,N,N,N,N,High,3,N,Basal,RD,RCB-0/I,N,RCB-0/I,M133,SET-Low,MDACC,NA,NA
GSM615191,M136,GSM615191,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M136",Homo sapiens,sample id: M136,source: MDACC,age_years: 37.0,er_status_ihc: N,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T1,clinical_nodal_status: N0,clinical_ajcc_stage: I,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 6.341,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615191/suppl/GSM615191_19893_AB01988722_17036.CEL.gz,22283,37,Rx Insensitive,I,N0,T1,pCR,0,6.341,N,N,N,N,High,3,N,Basal,pCR,RCB-0/I,P,RCB-0/I,M136,SET-Low,MDACC,NA,NA
GSM615192,M139,GSM615192,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M139",Homo sapiens,sample id: M139,source: MDACC,age_years: 51.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 7.326,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615192/suppl/GSM615192_19893_AB02014587_17020.CEL.gz,22283,51,Rx Sensitive,IIA,N0,T2,RD,0,7.326,P,P,N,P,High,2,N,LumA,RD,RCB-II,P,RCB-0/I,M139,SET-Low,MDACC,NA,NA
GSM615193,M146,GSM615193,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M146",Homo sapiens,sample id: M146,source: MDACC,age_years: 40.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T1,clinical_nodal_status: N0,clinical_ajcc_stage: I,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 6.439,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: Normal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615193/suppl/GSM615193_29539_AB01833769_35700.CEL.gz,22283,40,Rx Sensitive,I,N0,T1,pCR,0,6.439,N,N,N,N,Low,3,N,Normal,pCR,RCB-0/I,N,RCB-0/I,M146,SET-Low,MDACC,NA,NA
GSM615194,M153,GSM615194,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M153",Homo sapiens,sample id: M153,source: MDACC,age_years: 61.0,er_status_ihc: N,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T1,clinical_nodal_status: N1,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 6.519,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615194/suppl/GSM615194_19893_AB01913261_17092.CEL.gz,22283,61,Rx Sensitive,IIA,N1,T1,pCR,0,6.519,N,N,N,N,High,3,N,Basal,pCR,RCB-0/I,P,RCB-0/I,M153,SET-Low,MDACC,NA,NA
GSM615195,M154,GSM615195,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M154",Homo sapiens,sample id: M154,source: MDACC,age_years: 29.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T4,clinical_nodal_status: N2,clinical_ajcc_stage: IIIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 1,drfs_even_time_years: 0.764,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615195/suppl/GSM615195_19893_AB01860198_17037.CEL.gz,22283,29,Rx Insensitive,IIIB,N2,T4,pCR,1,0.764,N,N,N,N,High,3,N,Basal,RD,RCB-III,N,RCB-II/III,M154,SET-Low,MDACC,NA,NA
GSM615196,M155,GSM615196,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M155",Homo sapiens,sample id: M155,source: MDACC,age_years: 61.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 6.467,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615196/suppl/GSM615196_19893_AB01983892_17029.CEL.gz,22283,61,Rx Sensitive,IIA,N0,T2,RD,0,6.467,P,P,N,P,High,3,N,LumB,RD,RCB-II,P,RCB-0/I,M155,SET-Low,MDACC,NA,NA
GSM615197,M156,GSM615197,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M156",Homo sapiens,sample id: M156,source: MDACC,age_years: 67.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N2,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 6.612,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Her2,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615197/suppl/GSM615197_19893_AB01988622_17021.CEL.gz,22283,67,Rx Insensitive,IIIA,N2,T2,RD,0,6.612,N,N,N,N,High,3,N,Her2,RD,RCB-III,N,RCB-II/III,M156,SET-Low,MDACC,NA,NA
GSM615198,M157,GSM615198,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M157",Homo sapiens,sample id: M157,source: MDACC,age_years: 57.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 6.593,esr1_status: P,erbb2_status: N,set_class: SET-Int,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615198/suppl/GSM615198_19893_AB01778470_17038.CEL.gz,22283,57,Rx Sensitive,IIA,N0,T2,RD,0,6.593,P,P,N,P,High,2,N,LumA,RD,RCB-II,P,RCB-0/I,M157,SET-Int,MDACC,NA,NA
GSM615199,M158,GSM615199,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M158",Homo sapiens,sample id: M158,source: MDACC,age_years: 38.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N2,clinical_ajcc_stage: IIIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 6.535,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615199/suppl/GSM615199_19893_AB01988706_17039.CEL.gz,22283,38,Rx Insensitive,IIIA,N2,T2,RD,0,6.535,P,P,N,P,Low,2,N,LumA,RD,RCB-II,P,RCB-II/III,M158,SET-Low,MDACC,NA,NA
GSM615200,M165,GSM615200,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M165",Homo sapiens,sample id: M165,source: MDACC,age_years: 49.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 1,drfs_even_time_years: 3.452,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615200/suppl/GSM615200_19893_AB01860313_17041.CEL.gz,22283,49,Rx Sensitive,IIA,N1,T2,RD,1,3.452,P,P,N,P,High,3,N,LumB,RD,RCB-II,N,RCB-0/I,M165,SET-Low,MDACC,NA,NA
GSM615201,M177,GSM615201,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M177",Homo sapiens,sample id: M177,source: MDACC,age_years: 41.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T3,clinical_nodal_status: N0,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 6.111,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615201/suppl/GSM615201_19893_AB01943851_17042.CEL.gz,22283,41,Rx Sensitive,IIB,N0,T3,RD,0,6.111,P,P,N,P,High,3,N,LumB,pCR,RCB-0/I,N,RCB-0/I,M177,SET-Low,MDACC,NA,NA
GSM615202,M180,GSM615202,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M180",Homo sapiens,sample id: M180,source: MDACC,age_years: 42.0,er_status_ihc: N,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 6.453,esr1_status: P,erbb2_status: N,set_class: SET-High,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615202/suppl/GSM615202_19893_AB01983865_17043.CEL.gz,22283,42,Rx Sensitive,IIB,N1,T2,RD,0,6.453,N,N,N,P,High,3,N,Basal,pCR,RCB-0/I,P,RCB-0/I,M180,SET-High,MDACC,NA,NA
GSM615203,M181,GSM615203,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M181",Homo sapiens,sample id: M181,source: MDACC,age_years: 73.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T3,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 6.505,esr1_status: P,erbb2_status: P,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615203/suppl/GSM615203_20979_AB01988749_16984.CEL.gz,22283,73,Rx Insensitive,IIIA,N1,T3,RD,0,6.505,P,P,P,P,Low,2,N,LumA,RD,RCB-II,P,RCB-0/I,M181,SET-Low,MDACC,NA,NA
GSM615204,M182,GSM615204,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M182",Homo sapiens,sample id: M182,source: MDACC,age_years: 46.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T1,clinical_nodal_status: N0,clinical_ajcc_stage: I,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 6.311,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615204/suppl/GSM615204_20979_AB01913192_16985.CEL.gz,22283,46,Rx Insensitive,I,N0,T1,RD,0,6.311,P,P,N,P,Low,2,N,LumA,RD,RCB-II,P,RCB-II/III,M182,SET-Low,MDACC,NA,NA
GSM615205,M188,GSM615205,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M188",Homo sapiens,sample id: M188,source: MDACC,age_years: 68.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 6.059,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615205/suppl/GSM615205_19893_AB01988665_17044.CEL.gz,22283,68,Rx Insensitive,IIB,N1,T2,RD,0,6.059,P,P,N,P,High,2,N,LumB,RD,RCB-III,N,RCB-II/III,M188,SET-Low,MDACC,NA,NA
GSM615206,M189,GSM615206,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M189",Homo sapiens,sample id: M189,source: MDACC,age_years: 47.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T3,clinical_nodal_status: N0,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 5.829,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615206/suppl/GSM615206_20979_AB01988666_16986.CEL.gz,22283,47,Rx Sensitive,IIB,N0,T3,RD,0,5.829,P,P,N,P,High,3,N,LumB,RD,RCB-0/I,P,RCB-0/I,M189,SET-Low,MDACC,NA,NA
GSM615207,M195,GSM615207,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M195",Homo sapiens,sample id: M195,source: MDACC,age_years: 42.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 5.793,esr1_status: P,erbb2_status: N,set_class: SET-Int,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615207/suppl/GSM615207_FL824-195.CEL.gz,22283,42,Rx Sensitive,IIA,N0,T2,RD,0,5.793,P,P,N,P,Low,2,N,LumA,RD,RCB-II,P,RCB-II/III,M195,SET-Int,MDACC,NA,NA
GSM615208,M196,GSM615208,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M196",Homo sapiens,sample id: M196,source: MDACC,age_years: 69.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 5.870,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615208/suppl/GSM615208_19893_AB01778504_17045.CEL.gz,22283,69,Rx Insensitive,IIB,N1,T2,RD,0,5.87,P,P,N,P,Low,2,N,LumA,RD,RCB-III,P,RCB-II/III,M196,SET-Low,MDACC,NA,NA
GSM615209,M199,GSM615209,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M199",Homo sapiens,sample id: M199,source: MDACC,age_years: 56.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N3,clinical_ajcc_stage: IIIC,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 1,drfs_even_time_years: 2.133,esr1_status: N,erbb2_status: P,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615209/suppl/GSM615209_19893_AB01988711_17032.CEL.gz,22283,56,Rx Insensitive,IIIC,N3,T2,pCR,1,2.133,N,N,P,N,High,3,N,Basal,pCR,RCB-0/I,N,RCB-0/I,M199,SET-Low,MDACC,NA,NA
GSM615210,M201,GSM615210,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M201",Homo sapiens,sample id: M201,source: MDACC,age_years: 75.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 5.892,esr1_status: P,erbb2_status: P,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615210/suppl/GSM615210_19893_AB01988641_17024.CEL.gz,22283,75,Rx Insensitive,IIB,N1,T2,RD,0,5.892,P,P,P,P,Low,2,N,LumA,RD,RCB-II,N,RCB-II/III,M201,SET-Low,MDACC,NA,NA
GSM615211,M205,GSM615211,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M205",Homo sapiens,sample id: M205,source: MDACC,age_years: 35.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 5.142,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615211/suppl/GSM615211_20558_AB01724707_17204.CEL.gz,22283,35,Rx Sensitive,IIB,N1,T2,pCR,0,5.142,N,N,N,N,High,3,N,Basal,pCR,RCB-0/I,N,RCB-0/I,M205,SET-Low,MDACC,NA,NA
GSM615212,M206,GSM615212,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M206",Homo sapiens,sample id: M206,source: MDACC,age_years: 48.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.684,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615212/suppl/GSM615212_19893_AB01988742_17046.CEL.gz,22283,48,Rx Sensitive,IIA,N0,T2,pCR,0,4.684,N,N,N,N,High,3,N,Basal,pCR,RCB-0/I,N,RCB-0/I,M206,SET-Low,MDACC,NA,NA
GSM615213,M211,GSM615213,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M211",Homo sapiens,sample id: M211,source: MDACC,age_years: 53.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T3,clinical_nodal_status: N2,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.624,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615213/suppl/GSM615213_19893_AB01988743_17025.CEL.gz,22283,53,Rx Sensitive,IIIA,N2,T3,pCR,0,4.624,N,N,N,N,High,3,N,Basal,pCR,RCB-0/I,N,RCB-0/I,M211,SET-Low,MDACC,NA,NA
GSM615214,M214,GSM615214,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M214",Homo sapiens,sample id: M214,source: MDACC,age_years: 54.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 5.536,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615214/suppl/GSM615214_19893_AB01779182_17047.CEL.gz,22283,54,Rx Insensitive,IIB,N1,T2,RD,0,5.536,P,P,N,P,Low,2,N,LumA,RD,RCB-III,N,RCB-II/III,M214,SET-Low,MDACC,NA,NA
GSM615215,M215,GSM615215,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M215",Homo sapiens,sample id: M215,source: MDACC,age_years: 44.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 5.251,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Her2,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615215/suppl/GSM615215_19893_AB01988712_17033.CEL.gz,22283,44,Rx Sensitive,IIB,N1,T2,pCR,0,5.251,N,N,N,N,High,3,N,Her2,pCR,RCB-0/I,N,RCB-0/I,M215,SET-Low,MDACC,NA,NA
GSM615216,M216,GSM615216,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M216",Homo sapiens,sample id: M216,source: MDACC,age_years: 58.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 1,drfs_even_time_years: 2.669,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615216/suppl/GSM615216_19893_AB02014530_17059.CEL.gz,22283,58,Rx Sensitive,IIB,N1,T2,RD,1,2.669,P,P,N,P,High,2,N,LumB,RD,RCB-II,P,RCB-0/I,M216,SET-Low,MDACC,NA,NA
GSM615217,M217,GSM615217,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M217",Homo sapiens,sample id: M217,source: MDACC,age_years: 52.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 5.645,esr1_status: P,erbb2_status: N,set_class: SET-High,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615217/suppl/GSM615217_19893_AB01988746_17026.CEL.gz,22283,52,Rx Sensitive,IIA,N0,T2,RD,0,5.645,P,P,N,P,Low,2,N,LumA,RD,RCB-II,P,RCB-0/I,M217,SET-High,MDACC,NA,NA
GSM615218,M219,GSM615218,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M219",Homo sapiens,sample id: M219,source: MDACC,age_years: 56.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T4,clinical_nodal_status: N3,clinical_ajcc_stage: IIIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 1,drfs_even_time_years: 0.575,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615218/suppl/GSM615218_FL486-219.CEL.gz,22283,56,Rx Insensitive,IIIB,N3,T4,pCR,1,0.575,N,N,N,N,High,3,N,Basal,RD,RCB-III,N,RCB-II/III,M219,SET-Low,MDACC,NA,NA
GSM615219,M220,GSM615219,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M220",Homo sapiens,sample id: M220,source: MDACC,age_years: 38.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T4,clinical_nodal_status: N1,clinical_ajcc_stage: IIIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 0.482,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615219/suppl/GSM615219_19893_AB01913300_16991.CEL.gz,22283,38,Rx Sensitive,IIIB,N1,T4,RD,0,0.482,P,P,N,P,High,3,N,Basal,RD,RCB-0/I,N,RCB-0/I,M220,SET-Low,MDACC,NA,NA
GSM615220,M226,GSM615220,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M226",Homo sapiens,sample id: M226,source: MDACC,age_years: 31.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T4,clinical_nodal_status: N2,clinical_ajcc_stage: IIIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.966,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Normal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615220/suppl/GSM615220_19893_AB01988709_17027.CEL.gz,22283,31,Rx Sensitive,IIIB,N2,T4,RD,0,4.966,P,P,N,P,High,3,N,Normal,RD,RCB-0/I,P,RCB-0/I,M226,SET-Low,MDACC,NA,NA
GSM615221,M227,GSM615221,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M227",Homo sapiens,sample id: M227,source: MDACC,age_years: 38.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T4,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 1,drfs_even_time_years: 3.362,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615221/suppl/GSM615221_19893_AB01988136_17034.CEL.gz,22283,38,Rx Sensitive,IIB,N1,T4,RD,1,3.362,P,P,N,P,High,3,N,LumA,RD,RCB-II,P,RCB-0/I,M227,SET-Low,MDACC,NA,NA
GSM615222,M228,GSM615222,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M228",Homo sapiens,sample id: M228,source: MDACC,age_years: 48.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T4,clinical_nodal_status: N1,clinical_ajcc_stage: IIIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 1,drfs_even_time_years: 1.536,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615222/suppl/GSM615222_19893_AB01923090_16992.CEL.gz,22283,48,Rx Insensitive,IIIB,N1,T4,RD,1,1.536,P,P,N,P,Low,2,N,LumA,RD,RCB-II,N,RCB-0/I,M228,SET-Low,MDACC,NA,NA
GSM615223,M229,GSM615223,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M229",Homo sapiens,sample id: M229,source: MDACC,age_years: 57.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T3,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 1,drfs_even_time_years: 0.624,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615223/suppl/GSM615223_FL795-229.CEL.gz,22283,57,Rx Insensitive,IIIA,N1,T3,pCR,1,0.624,N,N,N,N,High,3,N,Basal,RD,RCB-III,N,RCB-II/III,M229,SET-Low,MDACC,NA,NA
GSM615224,M231,GSM615224,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M231",Homo sapiens,sample id: M231,source: MDACC,age_years: 52.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.597,esr1_status: P,erbb2_status: P,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615224/suppl/GSM615224_23678_AB01562130_24648.CEL.gz,22283,52,Rx Insensitive,IIA,N0,T2,RD,0,4.597,P,P,P,P,Low,2,N,LumA,RD,RCB-III,P,RCB-II/III,M231,SET-Low,MDACC,NA,NA
GSM615225,M233,GSM615225,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M233",Homo sapiens,sample id: M233,source: MDACC,age_years: 60.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T4,clinical_nodal_status: N3,clinical_ajcc_stage: IIIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.329,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615225/suppl/GSM615225_24817_AB02263389_26164.CEL.gz,22283,60,Rx Insensitive,IIIB,N3,T4,pCR,0,4.329,N,N,N,N,High,3,N,Basal,RD,RCB-III,N,RCB-II/III,M233,SET-Low,MDACC,NA,NA
GSM615226,M234,GSM615226,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M234",Homo sapiens,sample id: M234,source: MDACC,age_years: 58.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T3,clinical_nodal_status: N0,clinical_ajcc_stage: IIB,grade: 1,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.378,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: Normal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615226/suppl/GSM615226_24817_AB02261485_26161.CEL.gz,22283,58,Rx Sensitive,IIB,N0,T3,RD,0,4.378,P,P,N,N,Low,1,N,Normal,RD,RCB-0/I,N,RCB-0/I,M234,SET-Low,MDACC,NA,NA
GSM615227,M236,GSM615227,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M236",Homo sapiens,sample id: M236,source: MDACC,age_years: 52.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 5.183,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615227/suppl/GSM615227_23678_AB01233040_24639.CEL.gz,22283,52,Rx Sensitive,IIB,N1,T2,RD,0,5.183,P,P,N,P,High,2,N,LumB,RD,RCB-0/I,P,RCB-0/I,M236,SET-Low,MDACC,NA,NA
GSM615228,M246,GSM615228,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M246",Homo sapiens,sample id: M246,source: MDACC,age_years: 42.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T1,clinical_nodal_status: N1,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.580,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615228/suppl/GSM615228_23678_AB01299779_24642.CEL.gz,22283,42,Rx Insensitive,IIA,N1,T1,RD,0,4.58,P,P,N,P,Low,3,N,LumA,RD,RCB-III,N,RCB-0/I,M246,SET-Low,MDACC,NA,NA
GSM615229,M255,GSM615229,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M255",Homo sapiens,sample id: M255,source: MDACC,age_years: 48.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T4,clinical_nodal_status: N3,clinical_ajcc_stage: IIIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.890,esr1_status: N,erbb2_status: N,set_class: SET-Int,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: Normal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615229/suppl/GSM615229_24817_AB02262603_26162.CEL.gz,22283,48,Rx Sensitive,IIIB,N3,T4,RD,0,4.89,N,N,N,N,Low,2,N,Normal,RD,RCB-II,N,RCB-II/III,M255,SET-Int,MDACC,NA,NA
GSM615230,M259,GSM615230,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M259",Homo sapiens,sample id: M259,source: MDACC,age_years: 39.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.008,esr1_status: P,erbb2_status: P,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Her2,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615230/suppl/GSM615230_24817_AB02260707_26166.CEL.gz,22283,39,Rx Sensitive,IIA,N0,T2,RD,0,4.008,P,P,P,P,High,3,N,Her2,RD,RCB-0/I,P,RCB-0/I,M259,SET-Low,MDACC,NA,NA
GSM615231,M260,GSM615231,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M260",Homo sapiens,sample id: M260,source: MDACC,age_years: 49.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T3,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.528,esr1_status: P,erbb2_status: N,set_class: SET-Int,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615231/suppl/GSM615231_24817_AB02261512_26160.CEL.gz,22283,49,Rx Sensitive,IIIA,N1,T3,RD,0,4.528,P,P,N,P,Low,2,N,LumA,RD,RCB-III,P,RCB-0/I,M260,SET-Int,MDACC,NA,NA
GSM615232,M261,GSM615232,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M261",Homo sapiens,sample id: M261,source: MDACC,age_years: 56.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.888,esr1_status: P,erbb2_status: N,set_class: SET-Int,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615232/suppl/GSM615232_24817_AB02263410_26165.CEL.gz,22283,56,Rx Sensitive,IIA,N0,T2,RD,0,3.888,P,P,N,P,Low,2,N,LumA,RD,RCB-II,P,RCB-II/III,M261,SET-Int,MDACC,NA,NA
GSM615233,M263,GSM615233,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M263",Homo sapiens,sample id: M263,source: MDACC,age_years: 72.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 1,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 1,drfs_even_time_years: 0.791,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: Normal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615233/suppl/GSM615233_FL644-263.CEL.gz,22283,72,Rx Insensitive,IIB,N1,T2,RD,1,0.791,P,P,N,P,Low,1,N,Normal,RD,RCB-III,P,RCB-II/III,M263,SET-Low,MDACC,NA,NA
GSM615234,M266,GSM615234,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M266",Homo sapiens,sample id: M266,source: MDACC,age_years: 45.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N2,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.348,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Normal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615234/suppl/GSM615234_23678_AB01562113_24644.CEL.gz,22283,45,Rx Sensitive,IIIA,N2,T2,RD,0,4.348,P,P,N,P,High,3,N,Normal,RD,RCB-II,N,RCB-0/I,M266,SET-Low,MDACC,NA,NA
GSM615235,M270,GSM615235,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M270",Homo sapiens,sample id: M270,source: MDACC,age_years: 67.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T4,clinical_nodal_status: N0,clinical_ajcc_stage: IIIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.887,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615235/suppl/GSM615235_23678_AB01562218_24640.CEL.gz,22283,67,Rx Sensitive,IIIB,N0,T4,RD,0,4.887,P,P,N,P,High,3,N,LumB,RD,RCB-0/I,N,RCB-0/I,M270,SET-Low,MDACC,NA,NA
GSM615236,M280,GSM615236,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M280",Homo sapiens,sample id: M280,source: MDACC,age_years: 71.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N3,clinical_ajcc_stage: IIIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 1,drfs_even_time_years: 2.877,esr1_status: P,erbb2_status: P,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615236/suppl/GSM615236_23678_AB01542230_24645.CEL.gz,22283,71,Rx Insensitive,IIIB,N3,T2,RD,1,2.877,P,P,P,P,High,3,N,LumA,RD,RCB-II,P,RCB-0/I,M280,SET-Low,MDACC,NA,NA
GSM615237,M281,GSM615237,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M281",Homo sapiens,sample id: M281,source: MDACC,age_years: 45.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.575,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615237/suppl/GSM615237_FL747-281.CEL.gz,22283,45,Rx Insensitive,IIA,N0,T2,RD,0,4.575,P,P,N,P,Low,2,N,LumA,RD,RCB-II,P,RCB-II/III,M281,SET-Low,MDACC,NA,NA
GSM615238,M282,GSM615238,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M282",Homo sapiens,sample id: M282,source: MDACC,age_years: 44.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.233,esr1_status: P,erbb2_status: P,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615238/suppl/GSM615238_24817_AB02263400_26163.CEL.gz,22283,44,Rx Insensitive,IIB,N1,T2,RD,0,4.233,P,P,P,P,High,2,N,LumB,RD,RCB-II,N,RCB-II/III,M282,SET-Low,MDACC,NA,NA
GSM615239,M283,GSM615239,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M283",Homo sapiens,sample id: M283,source: MDACC,age_years: 46.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T4,clinical_nodal_status: N1,clinical_ajcc_stage: IIIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.110,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615239/suppl/GSM615239_FL826-283.CEL.gz,22283,46,Rx Insensitive,IIIB,N1,T4,RD,0,4.11,P,P,N,P,Low,3,N,LumA,RD,RCB-II,N,RCB-II/III,M283,SET-Low,MDACC,NA,NA
GSM615240,M295,GSM615240,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M295",Homo sapiens,sample id: M295,source: MDACC,age_years: 48.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.803,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615240/suppl/GSM615240_24817_AB02263399_26158.CEL.gz,22283,48,Rx Insensitive,IIB,N1,T2,pCR,0,3.803,N,N,N,N,High,3,N,Basal,pCR,RCB-0/I,N,RCB-0/I,M295,SET-Low,MDACC,NA,NA
GSM615241,M297,GSM615241,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M297",Homo sapiens,sample id: M297,source: MDACC,age_years: 63.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T4,clinical_nodal_status: N2,clinical_ajcc_stage: IIIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 1,drfs_even_time_years: 0.052,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615241/suppl/GSM615241_24817_AB02263395_26170.CEL.gz,22283,63,Rx Insensitive,IIIB,N2,T4,RD,1,0.052,P,P,N,P,Low,2,N,LumA,RD,RCB-III,N,RCB-0/I,M297,SET-Low,MDACC,NA,NA
GSM615242,M301,GSM615242,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M301",Homo sapiens,sample id: M301,source: MDACC,age_years: 46.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T3,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.485,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615242/suppl/GSM615242_24817_AB02260970_26172.CEL.gz,22283,46,Rx Sensitive,IIIA,N1,T3,pCR,0,4.485,N,N,N,N,High,3,N,Basal,pCR,RCB-0/I,N,RCB-0/I,M301,SET-Low,MDACC,NA,NA
GSM615243,M304,GSM615243,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M304",Homo sapiens,sample id: M304,source: MDACC,age_years: 46.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.298,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615243/suppl/GSM615243_24817_AB02263375_26169.CEL.gz,22283,46,Rx Sensitive,IIA,N0,T2,RD,0,4.298,P,P,N,P,High,2,N,LumA,RD,RCB-0/I,P,RCB-0/I,M304,SET-Low,MDACC,NA,NA
GSM615244,M310,GSM615244,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M310",Homo sapiens,sample id: M310,source: MDACC,age_years: 51.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T1,clinical_nodal_status: N1,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.063,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615244/suppl/GSM615244_24817_AB02261505_26168.CEL.gz,22283,51,Rx Sensitive,IIA,N1,T1,pCR,0,4.063,N,N,N,N,Low,3,N,Basal,RD,RCB-0/I,N,RCB-0/I,M310,SET-Low,MDACC,NA,NA
GSM615245,M315,GSM615245,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M315",Homo sapiens,sample id: M315,source: MDACC,age_years: 36.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 1,drfs_even_time_years: 2.256,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615245/suppl/GSM615245_29539_AB01723032_35694.CEL.gz,22283,36,Rx Insensitive,IIB,N1,T2,RD,1,2.256,P,P,N,P,Low,2,N,LumA,RD,RCB-III,P,RCB-II/III,M315,SET-Low,MDACC,NA,NA
GSM615246,M319,GSM615246,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M319",Homo sapiens,sample id: M319,source: MDACC,age_years: 26.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.542,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615246/suppl/GSM615246_FL645-319.CEL.gz,22283,26,Rx Sensitive,IIA,N0,T2,RD,0,4.542,P,P,N,P,Low,2,N,LumA,RD,RCB-0/I,P,RCB-0/I,M319,SET-Low,MDACC,NA,NA
GSM615247,M323,GSM615247,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M323",Homo sapiens,sample id: M323,source: MDACC,age_years: 40.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T1,clinical_nodal_status: N1,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.027,esr1_status: P,erbb2_status: N,set_class: SET-High,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615247/suppl/GSM615247_29539_AB01723009_35679.CEL.gz,22283,40,Rx Sensitive,IIA,N1,T1,RD,0,4.027,P,P,N,P,Low,3,N,LumA,RD,RCB-III,P,RCB-II/III,M323,SET-High,MDACC,NA,NA
GSM615248,M332,GSM615248,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M332",Homo sapiens,sample id: M332,source: MDACC,age_years: 42.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T3,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.214,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615248/suppl/GSM615248_28998_AB02090243_34890.CEL.gz,22283,42,Rx Insensitive,IIIA,N1,T3,pCR,0,3.214,P,P,N,N,High,3,N,Basal,RD,RCB-II,P,RCB-II/III,M332,SET-Low,MDACC,NA,NA
GSM615249,M333,GSM615249,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M333",Homo sapiens,sample id: M333,source: MDACC,age_years: 67.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 1,drfs_even_time_years: 3.756,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Her2,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615249/suppl/GSM615249_28998_AB02077268_34965.CEL.gz,22283,67,Rx Insensitive,IIB,N1,T2,RD,1,3.756,P,P,N,P,High,3,N,Her2,RD,RCB-II,P,RCB-II/III,M333,SET-Low,MDACC,NA,NA
GSM615250,M334,GSM615250,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M334",Homo sapiens,sample id: M334,source: MDACC,age_years: 63.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T1,clinical_nodal_status: N1,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.745,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Her2,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615250/suppl/GSM615250_29539_AB01833931_35690.CEL.gz,22283,63,Rx Insensitive,IIA,N1,T1,pCR,0,3.745,N,N,N,N,High,3,N,Her2,RD,RCB-II,N,RCB-II/III,M334,SET-Low,MDACC,NA,NA
GSM615251,M339,GSM615251,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M339",Homo sapiens,sample id: M339,source: MDACC,age_years: 44.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.754,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615251/suppl/GSM615251_FL494-339.CEL.gz,22283,44,Rx Insensitive,IIB,N1,T2,pCR,0,3.754,N,N,N,N,High,3,N,Basal,RD,RCB-II,N,RCB-II/III,M339,SET-Low,MDACC,NA,NA
GSM615252,M340,GSM615252,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M340",Homo sapiens,sample id: M340,source: MDACC,age_years: 54.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T4,clinical_nodal_status: N1,clinical_ajcc_stage: IIIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.194,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615252/suppl/GSM615252_FL489-340.CEL.gz,22283,54,Rx Insensitive,IIIB,N1,T4,RD,0,4.194,P,P,N,P,Low,2,N,LumA,RD,RCB-II,N,RCB-II/III,M340,SET-Low,MDACC,NA,NA
GSM615253,M341,GSM615253,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M341",Homo sapiens,sample id: M341,source: MDACC,age_years: 41.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.057,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615253/suppl/GSM615253_29539_AB01833841_35702.CEL.gz,22283,41,Rx Insensitive,IIB,N1,T2,RD,0,4.057,P,P,N,P,High,2,N,LumB,RD,RCB-III,N,RCB-II/III,M341,SET-Low,MDACC,NA,NA
GSM615254,M343,GSM615254,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M343",Homo sapiens,sample id: M343,source: MDACC,age_years: 49.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N3,clinical_ajcc_stage: IIIC,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.153,esr1_status: P,erbb2_status: N,set_class: SET-Int,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615254/suppl/GSM615254_29539_AB01833542_35683.CEL.gz,22283,49,Rx Sensitive,IIIC,N3,T2,RD,0,4.153,P,P,N,P,Low,2,N,LumA,RD,RCB-II,P,RCB-0/I,M343,SET-Int,MDACC,NA,NA
GSM615255,M345,GSM615255,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M345",Homo sapiens,sample id: M345,source: MDACC,age_years: 39.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T4,clinical_nodal_status: N2,clinical_ajcc_stage: IIIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 1,drfs_even_time_years: 0.854,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615255/suppl/GSM615255_FL490-345.CEL.gz,22283,39,Rx Insensitive,IIIB,N2,T4,pCR,1,0.854,N,N,N,N,High,3,N,Basal,RD,RCB-III,N,RCB-II/III,M345,SET-Low,MDACC,NA,NA
GSM615256,M353,GSM615256,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M353",Homo sapiens,sample id: M353,source: MDACC,age_years: 51.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T3,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.647,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615256/suppl/GSM615256_29539_AB01723041_35689.CEL.gz,22283,51,Rx Sensitive,IIIA,N1,T3,RD,0,3.647,P,P,N,P,High,3,N,LumB,pCR,RCB-0/I,N,RCB-0/I,M353,SET-Low,MDACC,NA,NA
GSM615257,M355,GSM615257,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M355",Homo sapiens,sample id: M355,source: MDACC,age_years: 59.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T3,clinical_nodal_status: N2,clinical_ajcc_stage: IIIA,grade: 1,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.540,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: Normal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615257/suppl/GSM615257_FL495-355.CEL.gz,22283,59,Rx Insensitive,IIIA,N2,T3,RD,0,3.54,P,P,N,P,Low,1,N,Normal,RD,RCB-II,P,RCB-II/III,M355,SET-Low,MDACC,NA,NA
GSM615258,M356,GSM615258,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M356",Homo sapiens,sample id: M356,source: MDACC,age_years: 55.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.469,esr1_status: P,erbb2_status: N,set_class: SET-Int,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: Normal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615258/suppl/GSM615258_29539_AB01723056_35693.CEL.gz,22283,55,Rx Sensitive,IIB,N1,T2,RD,0,3.469,P,P,N,P,Low,2,N,Normal,RD,RCB-II,P,RCB-II/III,M356,SET-Int,MDACC,NA,NA
GSM615259,M357,GSM615259,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M357",Homo sapiens,sample id: M357,source: MDACC,age_years: 62.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.775,esr1_status: P,erbb2_status: N,set_class: SET-High,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615259/suppl/GSM615259_29539_AB01833732_35677.CEL.gz,22283,62,Rx Sensitive,IIA,N0,T2,RD,0,3.775,P,P,N,P,High,2,N,LumA,RD,RCB-III,P,RCB-II/III,M357,SET-High,MDACC,NA,NA
GSM615260,M360,GSM615260,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M360",Homo sapiens,sample id: M360,source: MDACC,age_years: 56.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T0,clinical_nodal_status: N3,clinical_ajcc_stage: IIIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 1,drfs_even_time_years: 1.752,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615260/suppl/GSM615260_FL745-360.CEL.gz,22283,56,Rx Insensitive,IIIB,N3,T0,pCR,1,1.752,P,P,N,P,High,3,N,Basal,RD,RCB-II,P,RCB-0/I,M360,SET-Low,MDACC,NA,NA
GSM615261,M363,GSM615261,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M363",Homo sapiens,sample id: M363,source: MDACC,age_years: 58.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T3,clinical_nodal_status: N0,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.973,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615261/suppl/GSM615261_FL746-363.CEL.gz,22283,58,Rx Sensitive,IIB,N0,T3,RD,0,2.973,P,P,N,P,High,3,N,LumA,RD,RCB-II,P,RCB-0/I,M363,SET-Low,MDACC,NA,NA
GSM615262,M365,GSM615262,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M365",Homo sapiens,sample id: M365,source: MDACC,age_years: 42.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 1,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.783,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615262/suppl/GSM615262_U133A_80_FL_080_FL256-365_04_18_06.CEL.gz,22283,42,Rx Insensitive,IIB,N1,T2,RD,0,4.783,P,P,N,P,Low,1,N,LumA,RD,RCB-II,P,RCB-II/III,M365,SET-Low,MDACC,NA,NA
GSM615263,M367,GSM615263,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M367",Homo sapiens,sample id: M367,source: MDACC,age_years: 61.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T4,clinical_nodal_status: N1,clinical_ajcc_stage: IIIB,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.992,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Normal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615263/suppl/GSM615263_FL748-367.CEL.gz,22283,61,Rx Sensitive,IIIB,N1,T4,RD,0,2.992,N,N,N,N,High,3,N,Normal,pCR,RCB-0/I,N,RCB-0/I,M367,SET-Low,MDACC,NA,NA
GSM615264,M373,GSM615264,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M373",Homo sapiens,sample id: M373,source: MDACC,age_years: 45.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.732,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615264/suppl/GSM615264_29539_AB01833716_35658.CEL.gz,22283,45,Rx Insensitive,IIA,N0,T2,pCR,0,3.732,N,N,N,N,High,3,N,Basal,pCR,RCB-0/I,N,RCB-0/I,M373,SET-Low,MDACC,NA,NA
GSM615265,M375,GSM615265,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M375",Homo sapiens,sample id: M375,source: MDACC,age_years: 63.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.685,esr1_status: P,erbb2_status: N,set_class: SET-Int,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: Normal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615265/suppl/GSM615265_28998_AB02090183_34891.CEL.gz,22283,63,Rx Sensitive,IIB,N1,T2,RD,0,3.685,N,N,N,P,Low,3,N,Normal,RD,RCB-II,N,RCB-II/III,M375,SET-Int,MDACC,NA,NA
GSM615266,M384,GSM615266,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M384",Homo sapiens,sample id: M384,source: MDACC,age_years: 60.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T3,clinical_nodal_status: N0,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.518,esr1_status: P,erbb2_status: N,set_class: SET-Int,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615266/suppl/GSM615266_29539_AB01833747_35697.CEL.gz,22283,60,Rx Sensitive,IIB,N0,T3,RD,0,3.518,P,P,N,P,Low,2,N,LumA,RD,RCB-II,P,RCB-II/III,M384,SET-Int,MDACC,NA,NA
GSM615267,M386,GSM615267,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M386",Homo sapiens,sample id: M386,source: MDACC,age_years: 42.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 1,drfs_even_time_years: 3.277,esr1_status: P,erbb2_status: P,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615267/suppl/GSM615267_28998_AB02086509_34967.CEL.gz,22283,42,Rx Sensitive,IIA,N0,T2,RD,1,3.277,P,P,P,P,High,2,N,LumB,RD,RCB-II,N,RCB-0/I,M386,SET-Low,MDACC,NA,NA
GSM615268,M396,GSM615268,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M396",Homo sapiens,sample id: M396,source: MDACC,age_years: 35.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N2,clinical_ajcc_stage: IIIA,grade: 1,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.504,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615268/suppl/GSM615268_FL556-396.CEL.gz,22283,35,Rx Insensitive,IIIA,N2,T2,RD,0,3.504,P,P,N,P,Low,1,N,LumA,RD,RCB-III,N,RCB-II/III,M396,SET-Low,MDACC,NA,NA
GSM615269,M399,GSM615269,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M399",Homo sapiens,sample id: M399,source: MDACC,age_years: 40.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.283,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615269/suppl/GSM615269_29539_AB01723039_35684.CEL.gz,22283,40,Rx Insensitive,IIB,N1,T2,RD,0,3.283,P,P,N,P,Low,2,N,LumB,RD,RCB-II,P,RCB-II/III,M399,SET-Low,MDACC,NA,NA
GSM615270,M402,GSM615270,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M402",Homo sapiens,sample id: M402,source: MDACC,age_years: 38.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T4,clinical_nodal_status: N2,clinical_ajcc_stage: IIIB,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.715,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615270/suppl/GSM615270_28998_AB02086473_34898.CEL.gz,22283,38,Rx Insensitive,IIIB,N2,T4,pCR,0,3.715,N,N,N,N,High,3,N,Basal,pCR,RCB-0/I,N,RCB-0/I,M402,SET-Low,MDACC,NA,NA
GSM615271,M411,GSM615271,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M411",Homo sapiens,sample id: M411,source: MDACC,age_years: 44.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 1,drfs_even_time_years: 1.881,esr1_status: N,erbb2_status: P,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Her2,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615271/suppl/GSM615271_FL498-411.CEL.gz,22283,44,Rx Sensitive,IIB,N1,T2,pCR,1,1.881,P,P,P,N,High,2,N,Her2,RD,RCB-III,P,RCB-0/I,M411,SET-Low,MDACC,NA,NA
GSM615272,M417,GSM615272,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M417",Homo sapiens,sample id: M417,source: MDACC,age_years: 63.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.775,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumB,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615272/suppl/GSM615272_FL574-417.CEL.gz,22283,63,Rx Insensitive,IIB,N1,T2,pCR,0,3.775,P,P,N,P,Low,2,N,LumB,RD,RCB-II,P,RCB-II/III,M417,SET-Low,MDACC,NA,NA
GSM615273,M421,GSM615273,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M421",Homo sapiens,sample id: M421,source: MDACC,age_years: 48.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.281,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615273/suppl/GSM615273_29539_AB01833759_35699.CEL.gz,22283,48,Rx Insensitive,IIB,N1,T2,RD,0,2.281,P,P,N,P,High,2,N,LumA,RD,RCB-III,P,RCB-II/III,M421,SET-Low,MDACC,NA,NA
GSM615274,M423,GSM615274,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M423",Homo sapiens,sample id: M423,source: MDACC,age_years: 68.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T0,clinical_nodal_status: N3,clinical_ajcc_stage: IIIC,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 1,drfs_even_time_years: 0.794,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Her2,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615274/suppl/GSM615274_U133A_80_FL_082_FL258-423_04_18_06.CEL.gz,22283,68,Rx Insensitive,IIIC,N3,T0,pCR,1,0.794,P,P,N,N,High,2,N,Her2,RD,RCB-II,P,RCB-0/I,M423,SET-Low,MDACC,NA,NA
GSM615275,M425,GSM615275,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M425",Homo sapiens,sample id: M425,source: MDACC,age_years: 60.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T4,clinical_nodal_status: N1,clinical_ajcc_stage: IIIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 1,drfs_even_time_years: 2.396,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615275/suppl/GSM615275_FL749-425.CEL.gz,22283,60,Rx Insensitive,IIIB,N1,T4,pCR,1,2.396,N,N,N,N,High,2,N,Basal,RD,RCB-II,N,RCB-II/III,M425,SET-Low,MDACC,NA,NA
GSM615276,M430,GSM615276,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M430",Homo sapiens,sample id: M430,source: MDACC,age_years: 52.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T3,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.272,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615276/suppl/GSM615276_FL499-430.CEL.gz,22283,52,Rx Sensitive,IIIA,N1,T3,pCR,0,3.272,N,N,N,N,High,3,N,Basal,RD,RCB-0/I,N,RCB-0/I,M430,SET-Low,MDACC,NA,NA
GSM615277,M431,GSM615277,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M431",Homo sapiens,sample id: M431,source: MDACC,age_years: 50.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.587,esr1_status: P,erbb2_status: N,set_class: SET-High,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615277/suppl/GSM615277_FL557-431.CEL.gz,22283,50,Rx Sensitive,IIB,N1,T2,RD,0,3.587,P,P,N,P,Low,2,N,LumA,RD,RCB-II,P,RCB-II/III,M431,SET-High,MDACC,NA,NA
GSM615278,M433,GSM615278,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M433",Homo sapiens,sample id: M433,source: MDACC,age_years: 47.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.250,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615278/suppl/GSM615278_FL575-433.CEL.gz,22283,47,Rx Insensitive,IIA,N0,T2,RD,0,3.25,P,P,N,P,Low,3,N,LumA,RD,RCB-II,P,RCB-II/III,M433,SET-Low,MDACC,NA,NA
GSM615279,M434,GSM615279,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M434",Homo sapiens,sample id: M434,source: MDACC,age_years: 50.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 1,drfs_even_time_years: 2.188,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615279/suppl/GSM615279_29539_AB01833876_35613.CEL.gz,22283,50,Rx Insensitive,IIB,N1,T2,RD,1,2.188,P,P,N,P,High,2,N,LumB,RD,RCB-III,P,RCB-II/III,M434,SET-Low,MDACC,NA,NA
GSM615280,M442,GSM615280,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M442",Homo sapiens,sample id: M442,source: MDACC,age_years: 41.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T3,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.447,esr1_status: P,erbb2_status: P,set_class: SET-High,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Her2,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615280/suppl/GSM615280_29539_AB01723028_35692.CEL.gz,22283,41,Rx Sensitive,IIIA,N1,T3,RD,0,3.447,P,P,P,P,High,3,N,Her2,pCR,RCB-0/I,P,RCB-0/I,M442,SET-High,MDACC,NA,NA
GSM615281,M447,GSM615281,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M447",Homo sapiens,sample id: M447,source: MDACC,age_years: 44.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.489,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615281/suppl/GSM615281_29539_AB01723044_35687.CEL.gz,22283,44,Rx Sensitive,IIA,N0,T2,RD,0,2.489,P,P,N,P,High,2,N,LumB,RD,RCB-0/I,N,RCB-0/I,M447,SET-Low,MDACC,NA,NA
GSM615282,M463,GSM615282,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M463",Homo sapiens,sample id: M463,source: MDACC,age_years: 60.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T4,clinical_nodal_status: N1,clinical_ajcc_stage: IIIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.009,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Her2,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615282/suppl/GSM615282_29539_AB01833728_35659.CEL.gz,22283,60,Rx Sensitive,IIIB,N1,T4,RD,0,3.009,P,P,N,P,High,2,N,Her2,RD,RCB-II,N,RCB-0/I,M463,SET-Low,MDACC,NA,NA
GSM615283,M469,GSM615283,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M469",Homo sapiens,sample id: M469,source: MDACC,age_years: 57.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N3,clinical_ajcc_stage: IIIC,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.187,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615283/suppl/GSM615283_29539_AB01833832_35608.CEL.gz,22283,57,Rx Insensitive,IIIC,N3,T2,RD,0,3.187,P,P,N,P,High,2,N,LumA,RD,RCB-II,N,RCB-II/III,M469,SET-Low,MDACC,NA,NA
GSM615284,M485,GSM615284,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M485",Homo sapiens,sample id: M485,source: MDACC,age_years: 50.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T4,clinical_nodal_status: N2,clinical_ajcc_stage: IIIB,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.842,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615284/suppl/GSM615284_29539_AB01833699_35605.CEL.gz,22283,50,Rx Sensitive,IIIB,N2,T4,pCR,0,2.842,N,N,N,N,High,3,N,Basal,pCR,RCB-0/I,N,RCB-0/I,M485,SET-Low,MDACC,NA,NA
GSM615285,M486,GSM615285,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M486",Homo sapiens,sample id: M486,source: MDACC,age_years: 44.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.368,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615285/suppl/GSM615285_FL750-486.CEL.gz,22283,44,Rx Insensitive,IIA,N0,T2,RD,0,3.368,P,P,N,P,Low,3,N,LumA,RD,RCB-II,P,RCB-II/III,M486,SET-Low,MDACC,NA,NA
GSM615286,M497,GSM615286,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M497",Homo sapiens,sample id: M497,source: MDACC,age_years: 62.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N3,clinical_ajcc_stage: IIIC,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.159,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Her2,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615286/suppl/GSM615286_29539_AB01833749_35607.CEL.gz,22283,62,Rx Sensitive,IIIC,N3,T2,RD,0,3.159,P,P,N,N,High,2,N,Her2,RD,RCB-0/I,N,RCB-0/I,M497,SET-Low,MDACC,NA,NA
GSM615287,M502,GSM615287,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M502",Homo sapiens,sample id: M502,source: MDACC,age_years: 50.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 1,drfs_even_time_years: 1.717,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: Normal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615287/suppl/GSM615287_FL686-502.CEL.gz,22283,50,Rx Insensitive,IIA,N0,T2,RD,1,1.717,N,N,N,N,Low,2,N,Normal,RD,RCB-III,N,RCB-II/III,M502,SET-Low,MDACC,NA,NA
GSM615288,M503,GSM615288,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M503",Homo sapiens,sample id: M503,source: MDACC,age_years: 38.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T1,clinical_nodal_status: N0,clinical_ajcc_stage: I,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.604,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615288/suppl/GSM615288_29539_AB01833756_35615.CEL.gz,22283,38,Rx Insensitive,I,N0,T1,pCR,0,2.604,N,N,N,N,High,3,N,Basal,RD,RCB-0/I,N,RCB-0/I,M503,SET-Low,MDACC,NA,NA
GSM615289,M506,GSM615289,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M506",Homo sapiens,sample id: M506,source: MDACC,age_years: 46.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.028,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615289/suppl/GSM615289_29539_AB01833780_35612.CEL.gz,22283,46,Rx Sensitive,IIB,N1,T2,RD,0,3.028,P,P,N,P,High,2,N,LumB,RD,RCB-II,P,RCB-0/I,M506,SET-Low,MDACC,NA,NA
GSM615290,M507,GSM615290,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M507",Homo sapiens,sample id: M507,source: MDACC,age_years: 66.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.151,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615290/suppl/GSM615290_FL646-507.CEL.gz,22283,66,Rx Insensitive,IIA,N0,T2,pCR,0,3.151,P,P,N,N,High,2,N,Basal,RD,RCB-II,P,RCB-II/III,M507,SET-Low,MDACC,NA,NA
GSM615291,M513,GSM615291,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M513",Homo sapiens,sample id: M513,source: MDACC,age_years: 59.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 1,drfs_even_time_years: 0.709,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615291/suppl/GSM615291_FL491-513.CEL.gz,22283,59,Rx Sensitive,IIB,N1,T2,pCR,1,0.709,N,N,N,N,High,3,N,Basal,pCR,RCB-0/I,N,RCB-0/I,M513,SET-Low,MDACC,NA,NA
GSM615292,M523,GSM615292,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M523",Homo sapiens,sample id: M523,source: MDACC,age_years: 47.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.371,esr1_status: P,erbb2_status: N,set_class: SET-High,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615292/suppl/GSM615292_29539_AB01723031_35678.CEL.gz,22283,47,Rx Sensitive,IIB,N1,T2,RD,0,2.371,P,P,N,P,Low,2,N,LumA,RD,RCB-II,P,RCB-0/I,M523,SET-High,MDACC,NA,NA
GSM615293,M524,GSM615293,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M524",Homo sapiens,sample id: M524,source: MDACC,age_years: 31.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 1,drfs_even_time_years: 1.372,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615293/suppl/GSM615293_29539_AB01723040_35686.CEL.gz,22283,31,Rx Insensitive,IIA,N1,T2,pCR,1,1.372,N,N,N,N,High,3,N,Basal,pCR,RCB-0/I,N,RCB-0/I,M524,SET-Low,MDACC,NA,NA
GSM615294,M525,GSM615294,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M525",Homo sapiens,sample id: M525,source: MDACC,age_years: 45.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.047,esr1_status: P,erbb2_status: N,set_class: SET-Int,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Normal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615294/suppl/GSM615294_29539_AB01833821_35682.CEL.gz,22283,45,Rx Sensitive,IIA,N0,T2,RD,0,3.047,P,P,N,P,High,3,N,Normal,RD,RCB-II,N,RCB-II/III,M525,SET-Int,MDACC,NA,NA
GSM615295,M531,GSM615295,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M531",Homo sapiens,sample id: M531,source: MDACC,age_years: 53.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T4,clinical_nodal_status: N3,clinical_ajcc_stage: IIIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.856,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: Normal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615295/suppl/GSM615295_FL500-531.CEL.gz,22283,53,Rx Insensitive,IIIB,N3,T4,RD,0,1.856,N,N,N,P,Low,3,N,Normal,RD,RCB-II,N,RCB-0/I,M531,SET-Low,MDACC,NA,NA
GSM615296,M534,GSM615296,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M534",Homo sapiens,sample id: M534,source: MDACC,age_years: 46.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T4,clinical_nodal_status: N3,clinical_ajcc_stage: IIIC,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.105,esr1_status: P,erbb2_status: N,set_class: SET-Int,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615296/suppl/GSM615296_29539_AB01723043_35685.CEL.gz,22283,46,Rx Sensitive,IIIC,N3,T4,RD,0,2.105,P,P,N,P,High,2,N,LumA,RD,RCB-II,P,RCB-0/I,M534,SET-Int,MDACC,NA,NA
GSM615297,M545,GSM615297,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M545",Homo sapiens,sample id: M545,source: MDACC,age_years: 58.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 1,drfs_even_time_years: 2.341,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615297/suppl/GSM615297_FL501-545.CEL.gz,22283,58,Rx Insensitive,IIB,N1,T2,RD,1,2.341,N,N,N,P,High,3,N,Basal,RD,RCB-II,N,RCB-II/III,M545,SET-Low,MDACC,NA,NA
GSM615298,M549,GSM615298,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M549",Homo sapiens,sample id: M549,source: MDACC,age_years: 40.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.990,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615298/suppl/GSM615298_FL796-549.CEL.gz,22283,40,Rx Insensitive,IIB,N1,T2,RD,0,2.99,P,P,N,P,Low,2,N,LumA,RD,RCB-III,P,RCB-II/III,M549,SET-Low,MDACC,NA,NA
GSM615299,M556,GSM615299,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M556",Homo sapiens,sample id: M556,source: MDACC,age_years: 47.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T1,clinical_nodal_status: N1,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.667,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615299/suppl/GSM615299_FL457-556.CEL.gz,22283,47,Rx Insensitive,IIA,N1,T1,RD,0,2.667,P,P,N,P,Low,2,N,LumA,RD,RCB-II,P,RCB-0/I,M556,SET-Low,MDACC,NA,NA
GSM615300,M557,GSM615300,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M557",Homo sapiens,sample id: M557,source: MDACC,age_years: 57.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N3,clinical_ajcc_stage: IIIB,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.884,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615300/suppl/GSM615300_FL597-557.CEL.gz,22283,57,Rx Insensitive,IIIB,N3,T2,pCR,0,1.884,N,N,N,N,High,3,N,Basal,pCR,RCB-0/I,N,RCB-0/I,M557,SET-Low,MDACC,NA,NA
GSM615301,M558,GSM615301,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M558",Homo sapiens,sample id: M558,source: MDACC,age_years: 62.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T4,clinical_nodal_status: N3,clinical_ajcc_stage: IIIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 1,drfs_even_time_years: 2.552,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615301/suppl/GSM615301_FL752-558.CEL.gz,22283,62,Rx Insensitive,IIIB,N3,T4,pCR,1,2.552,N,N,N,N,High,3,N,Basal,RD,RCB-III,N,RCB-II/III,M558,SET-Low,MDACC,NA,NA
GSM615302,M559,GSM615302,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M559",Homo sapiens,sample id: M559,source: MDACC,age_years: 55.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.851,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Her2,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615302/suppl/GSM615302_FL598-559.CEL.gz,22283,55,Rx Insensitive,IIB,N1,T2,RD,0,1.851,P,P,N,P,High,2,N,Her2,RD,RCB-II,N,RCB-II/III,M559,SET-Low,MDACC,NA,NA
GSM615303,M564,GSM615303,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M564",Homo sapiens,sample id: M564,source: MDACC,age_years: 68.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T4,clinical_nodal_status: N2,clinical_ajcc_stage: IIIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.344,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615303/suppl/GSM615303_FL599-564.CEL.gz,22283,68,Rx Insensitive,IIIB,N2,T4,pCR,0,2.344,N,N,N,N,High,3,N,Basal,RD,RCB-III,N,RCB-II/III,M564,SET-Low,MDACC,NA,NA
GSM615304,M565,GSM615304,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M565",Homo sapiens,sample id: M565,source: MDACC,age_years: 57.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T1,clinical_nodal_status: N2,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.916,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615304/suppl/GSM615304_U133A_80_FL_083_FL259-565_04_20_06.CEL.gz,22283,57,Rx Insensitive,IIIA,N2,T1,RD,0,1.916,P,P,N,P,High,3,N,LumB,RD,RCB-II,P,RCB-II/III,M565,SET-Low,MDACC,NA,NA
GSM615305,M566,GSM615305,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M566",Homo sapiens,sample id: M566,source: MDACC,age_years: 39.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N3,clinical_ajcc_stage: IIIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 1,drfs_even_time_years: 2.648,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615305/suppl/GSM615305_FL600-566.CEL.gz,22283,39,Rx Insensitive,IIIB,N3,T2,RD,1,2.648,P,P,N,P,Low,2,N,LumA,RD,RCB-III,N,RCB-II/III,M566,SET-Low,MDACC,NA,NA
GSM615306,M569,GSM615306,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M569",Homo sapiens,sample id: M569,source: MDACC,age_years: 58.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T3,clinical_nodal_status: N2,clinical_ajcc_stage: IIIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 1,drfs_even_time_years: 1.818,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615306/suppl/GSM615306_U133A_80-FL-107_FL283-569_05_19_06.CEL.gz,22283,58,Rx Insensitive,IIIA,N2,T3,RD,1,1.818,P,P,N,P,High,2,N,LumA,RD,RCB-III,P,RCB-II/III,M569,SET-Low,MDACC,NA,NA
GSM615307,M571,GSM615307,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M571",Homo sapiens,sample id: M571,source: MDACC,age_years: 32.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.817,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615307/suppl/GSM615307_U133A_80-FL-206-FL370-571_08_25_06.CEL.gz,22283,32,Rx Sensitive,IIB,N1,T2,pCR,0,2.817,N,N,N,N,High,3,N,Basal,pCR,RCB-0/I,N,RCB-0/I,M571,SET-Low,MDACC,NA,NA
GSM615308,M577,GSM615308,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M577",Homo sapiens,sample id: M577,source: MDACC,age_years: 51.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.754,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615308/suppl/GSM615308_U133A_80-FL-111_FL287-577_05_22_06.CEL.gz,22283,51,Rx Insensitive,IIB,N1,T2,RD,0,2.754,P,P,N,P,High,3,N,LumB,RD,RCB-II,P,RCB-II/III,M577,SET-Low,MDACC,NA,NA
GSM615309,M578,GSM615309,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M578",Homo sapiens,sample id: M578,source: MDACC,age_years: 45.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T4,clinical_nodal_status: N1,clinical_ajcc_stage: IIIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 1,drfs_even_time_years: 1.845,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615309/suppl/GSM615309_FL502-578.CEL.gz,22283,45,Rx Insensitive,IIIB,N1,T4,RD,1,1.845,P,P,N,P,High,3,N,LumB,RD,RCB-III,P,RCB-II/III,M578,SET-Low,MDACC,NA,NA
GSM615310,M580,GSM615310,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M580",Homo sapiens,sample id: M580,source: MDACC,age_years: 64.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N2,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.338,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615310/suppl/GSM615310_U133A_80-FL-112_FL288-580_05_22_06.CEL.gz,22283,64,Rx Sensitive,IIIA,N2,T2,pCR,0,2.338,P,P,N,N,High,3,N,Basal,pCR,RCB-0/I,N,RCB-0/I,M580,SET-Low,MDACC,NA,NA
GSM615311,M581,GSM615311,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M581",Homo sapiens,sample id: M581,source: MDACC,age_years: 34.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T3,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.694,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615311/suppl/GSM615311_U133A_80-FL-113_FL289-581_05_22_06.CEL.gz,22283,34,Rx Insensitive,IIIA,N1,T3,RD,0,2.694,P,P,N,P,High,2,N,LumA,RD,RCB-II,P,RCB-II/III,M581,SET-Low,MDACC,NA,NA
GSM615312,M583,GSM615312,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M583",Homo sapiens,sample id: M583,source: MDACC,age_years: 51.0,er_status_ihc: N,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N3,clinical_ajcc_stage: IIIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 1,drfs_even_time_years: 1.706,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: Basal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615312/suppl/GSM615312_FL503-583.CEL.gz,22283,51,Rx Insensitive,IIIB,N3,T2,RD,1,1.706,N,N,N,N,Low,2,N,Basal,RD,RCB-III,P,RCB-II/III,M583,SET-Low,MDACC,NA,NA
GSM615313,M599,GSM615313,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M599",Homo sapiens,sample id: M599,source: MDACC,age_years: 50.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T1,clinical_nodal_status: N1,clinical_ajcc_stage: IIA,grade: 1,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.617,esr1_status: P,erbb2_status: N,set_class: SET-Int,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: Normal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615313/suppl/GSM615313_FL557-599.CEL.gz,22283,50,Rx Sensitive,IIA,N1,T1,RD,0,2.617,P,P,N,P,Low,1,N,Normal,RD,RCB-II,P,RCB-II/III,M599,SET-Int,MDACC,NA,NA
GSM615314,M601,GSM615314,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M601",Homo sapiens,sample id: M601,source: MDACC,age_years: 71.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.264,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615314/suppl/GSM615314_FL753-601.CEL.gz,22283,71,Rx Insensitive,IIB,N1,T2,RD,0,2.264,P,P,N,P,Low,2,N,LumA,RD,RCB-III,P,RCB-II/III,M601,SET-Low,MDACC,NA,NA
GSM615315,M603,GSM615315,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M603",Homo sapiens,sample id: M603,source: MDACC,age_years: 32.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T4,clinical_nodal_status: N3,clinical_ajcc_stage: IIIC,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 1,drfs_even_time_years: 0.890,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615315/suppl/GSM615315_U133A_80-FL-118_FL294-603_05_23_06.CEL.gz,22283,32,Rx Insensitive,IIIC,N3,T4,pCR,1,0.89,N,N,N,N,High,3,N,Basal,RD,RCB-II,N,RCB-II/III,M603,SET-Low,MDACC,NA,NA
GSM615316,M607,GSM615316,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M607",Homo sapiens,sample id: M607,source: MDACC,age_years: 67.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T1,clinical_nodal_status: N1,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.884,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615316/suppl/GSM615316_FL647-607-2.CEL.gz,22283,67,Rx Insensitive,IIA,N1,T1,RD,0,1.884,P,P,N,P,Low,2,N,LumA,RD,RCB-II,N,RCB-II/III,M607,SET-Low,MDACC,NA,NA
GSM615317,M608,GSM615317,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M608",Homo sapiens,sample id: M608,source: MDACC,age_years: 47.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N3,clinical_ajcc_stage: IIIC,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.700,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615317/suppl/GSM615317_U133A_80-FL-120_FL296-608_05_23_06.CEL.gz,22283,47,Rx Insensitive,IIIC,N3,T2,pCR,0,2.7,N,N,N,N,High,3,N,Basal,RD,RCB-II,N,RCB-II/III,M608,SET-Low,MDACC,NA,NA
GSM615318,M610,GSM615318,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M610",Homo sapiens,sample id: M610,source: MDACC,age_years: 47.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T3,clinical_nodal_status: N2,clinical_ajcc_stage: IIIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.371,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615318/suppl/GSM615318_FL602-610.CEL.gz,22283,47,Rx Insensitive,IIIA,N2,T3,RD,0,2.371,P,P,N,P,Low,2,N,LumA,RD,RCB-III,P,RCB-II/III,M610,SET-Low,MDACC,NA,NA
GSM615319,M611,GSM615319,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M611",Homo sapiens,sample id: M611,source: MDACC,age_years: 63.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N3,clinical_ajcc_stage: IIIC,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 1,drfs_even_time_years: 2.278,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615319/suppl/GSM615319_U133A_80-FL-121_FL297-611_05_23_06.CEL.gz,22283,63,Rx Insensitive,IIIC,N3,T2,pCR,1,2.278,N,N,N,N,Low,3,N,Basal,RD,RCB-II,N,RCB-II/III,M611,SET-Low,MDACC,NA,NA
GSM615320,M612,GSM615320,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M612",Homo sapiens,sample id: M612,source: MDACC,age_years: 40.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N2,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 1,drfs_even_time_years: 1.350,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615320/suppl/GSM615320_FL690-612.CEL.gz,22283,40,Rx Insensitive,IIIA,N2,T2,pCR,1,1.35,N,N,N,N,High,3,N,Basal,RD,RCB-III,N,RCB-II/III,M612,SET-Low,MDACC,NA,NA
GSM615321,M617,GSM615321,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M617",Homo sapiens,sample id: M617,source: MDACC,age_years: 50.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.516,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615321/suppl/GSM615321_U133A_80-FL-131-FL299-617_06_09_06.CEL.gz,22283,50,Rx Insensitive,IIB,N1,T2,pCR,0,2.516,N,N,N,N,High,3,N,Basal,RD,RCB-II,N,RCB-II/III,M617,SET-Low,MDACC,NA,NA
GSM615322,M619,GSM615322,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M619",Homo sapiens,sample id: M619,source: MDACC,age_years: 52.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T4,clinical_nodal_status: N2,clinical_ajcc_stage: IIIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 1,drfs_even_time_years: 0.799,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615322/suppl/GSM615322_FL678-619.CEL.gz,22283,52,Rx Insensitive,IIIB,N2,T4,pCR,1,0.799,N,N,N,N,High,3,N,Basal,RD,RCB-III,N,RCB-II/III,M619,SET-Low,MDACC,NA,NA
GSM615323,M624,GSM615323,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M624",Homo sapiens,sample id: M624,source: MDACC,age_years: 32.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T4,clinical_nodal_status: N3,clinical_ajcc_stage: IIIC,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.881,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: Normal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615323/suppl/GSM615323_U133A_80-FL-133-FL301-624_06_09_06.CEL.gz,22283,32,Rx Insensitive,IIIC,N3,T4,RD,0,1.881,N,N,N,N,Low,3,N,Normal,RD,RCB-II,N,RCB-II/III,M624,SET-Low,MDACC,NA,NA
GSM615324,M625,GSM615324,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M625",Homo sapiens,sample id: M625,source: MDACC,age_years: 49.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T1,clinical_nodal_status: N1,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.456,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615324/suppl/GSM615324_U133A_80-FL-096_FL272-625_05_11_06.CEL.gz,22283,49,Rx Sensitive,IIA,N1,T1,pCR,0,2.456,N,N,N,N,High,3,N,Basal,pCR,RCB-0/I,N,RCB-0/I,M625,SET-Low,MDACC,NA,NA
GSM615325,M635,GSM615325,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M635",Homo sapiens,sample id: M635,source: MDACC,age_years: 43.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T1,clinical_nodal_status: N3,clinical_ajcc_stage: IIIC,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.146,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615325/suppl/GSM615325_U133A_80-FL-135-FL303-635_06_15_06.CEL.gz,22283,43,Rx Sensitive,IIIC,N3,T1,pCR,0,2.146,N,N,N,N,High,3,N,Basal,pCR,RCB-0/I,N,RCB-0/I,M635,SET-Low,MDACC,NA,NA
GSM615326,M636,GSM615326,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M636",Homo sapiens,sample id: M636,source: MDACC,age_years: 57.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.480,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615326/suppl/GSM615326_U133A_80-FL-136-FL304-636_06_15_06.CEL.gz,22283,57,Rx Insensitive,IIA,N0,T2,pCR,0,2.48,P,P,N,N,High,3,N,Basal,RD,RCB-II,N,RCB-II/III,M636,SET-Low,MDACC,NA,NA
GSM615327,M639,GSM615327,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M639",Homo sapiens,sample id: M639,source: MDACC,age_years: 65.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T3,clinical_nodal_status: N0,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 1,drfs_even_time_years: 2.533,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615327/suppl/GSM615327_FL779-639.CEL.gz,22283,65,Rx Insensitive,IIB,N0,T3,pCR,1,2.533,N,N,N,N,High,3,N,Basal,RD,RCB-II,N,RCB-II/III,M639,SET-Low,MDACC,NA,NA
GSM615328,M642,GSM615328,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M642",Homo sapiens,sample id: M642,source: MDACC,age_years: 45.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T4,clinical_nodal_status: N2,clinical_ajcc_stage: IIIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.357,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615328/suppl/GSM615328_FL786_642.CEL.gz,22283,45,Rx Insensitive,IIIB,N2,T4,RD,0,2.357,P,P,N,P,Low,2,N,LumA,RD,RCB-III,P,RCB-II/III,M642,SET-Low,MDACC,NA,NA
GSM615329,M643,GSM615329,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M643",Homo sapiens,sample id: M643,source: MDACC,age_years: 41.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.059,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615329/suppl/GSM615329_FL797-643.CEL.gz,22283,41,Rx Insensitive,IIA,N0,T2,RD,0,2.059,P,P,N,P,Low,2,N,LumA,RD,RCB-III,P,RCB-II/III,M643,SET-Low,MDACC,NA,NA
GSM615330,M647,GSM615330,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M647",Homo sapiens,sample id: M647,source: MDACC,age_years: 65.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T3,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 1,drfs_even_time_years: 0.797,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615330/suppl/GSM615330_FL688-647.CEL.gz,22283,65,Rx Insensitive,IIIA,N1,T3,RD,1,0.797,N,N,N,P,High,3,N,Basal,RD,RCB-III,N,RCB-0/I,M647,SET-Low,MDACC,NA,NA
GSM615331,M651,GSM615331,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M651",Homo sapiens,sample id: M651,source: MDACC,age_years: 61.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.188,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615331/suppl/GSM615331_FL604-651.CEL.gz,22283,61,Rx Sensitive,IIB,N1,T2,RD,0,2.188,P,P,N,P,High,3,N,Basal,pCR,RCB-0/I,P,RCB-0/I,M651,SET-Low,MDACC,NA,NA
GSM615332,M652,GSM615332,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M652",Homo sapiens,sample id: M652,source: MDACC,age_years: 66.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 1,drfs_even_time_years: 1.437,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615332/suppl/GSM615332_FL605-652.CEL.gz,22283,66,Rx Insensitive,IIB,N1,T2,RD,1,1.437,P,P,N,P,High,2,N,LumB,RD,RCB-II,N,RCB-II/III,M652,SET-Low,MDACC,NA,NA
GSM615333,M657,GSM615333,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M657",Homo sapiens,sample id: M657,source: MDACC,age_years: 48.0,er_status_ihc: N,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T1,clinical_nodal_status: N0,clinical_ajcc_stage: I,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.234,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615333/suppl/GSM615333_FL756-657.CEL.gz,22283,48,Rx Insensitive,I,N0,T1,pCR,0,2.234,N,N,N,N,High,2,N,Basal,RD,RCB-0/I,P,RCB-0/I,M657,SET-Low,MDACC,NA,NA
GSM615334,M658,GSM615334,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M658",Homo sapiens,sample id: M658,source: MDACC,age_years: 61.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T3,clinical_nodal_status: N3,clinical_ajcc_stage: IIIB,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.198,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615334/suppl/GSM615334_FL606-658.CEL.gz,22283,61,Rx Sensitive,IIIB,N3,T3,pCR,0,2.198,N,N,N,N,High,3,N,Basal,pCR,RCB-0/I,N,RCB-0/I,M658,SET-Low,MDACC,NA,NA
GSM615335,M659,GSM615335,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M659",Homo sapiens,sample id: M659,source: MDACC,age_years: 51.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 1,drfs_even_time_years: 0.923,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615335/suppl/GSM615335_FL827-659.CEL.gz,22283,51,Rx Insensitive,IIB,N1,T2,pCR,1,0.923,N,N,N,N,High,3,N,Basal,RD,RCB-III,N,RCB-II/III,M659,SET-Low,MDACC,NA,NA
GSM615336,M661,GSM615336,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M661",Homo sapiens,sample id: M661,source: MDACC,age_years: 49.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.261,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615336/suppl/GSM615336_FL679-661.CEL.gz,22283,49,Rx Sensitive,IIB,N1,T2,pCR,0,2.261,N,N,N,N,High,3,N,Basal,pCR,RCB-0/I,N,RCB-0/I,M661,SET-Low,MDACC,NA,NA
GSM615337,M662,GSM615337,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M662",Homo sapiens,sample id: M662,source: MDACC,age_years: 46.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.182,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615337/suppl/GSM615337_FL577-662.CEL.gz,22283,46,Rx Insensitive,IIB,N1,T2,RD,0,2.182,P,P,N,P,Low,2,N,LumA,RD,RCB-II,P,RCB-II/III,M662,SET-Low,MDACC,NA,NA
GSM615338,M665,GSM615338,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M665",Homo sapiens,sample id: M665,source: MDACC,age_years: 57.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.064,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615338/suppl/GSM615338_FL780-665.CEL.gz,22283,57,Rx Sensitive,IIB,N1,T2,pCR,0,2.064,N,N,N,N,High,3,N,Basal,pCR,RCB-0/I,N,RCB-0/I,M665,SET-Low,MDACC,NA,NA
GSM615339,M666,GSM615339,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M666",Homo sapiens,sample id: M666,source: MDACC,age_years: 58.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.171,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615339/suppl/GSM615339_FL559-666.CEL.gz,22283,58,Rx Sensitive,IIA,N0,T2,RD,0,2.171,P,P,N,P,Low,2,N,LumA,RD,RCB-0/I,P,RCB-0/I,M666,SET-Low,MDACC,NA,NA
GSM615340,M668,GSM615340,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M668",Homo sapiens,sample id: M668,source: MDACC,age_years: 50.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T3,clinical_nodal_status: N2,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.094,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Her2,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615340/suppl/GSM615340_FL680-668.CEL.gz,22283,50,Rx Insensitive,IIIA,N2,T3,RD,0,2.094,P,P,N,N,High,3,N,Her2,RD,RCB-II,P,RCB-II/III,M668,SET-Low,MDACC,NA,NA
GSM615341,M669,GSM615341,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M669",Homo sapiens,sample id: M669,source: MDACC,age_years: 47.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.223,esr1_status: P,erbb2_status: N,set_class: SET-Int,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615341/suppl/GSM615341_FL578-669.CEL.gz,22283,47,Rx Sensitive,IIB,N1,T2,RD,0,2.223,P,P,N,P,Low,2,N,LumA,RD,RCB-II,P,RCB-II/III,M669,SET-Int,MDACC,NA,NA
GSM615342,M670,GSM615342,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M670",Homo sapiens,sample id: M670,source: MDACC,age_years: 43.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.958,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Her2,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615342/suppl/GSM615342_FL781-670.CEL.gz,22283,43,Rx Insensitive,IIB,N1,T2,pCR,0,1.958,N,N,N,N,High,2,N,Her2,RD,RCB-II,N,RCB-II/III,M670,SET-Low,MDACC,NA,NA
GSM615343,M671,GSM615343,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M671",Homo sapiens,sample id: M671,source: MDACC,age_years: 30.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T1,clinical_nodal_status: N1,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.845,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615343/suppl/GSM615343_FL560-671.CEL.gz,22283,30,Rx Insensitive,IIA,N1,T1,RD,0,1.845,P,P,N,P,High,3,N,LumB,RD,RCB-II,P,RCB-II/III,M671,SET-Low,MDACC,NA,NA
GSM615344,M673,GSM615344,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M673",Homo sapiens,sample id: M673,source: MDACC,age_years: 58.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N3,clinical_ajcc_stage: IIIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 1,drfs_even_time_years: 1.377,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: Normal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615344/suppl/GSM615344_FL689-673.CEL.gz,22283,58,Rx Insensitive,IIIB,N3,T2,pCR,1,1.377,N,N,N,N,Low,3,N,Normal,RD,RCB-II,N,RCB-II/III,M673,SET-Low,MDACC,NA,NA
GSM615345,M675,GSM615345,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M675",Homo sapiens,sample id: M675,source: MDACC,age_years: 64.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.059,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615345/suppl/GSM615345_FL579-675.CEL.gz,22283,64,Rx Insensitive,IIB,N1,T2,RD,0,2.059,N,N,N,P,High,2,N,LumB,RD,RCB-III,N,RCB-II/III,M675,SET-Low,MDACC,NA,NA
GSM615346,M677,GSM615346,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M677",Homo sapiens,sample id: M677,source: MDACC,age_years: 42.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.306,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615346/suppl/GSM615346_FL782-677.CEL.gz,22283,42,Rx Insensitive,IIB,N1,T2,pCR,0,1.306,N,N,N,N,High,3,N,Basal,RD,RCB-II,N,RCB-II/III,M677,SET-Low,MDACC,NA,NA
GSM615347,M679,GSM615347,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M679",Homo sapiens,sample id: M679,source: MDACC,age_years: 72.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 1,drfs_even_time_years: 2.253,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615347/suppl/GSM615347_FL580-679.CEL.gz,22283,72,Rx Insensitive,IIA,N0,T2,pCR,1,2.253,N,N,N,N,High,3,N,Basal,RD,RCB-II,N,RCB-II/III,M679,SET-Low,MDACC,NA,NA
GSM615348,M681,GSM615348,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M681",Homo sapiens,sample id: M681,source: MDACC,age_years: 33.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T3,clinical_nodal_status: N0,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.303,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615348/suppl/GSM615348_FL783-681.CEL.gz,22283,33,Rx Insensitive,IIB,N0,T3,pCR,0,2.303,N,N,N,N,High,3,N,Basal,RD,RCB-II,N,RCB-II/III,M681,SET-Low,MDACC,NA,NA
GSM615349,M682,GSM615349,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M682",Homo sapiens,sample id: M682,source: MDACC,age_years: 50.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.333,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615349/suppl/GSM615349_FL761-682.CEL.gz,22283,50,Rx Insensitive,IIA,N0,T2,RD,0,2.333,P,P,N,P,Low,2,N,LumA,RD,RCB-II,P,RCB-II/III,M682,SET-Low,MDACC,NA,NA
GSM615350,M683,GSM615350,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M683",Homo sapiens,sample id: M683,source: MDACC,age_years: 59.0,er_status_ihc: N,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.281,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615350/suppl/GSM615350_FL581-683.CEL.gz,22283,59,Rx Insensitive,IIA,N0,T2,RD,0,2.281,N,N,N,P,High,3,N,LumB,RD,RCB-II,P,RCB-0/I,M683,SET-Low,MDACC,NA,NA
GSM615351,M685,GSM615351,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M685",Homo sapiens,sample id: M685,source: MDACC,age_years: 53.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 1,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.393,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615351/suppl/GSM615351_FL787-685.CEL.gz,22283,53,Rx Insensitive,IIA,N0,T2,RD,0,2.393,P,P,N,P,Low,1,N,LumA,RD,RCB-III,P,RCB-0/I,M685,SET-Low,MDACC,NA,NA
GSM615352,M690,GSM615352,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M690",Homo sapiens,sample id: M690,source: MDACC,age_years: 73.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 1,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.160,esr1_status: P,erbb2_status: N,set_class: SET-Int,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615352/suppl/GSM615352_FL561-690.CEL.gz,22283,73,Rx Sensitive,IIB,N1,T2,RD,0,2.16,P,P,N,P,Low,1,N,LumA,RD,RCB-II,P,RCB-II/III,M690,SET-Int,MDACC,NA,NA
GSM615353,M691,GSM615353,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M691",Homo sapiens,sample id: M691,source: MDACC,age_years: 46.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T1,clinical_nodal_status: N1,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.670,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615353/suppl/GSM615353_FL402-691.CEL.gz,22283,46,Rx Sensitive,IIA,N1,T1,RD,0,1.67,P,P,N,P,High,3,N,LumB,pCR,RCB-0/I,P,RCB-0/I,M691,SET-Low,MDACC,NA,NA
GSM615354,M692,GSM615354,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M692",Homo sapiens,sample id: M692,source: MDACC,age_years: 46.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N3,clinical_ajcc_stage: IIIB,grade: 2,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.415,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615354/suppl/GSM615354_FL582-692.CEL.gz,22283,46,Rx Sensitive,IIIB,N3,T2,pCR,0,1.415,N,N,N,N,High,2,N,Basal,pCR,RCB-0/I,N,RCB-0/I,M692,SET-Low,MDACC,NA,NA
GSM615355,M693,GSM615355,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M693",Homo sapiens,sample id: M693,source: MDACC,age_years: 47.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.010,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615355/suppl/GSM615355_FL562-693.CEL.gz,22283,47,Rx Insensitive,IIA,N0,T2,RD,0,2.01,P,P,N,P,Low,2,N,LumA,RD,RCB-II,P,RCB-II/III,M693,SET-Low,MDACC,NA,NA
GSM615356,M695,GSM615356,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M695",Homo sapiens,sample id: M695,source: MDACC,age_years: 43.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.161,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615356/suppl/GSM615356_FL648-695.CEL.gz,22283,43,Rx Insensitive,IIA,N0,T2,RD,0,1.161,N,N,N,P,High,3,N,LumB,RD,RCB-II,N,RCB-II/III,M695,SET-Low,MDACC,NA,NA
GSM615357,M696,GSM615357,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M696",Homo sapiens,sample id: M696,source: MDACC,age_years: 53.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.744,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615357/suppl/GSM615357_FL607-696.CEL.gz,22283,53,Rx Insensitive,IIB,N1,T2,pCR,0,1.744,N,N,N,N,High,3,N,Basal,pCR,RCB-0/I,N,RCB-0/I,M696,SET-Low,MDACC,NA,NA
GSM615358,M706,GSM615358,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M706",Homo sapiens,sample id: M706,source: MDACC,age_years: 69.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T4,clinical_nodal_status: N0,clinical_ajcc_stage: IIIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.076,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615358/suppl/GSM615358_FL469-706_3_.CEL.gz,22283,69,Rx Insensitive,IIIB,N0,T4,RD,0,1.076,P,P,N,P,High,2,N,LumB,RD,RCB-III,N,RCB-II/III,M706,SET-Low,MDACC,NA,NA
GSM615359,M709,GSM615359,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M709",Homo sapiens,sample id: M709,source: MDACC,age_years: 51.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T4,clinical_nodal_status: N2,clinical_ajcc_stage: IIIB,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.728,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615359/suppl/GSM615359_FL608-709.CEL.gz,22283,51,Rx Insensitive,IIIB,N2,T4,pCR,0,1.728,N,N,N,N,High,3,N,Basal,pCR,RCB-0/I,N,RCB-0/I,M709,SET-Low,MDACC,NA,NA
GSM615360,M710,GSM615360,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M710",Homo sapiens,sample id: M710,source: MDACC,age_years: 53.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.979,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615360/suppl/GSM615360_FL682-710.CEL.gz,22283,53,Rx Insensitive,IIB,N1,T2,RD,0,1.979,P,P,N,P,High,2,N,LumA,RD,RCB-II,P,RCB-II/III,M710,SET-Low,MDACC,NA,NA
GSM615361,M714,GSM615361,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M714",Homo sapiens,sample id: M714,source: MDACC,age_years: 64.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.892,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: Normal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615361/suppl/GSM615361_FL788-714.CEL.gz,22283,64,Rx Insensitive,IIB,N1,T2,RD,0,1.892,P,P,N,N,Low,3,N,Normal,RD,RCB-II,N,RCB-II/III,M714,SET-Low,MDACC,NA,NA
GSM615362,M717,GSM615362,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M717",Homo sapiens,sample id: M717,source: MDACC,age_years: 52.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 1,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.963,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615362/suppl/GSM615362_FL609-717.CEL.gz,22283,52,Rx Sensitive,IIA,N0,T2,RD,0,1.963,P,P,N,P,Low,1,N,LumA,RD,RCB-II,P,RCB-0/I,M717,SET-Low,MDACC,NA,NA
GSM615363,M718,GSM615363,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M718",Homo sapiens,sample id: M718,source: MDACC,age_years: 36.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.613,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615363/suppl/GSM615363_FL610-718.CEL.gz,22283,36,Rx Insensitive,IIA,N0,T2,pCR,0,1.613,N,N,N,N,High,3,N,Basal,RD,RCB-0/I,N,RCB-0/I,M718,SET-Low,MDACC,NA,NA
GSM615364,M722,GSM615364,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M722",Homo sapiens,sample id: M722,source: MDACC,age_years: 34.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N2,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.541,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615364/suppl/GSM615364_FL563-722.CEL.gz,22283,34,Rx Insensitive,IIIA,N2,T2,pCR,0,1.541,N,N,N,N,High,3,N,Basal,RD,RCB-II,N,RCB-II/III,M722,SET-Low,MDACC,NA,NA
GSM615365,M723,GSM615365,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M723",Homo sapiens,sample id: M723,source: MDACC,age_years: 63.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.927,esr1_status: P,erbb2_status: P,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615365/suppl/GSM615365_FL564-723.CEL.gz,22283,63,Rx Sensitive,IIB,N1,T2,RD,0,1.927,P,P,P,P,Low,2,N,LumA,RD,RCB-II,P,RCB-0/I,M723,SET-Low,MDACC,NA,NA
GSM615366,M725,GSM615366,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M725",Homo sapiens,sample id: M725,source: MDACC,age_years: 46.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N3,clinical_ajcc_stage: IIIB,grade: 1,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.878,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615366/suppl/GSM615366_FL683-725.CEL.gz,22283,46,Rx Insensitive,IIIB,N3,T2,RD,0,1.878,P,P,N,P,High,1,N,LumA,RD,RCB-II,P,RCB-II/III,M725,SET-Low,MDACC,NA,NA
GSM615367,M728,GSM615367,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M728",Homo sapiens,sample id: M728,source: MDACC,age_years: 49.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T3,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.517,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615367/suppl/GSM615367_FL611-728.CEL.gz,22283,49,Rx Insensitive,IIIA,N1,T3,RD,0,1.517,P,P,N,P,High,3,N,LumB,RD,RCB-III,P,RCB-0/I,M728,SET-Low,MDACC,NA,NA
GSM615368,M729,GSM615368,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M729",Homo sapiens,sample id: M729,source: MDACC,age_years: 28.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 1,drfs_even_time_years: 0.728,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615368/suppl/GSM615368_FL785-729.CEL.gz,22283,28,Rx Insensitive,IIB,N1,T2,pCR,1,0.728,N,N,N,N,High,3,N,Basal,RD,RCB-III,N,RCB-II/III,M729,SET-Low,MDACC,NA,NA
GSM615369,M732,GSM615369,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M732",Homo sapiens,sample id: M732,source: MDACC,age_years: 50.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N2,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.900,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615369/suppl/GSM615369_FL612-732.CEL.gz,22283,50,Rx Insensitive,IIIA,N2,T2,pCR,0,1.9,N,N,N,N,High,3,N,Basal,RD,RCB-III,N,RCB-II/III,M732,SET-Low,MDACC,NA,NA
GSM615370,M734,GSM615370,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M734",Homo sapiens,sample id: M734,source: MDACC,age_years: 36.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.336,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615370/suppl/GSM615370_FL789-734.CEL.gz,22283,36,Rx Insensitive,IIA,N0,T2,RD,0,1.336,P,P,N,P,Low,2,N,LumA,RD,RCB-0/I,P,RCB-0/I,M734,SET-Low,MDACC,NA,NA
GSM615371,M735,GSM615371,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M735",Homo sapiens,sample id: M735,source: MDACC,age_years: 67.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.711,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615371/suppl/GSM615371_FL613-735.CEL.gz,22283,67,Rx Sensitive,IIB,N1,T2,pCR,0,1.711,N,N,N,N,High,3,N,Basal,pCR,RCB-0/I,N,RCB-0/I,M735,SET-Low,MDACC,NA,NA
GSM615372,M739,GSM615372,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M739",Homo sapiens,sample id: M739,source: MDACC,age_years: 39.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.695,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615372/suppl/GSM615372_FL790-739.CEL.gz,22283,39,Rx Sensitive,IIB,N1,T2,pCR,0,1.695,N,N,N,N,High,3,N,Basal,RD,RCB-0/I,N,RCB-0/I,M739,SET-Low,MDACC,NA,NA
GSM615373,M744,GSM615373,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M744",Homo sapiens,sample id: M744,source: MDACC,age_years: 44.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.029,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615373/suppl/GSM615373_FL614-744.CEL.gz,22283,44,Rx Insensitive,IIB,N1,T2,RD,0,1.029,P,P,N,P,Low,2,N,LumB,RD,RCB-III,N,RCB-0/I,M744,SET-Low,MDACC,NA,NA
GSM615374,M746,GSM615374,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M746",Homo sapiens,sample id: M746,source: MDACC,age_years: 56.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T3,clinical_nodal_status: N0,clinical_ajcc_stage: IIB,grade: 1,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.665,esr1_status: P,erbb2_status: P,set_class: SET-Int,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615374/suppl/GSM615374_FL685-746.CEL.gz,22283,56,Rx Sensitive,IIB,N0,T3,RD,0,1.665,P,P,P,P,Low,1,N,LumA,RD,RCB-II,P,RCB-II/III,M746,SET-Int,MDACC,NA,NA
GSM615375,M750,GSM615375,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M750",Homo sapiens,sample id: M750,source: MDACC,age_years: 75.0,er_status_ihc: N,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N2,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.240,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615375/suppl/GSM615375_FL791-750.CEL.gz,22283,75,Rx Insensitive,IIIA,N2,T2,pCR,0,1.24,N,N,N,N,High,3,N,Basal,pCR,RCB-0/I,P,RCB-0/I,M750,SET-Low,MDACC,NA,NA
GSM615376,M751,GSM615376,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M751",Homo sapiens,sample id: M751,source: MDACC,age_years: 51.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 1,drfs_even_time_years: 1.133,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615376/suppl/GSM615376_U133A_80-FL-196-FL360-751_08_18_06.CEL.gz,22283,51,Rx Insensitive,IIB,N1,T2,pCR,1,1.133,N,N,N,N,High,2,N,Basal,RD,RCB-III,N,RCB-II/III,M751,SET-Low,MDACC,NA,NA
GSM615377,M753,GSM615377,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M753",Homo sapiens,sample id: M753,source: MDACC,age_years: 49.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T4,clinical_nodal_status: N0,clinical_ajcc_stage: IIIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.719,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615377/suppl/GSM615377_FL701-753.CEL.gz,22283,49,Rx Insensitive,IIIB,N0,T4,RD,0,1.719,P,P,N,P,High,2,N,LumB,RD,RCB-II,P,RCB-II/III,M753,SET-Low,MDACC,NA,NA
GSM615378,M757,GSM615378,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M757",Homo sapiens,sample id: M757,source: MDACC,age_years: 41.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N3,clinical_ajcc_stage: IIIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.120,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615378/suppl/GSM615378_FL667-757.CEL.gz,22283,41,Rx Insensitive,IIIB,N3,T2,pCR,0,1.12,N,N,N,N,High,3,N,Basal,RD,RCB-0/I,N,RCB-0/I,M757,SET-Low,MDACC,NA,NA
GSM615379,M758,GSM615379,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M758",Homo sapiens,sample id: M758,source: MDACC,age_years: 62.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T4,clinical_nodal_status: N1,clinical_ajcc_stage: IIIB,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.144,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615379/suppl/GSM615379_FL668-758.CEL.gz,22283,62,Rx Insensitive,IIIB,N1,T4,pCR,0,1.144,N,N,N,N,High,3,N,Basal,pCR,RCB-0/I,N,RCB-0/I,M758,SET-Low,MDACC,NA,NA
GSM615380,M763,GSM615380,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M763",Homo sapiens,sample id: M763,source: MDACC,age_years: 40.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T3,clinical_nodal_status: N2,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 1,drfs_even_time_years: 0.170,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615380/suppl/GSM615380_FL792-763.CEL.gz,22283,40,Rx Insensitive,IIIA,N2,T3,pCR,1,0.17,N,N,N,N,High,3,N,Basal,RD,RCB-III,N,RCB-II/III,M763,SET-Low,MDACC,NA,NA
GSM615381,M765,GSM615381,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M765",Homo sapiens,sample id: M765,source: MDACC,age_years: 62.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T4,clinical_nodal_status: N1,clinical_ajcc_stage: IIIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.008,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615381/suppl/GSM615381_FL681-765.CEL.gz,22283,62,Rx Insensitive,IIIB,N1,T4,RD,0,1.008,P,P,N,P,Low,3,N,LumA,RD,RCB-III,P,RCB-II/III,M765,SET-Low,MDACC,NA,NA
GSM615382,M766,GSM615382,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M766",Homo sapiens,sample id: M766,source: MDACC,age_years: 59.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.142,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615382/suppl/GSM615382_FL566-766.CEL.gz,22283,59,Rx Insensitive,IIA,N0,T2,pCR,0,1.142,N,N,N,N,Low,3,N,Basal,RD,RCB-II,N,RCB-II/III,M766,SET-Low,MDACC,NA,NA
GSM615383,M767,GSM615383,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M767",Homo sapiens,sample id: M767,source: MDACC,age_years: 51.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.243,esr1_status: P,erbb2_status: N,set_class: SET-Int,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615383/suppl/GSM615383_FL670-767.CEL.gz,22283,51,Rx Sensitive,IIA,N0,T2,RD,0,1.243,P,P,N,P,Low,2,N,LumA,pCR,RCB-0/I,P,RCB-0/I,M767,SET-Int,MDACC,NA,NA
GSM615384,M768,GSM615384,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M768",Homo sapiens,sample id: M768,source: MDACC,age_years: 57.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T3,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.284,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615384/suppl/GSM615384_FL671-768.CEL.gz,22283,57,Rx Insensitive,IIIA,N1,T3,pCR,0,1.284,N,N,N,N,High,3,N,Basal,RD,RCB-II,N,RCB-II/III,M768,SET-Low,MDACC,NA,NA
GSM615385,M771,GSM615385,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M771",Homo sapiens,sample id: M771,source: MDACC,age_years: 37.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T3,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.128,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615385/suppl/GSM615385_FL702-771.CEL.gz,22283,37,Rx Insensitive,IIIA,N1,T3,pCR,0,1.128,N,N,N,N,Low,2,N,Basal,RD,RCB-II,N,RCB-II/III,M771,SET-Low,MDACC,NA,NA
GSM615386,M774,GSM615386,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M774",Homo sapiens,sample id: M774,source: MDACC,age_years: 49.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 0.879,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615386/suppl/GSM615386_FL658-774.CEL.gz,22283,49,Rx Insensitive,IIB,N1,T2,RD,0,0.879,P,P,N,P,Low,2,N,LumA,RD,RCB-III,P,RCB-II/III,M774,SET-Low,MDACC,NA,NA
GSM615387,M779,GSM615387,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M779",Homo sapiens,sample id: M779,source: MDACC,age_years: 38.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.391,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615387/suppl/GSM615387_FL663-779.CEL.gz,22283,38,Rx Insensitive,IIB,N1,T2,RD,0,1.391,N,N,N,N,High,3,N,Basal,RD,RCB-III,N,RCB-II/III,M779,SET-Low,MDACC,NA,NA
GSM615388,M781,GSM615388,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M781",Homo sapiens,sample id: M781,source: MDACC,age_years: 40.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T3,clinical_nodal_status: N0,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 0.778,esr1_status: P,erbb2_status: N,set_class: SET-Int,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615388/suppl/GSM615388_FL660-781.CEL.gz,22283,40,Rx Sensitive,IIB,N0,T3,RD,0,0.778,P,P,N,P,Low,2,N,LumA,RD,RCB-II,P,RCB-II/III,M781,SET-Int,MDACC,NA,NA
GSM615389,M782,GSM615389,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M782",Homo sapiens,sample id: M782,source: MDACC,age_years: 53.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N3,clinical_ajcc_stage: IIIB,grade: 1,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.147,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615389/suppl/GSM615389_FL703-782.CEL.gz,22283,53,Rx Insensitive,IIIB,N3,T2,RD,0,1.147,P,P,N,P,Low,1,N,LumA,RD,RCB-III,N,RCB-II/III,M782,SET-Low,MDACC,NA,NA
GSM615390,M783,GSM615390,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M783",Homo sapiens,sample id: M783,source: MDACC,age_years: 46.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N2,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.487,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615390/suppl/GSM615390_FL661-783.CEL.gz,22283,46,Rx Insensitive,IIIA,N2,T2,pCR,0,1.487,N,N,N,N,High,3,N,Basal,RD,RCB-III,N,RCB-II/III,M783,SET-Low,MDACC,NA,NA
GSM615391,M784,GSM615391,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M784",Homo sapiens,sample id: M784,source: MDACC,age_years: 58.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T4,clinical_nodal_status: N0,clinical_ajcc_stage: IIIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.188,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615391/suppl/GSM615391_FL704-784.CEL.gz,22283,58,Rx Insensitive,IIIB,N0,T4,RD,0,1.188,P,P,N,P,High,3,N,LumB,RD,RCB-II,P,RCB-II/III,M784,SET-Low,MDACC,NA,NA
GSM615392,M791,GSM615392,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M791",Homo sapiens,sample id: M791,source: MDACC,age_years: 65.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T4,clinical_nodal_status: N2,clinical_ajcc_stage: IIIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 1,drfs_even_time_years: 0.085,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615392/suppl/GSM615392_FL830-791_B_.CEL.gz,22283,65,Rx Insensitive,IIIB,N2,T4,pCR,1,0.085,N,N,N,N,High,3,N,Basal,RD,RCB-III,N,RCB-II/III,M791,SET-Low,MDACC,NA,NA
GSM615393,M792,GSM615393,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M792",Homo sapiens,sample id: M792,source: MDACC,age_years: 43.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T3,clinical_nodal_status: N2,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.265,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615393/suppl/GSM615393_FL706-792.CEL.gz,22283,43,Rx Insensitive,IIIA,N2,T3,pCR,0,1.265,N,N,N,N,High,3,N,Basal,pCR,RCB-0/I,N,RCB-0/I,M792,SET-Low,MDACC,NA,NA
GSM615394,M794,GSM615394,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M794",Homo sapiens,sample id: M794,source: MDACC,age_years: 62.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.194,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615394/suppl/GSM615394_FL775-794.CEL.gz,22283,62,Rx Insensitive,IIA,N0,T2,pCR,0,1.194,N,N,N,N,High,3,N,Basal,pCR,RCB-0/I,N,RCB-0/I,M794,SET-Low,MDACC,NA,NA
GSM615395,M795,GSM615395,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M795",Homo sapiens,sample id: M795,source: MDACC,age_years: 64.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.062,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615395/suppl/GSM615395_FL799-795.CEL.gz,22283,64,Rx Sensitive,IIA,N0,T2,RD,0,1.062,P,P,N,P,Low,2,N,LumA,RD,RCB-0/I,N,RCB-0/I,M795,SET-Low,MDACC,NA,NA
GSM615396,M802,GSM615396,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M802",Homo sapiens,sample id: M802,source: MDACC,age_years: 32.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T3,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 0.824,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615396/suppl/GSM615396_FL833-802.CEL.gz,22283,32,Rx Sensitive,IIIA,N1,T3,pCR,0,0.824,N,N,N,N,High,3,N,Basal,pCR,RCB-0/I,N,RCB-0/I,M802,SET-Low,MDACC,NA,NA
GSM615397,M805,GSM615397,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M805",Homo sapiens,sample id: M805,source: MDACC,age_years: 57.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T2,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: pCR,pathologic_response_rcb_class: RCB-0/I,drfs_1_event_0_censored: 0,drfs_even_time_years: 0.931,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615397/suppl/GSM615397_FL801-805.CEL.gz,22283,57,Rx Sensitive,IIB,N1,T2,pCR,0,0.931,N,N,N,N,High,2,N,Basal,pCR,RCB-0/I,N,RCB-0/I,M805,SET-Low,MDACC,NA,NA
GSM615398,M806,GSM615398,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M806",Homo sapiens,sample id: M806,source: MDACC,age_years: 49.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T4,clinical_nodal_status: N2,clinical_ajcc_stage: IIIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 1,drfs_even_time_years: 0.192,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615398/suppl/GSM615398_FL802-806.CEL.gz,22283,49,Rx Insensitive,IIIB,N2,T4,RD,1,0.192,P,P,N,P,High,3,N,LumB,RD,RCB-III,P,RCB-II/III,M806,SET-Low,MDACC,NA,NA
GSM615399,M810,GSM615399,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-M810",Homo sapiens,sample id: M810,source: MDACC,age_years: 51.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T3,clinical_nodal_status: N2,clinical_ajcc_stage: IIIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.051,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615399/suppl/GSM615399_FL803-810.CEL.gz,22283,51,Rx Insensitive,IIIA,N2,T3,RD,0,1.051,P,P,N,P,Low,2,N,LumA,RD,RCB-III,P,RCB-II/III,M810,SET-Low,MDACC,NA,NA
GSM615400,PERU01,GSM615400,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-PERU01",Homo sapiens,sample id: PERU01,source: MDACC,age_years: 73.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T4,clinical_nodal_status: N1,clinical_ajcc_stage: IIIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.746,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615400/suppl/GSM615400_29539_AB01833935_35648.CEL.gz,22283,73,Rx Insensitive,IIIB,N1,T4,RD,0,2.746,P,P,N,P,Low,2,N,LumA,RD,RCB-II,N,RCB-0/I,PERU01,SET-Low,MDACC,NA,NA
GSM615401,PERU07,GSM615401,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-PERU07",Homo sapiens,sample id: PERU07,source: MDACC,age_years: 71.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T4,clinical_nodal_status: N1,clinical_ajcc_stage: IIIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.511,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615401/suppl/GSM615401_29539_AB01833754_35654.CEL.gz,22283,71,Rx Insensitive,IIIB,N1,T4,RD,0,2.511,P,P,N,P,High,3,N,LumB,RD,RCB-II,N,RCB-II/III,PERU07,SET-Low,MDACC,NA,NA
GSM615402,PERU09,GSM615402,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-PERU09",Homo sapiens,sample id: PERU09,source: MDACC,age_years: 47.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T4,clinical_nodal_status: N1,clinical_ajcc_stage: IIIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.363,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615402/suppl/GSM615402_29539_AB01833820_35655.CEL.gz,22283,47,Rx Insensitive,IIIB,N1,T4,RD,0,2.363,P,P,N,P,High,2,N,LumA,RD,RCB-III,P,RCB-II/III,PERU09,SET-Low,MDACC,NA,NA
GSM615403,PERU11,GSM615403,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-PERU11",Homo sapiens,sample id: PERU11,source: MDACC,age_years: 50.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T4,clinical_nodal_status: N1,clinical_ajcc_stage: IIIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-II,drfs_1_event_0_censored: 1,drfs_even_time_years: 1.265,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615403/suppl/GSM615403_29539_AB01833522_35706.CEL.gz,22283,50,Rx Insensitive,IIIB,N1,T4,pCR,1,1.265,N,N,N,N,High,2,N,Basal,RD,RCB-II,N,RCB-II/III,PERU11,SET-Low,MDACC,NA,NA
GSM615404,PERU12_14,GSM615404,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-PERU12_14",Homo sapiens,sample id: PERU12_14,source: MDACC,age_years: 65.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc_esr1_for indeterminate: P,clinical_t_stage: T2,clinical_nodal_status: N2,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.198,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615404/suppl/GSM615404_29539_AB01833741_35650.CEL.gz,22283,65,Rx Insensitive,IIIA,N2,T2,RD,0,2.198,P,P,N,P,High,3,N,LumB,RD,RCB-III,P,RCB-II/III,PERU12_14,SET-Low,MDACC,NA,NA
GSM615405,PERU14_16,GSM615405,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-PERU14_16",Homo sapiens,sample id: PERU14_16,source: MDACC,age_years: 58.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc_esr1_for indeterminate: N,clinical_t_stage: T4,clinical_nodal_status: N2,clinical_ajcc_stage: IIIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_rcb_class: RCB-III,drfs_1_event_0_censored: 1,drfs_even_time_years: 0.517,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Her2,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615405/suppl/GSM615405_29539_AB01723030_35657.CEL.gz,22283,58,Rx Insensitive,IIIB,N2,T4,pCR,1,0.517,N,N,N,N,High,3,N,Her2,RD,RCB-III,N,RCB-II/III,PERU14_16,SET-Low,MDACC,NA,NA
GSM615631,1,GSM615631,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-1",Homo sapiens,sample id: 1,source: USO,age_years: 32.2,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 1,drfs_even_time_years: 4.54757015742642,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615631/suppl/GSM615631_U133A_FL28-US1_05_05_05.CEL.gz,22283,32.2,Rx Insensitive,IIA,N0,T2,RD,1,4.54757015742642,NA,P,N,P,Low,2,N,LumA,RD,NA,P,RCB-II/III,1,SET-Low,USO,breast cancer tumor,Taxotere
GSM615632,5,GSM615632,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-5",Homo sapiens,sample id: 5,source: USO,age_years: 41.9,er_status_ihc: N,pr_status_ihc: P,her2_status: P,er_status_ihc: N,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_pcr_rd: pCR,drfs_1_event_0_censored: 0,drfs_even_time_years: 5.14442162902122,type_taxane: Taxotere,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615632/suppl/GSM615632_U133A_FL31-US05_05_19_05.CEL.gz,22283,41.9,Rx Insensitive,IIB,N1,T2,pCR,0,5.14442162902122,NA,N,N,N,High,3,P,Basal,pCR,NA,P,RCB-0/I,5,SET-Low,USO,breast cancer tumor,Taxotere
GSM615633,12,GSM615633,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-12",Homo sapiens,sample id: 12,source: USO,age_years: 36.7,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 5.36892539356605,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615633/suppl/GSM615633_U133A_FL27-US11_05_05_05.CEL.gz,22283,36.7,Rx Insensitive,IIB,N1,T2,RD,0,5.36892539356605,NA,P,N,P,Low,2,N,LumB,RD,NA,P,RCB-II/III,12,SET-Low,USO,breast cancer tumor,Taxotere
GSM615634,13,GSM615634,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-13",Homo sapiens,sample id: 13,source: USO,age_years: 47.1,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: pCR,pathologic_response_pcr_rd: pCR,drfs_1_event_0_censored: 0,drfs_even_time_years: 5.05407255304586,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615634/suppl/GSM615634_U133A_FL24-US14_04_21_05.CEL.gz,22283,47.1,Rx Insensitive,IIA,N0,T2,RD,0,5.05407255304586,NA,P,N,P,High,2,N,LumB,pCR,NA,P,RCB-0/I,13,SET-Low,USO,breast cancer tumor,Taxotere
GSM615635,18,GSM615635,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-18",Homo sapiens,sample id: 18,source: USO,age_years: 43.8,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N3,clinical_ajcc_stage: IIIC,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_pcr_rd: pCR,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.97741273100616,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615635/suppl/GSM615635_U133A_FL35-US19_06_10_05.CEL.gz,22283,43.8,Rx Insensitive,IIIC,N3,T3,RD,0,4.97741273100616,NA,P,N,P,High,3,N,LumB,pCR,NA,P,RCB-II/III,18,SET-Low,USO,breast cancer tumor,Taxotere
GSM615636,20,GSM615636,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-20",Homo sapiens,sample id: 20,source: USO,age_years: 50.8,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_pcr_rd: pCR,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.48596851471595,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615636/suppl/GSM615636_U133A_FL22-US22_04_21_05.CEL.gz,22283,50.8,Rx Sensitive,IIIA,N1,T3,RD,0,2.48596851471595,NA,P,N,P,High,3,N,LumB,pCR,NA,P,RCB-0/I,20,SET-Low,USO,breast cancer tumor,Taxotere
GSM615637,23,GSM615637,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-23",Homo sapiens,sample id: 23,source: USO,age_years: 34.1,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N0,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_pcr_rd: pCR,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.94455852156057,type_taxane: Taxotere,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615637/suppl/GSM615637_U133A_FL20-US24_04_22_05.CEL.gz,22283,34.1,Rx Insensitive,IIB,N0,T3,RD,0,4.94455852156057,NA,N,N,N,High,3,N,Basal,pCR,NA,N,RCB-0/I,23,SET-Low,USO,breast cancer tumor,Taxotere
GSM615638,24,GSM615638,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-24",Homo sapiens,sample id: 24,source: USO,age_years: 57.5,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 1,drfs_even_time_years: 3.49349760438056,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615638/suppl/GSM615638_U133A_FL23-US26_04_21_05.CEL.gz,22283,57.5,Rx Insensitive,IIB,N1,T2,pCR,1,3.49349760438056,NA,P,N,P,High,3,N,Basal,RD,NA,N,RCB-II/III,24,SET-Low,USO,breast cancer tumor,Taxotere
GSM615639,30,GSM615639,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-30",Homo sapiens,sample id: 30,source: USO,age_years: 43.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_pcr_rd: pCR,drfs_1_event_0_censored: 1,drfs_even_time_years: 1.44284736481862,type_taxane: Taxotere,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615639/suppl/GSM615639_U133A_FL11_03_16_05.CEL.gz,22283,43,Rx Insensitive,IIIA,N1,T3,pCR,1,1.44284736481862,NA,N,N,N,High,3,N,Basal,pCR,NA,N,RCB-0/I,30,SET-Low,USO,breast cancer tumor,Taxotere
GSM615640,31,GSM615640,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-31",Homo sapiens,sample id: 31,source: USO,age_years: 49.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N0,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 1,drfs_even_time_years: 1.1937029431896,type_taxane: Taxotere,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615640/suppl/GSM615640_U133A_FL21-US34_04_21_05.CEL.gz,22283,49,Rx Insensitive,IIB,N0,T3,pCR,1,1.1937029431896,NA,N,N,N,High,3,N,Basal,RD,NA,N,RCB-II/III,31,SET-Low,USO,breast cancer tumor,Taxotere
GSM615641,32,GSM615641,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-32",Homo sapiens,sample id: 32,source: USO,age_years: 40.3,er_status_ihc: N,pr_status_ihc: P,her2_status: N,er_status_ihc: N,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.46269678302532,type_taxane: Taxotere,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615641/suppl/GSM615641_U133A_FL19-US33_04_22_05.CEL.gz,22283,40.3,Rx Sensitive,IIB,N1,T2,pCR,0,4.46269678302532,NA,N,N,N,High,3,N,Basal,RD,NA,P,RCB-0/I,32,SET-Low,USO,breast cancer tumor,Taxotere
GSM615642,35,GSM615642,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-35",Homo sapiens,sample id: 35,source: USO,age_years: 54.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.82683093771389,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-High,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615642/suppl/GSM615642_U133A_FL09_03_16_05.CEL.gz,22283,54,Rx Sensitive,IIB,N0,T3,RD,0,4.82683093771389,NA,P,N,P,Low,3,N,LumA,RD,NA,P,RCB-0/I,35,SET-High,USO,breast cancer tumor,Taxotere
GSM615643,36,GSM615643,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-36",Homo sapiens,sample id: 36,source: USO,age_years: 65.1,er_status_ihc: N,pr_status_ihc: N,her2_status: P,er_status_ihc: N,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.81587953456537,type_taxane: Taxotere,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615643/suppl/GSM615643_U133A_FL25-US37_04_22_05.CEL.gz,22283,65.1,Rx Insensitive,IIIA,N1,T3,pCR,0,4.81587953456537,NA,N,N,N,High,2,P,Basal,RD,NA,N,RCB-0/I,36,SET-Low,USO,breast cancer tumor,Taxotere
GSM615644,45,GSM615644,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-45",Homo sapiens,sample id: 45,source: USO,age_years: 50.1,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_pcr_rd: pCR,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.45995893223819,type_taxane: Taxotere,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615644/suppl/GSM615644_U133A_FL13_03_17_05.CEL.gz,22283,50.1,Rx Sensitive,IIIA,N1,T3,pCR,0,4.45995893223819,NA,N,N,N,High,3,N,Basal,pCR,NA,N,RCB-0/I,45,SET-Low,USO,breast cancer tumor,Taxotere
GSM615645,46,GSM615645,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-46",Homo sapiens,sample id: 46,source: USO,age_years: 46.9,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.91718001368925,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615645/suppl/GSM615645_U133A_FL12_03_16_05.CEL.gz,22283,46.9,Rx Insensitive,IIIA,N1,T3,RD,0,4.91718001368925,NA,P,N,P,High,3,N,LumB,RD,NA,P,RCB-0/I,46,SET-Low,USO,breast cancer tumor,Taxotere
GSM615646,48,GSM615646,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-48",Homo sapiens,sample id: 48,source: USO,age_years: 51.5,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.68720054757016,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615646/suppl/GSM615646_U133A_FL16_03_17_05.CEL.gz,22283,51.5,Rx Insensitive,IIB,N0,T3,RD,0,4.68720054757016,NA,P,N,P,Low,2,N,LumA,RD,NA,P,RCB-II/III,48,SET-Low,USO,breast cancer tumor,Taxotere
GSM615647,51,GSM615647,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-51",Homo sapiens,sample id: 51,source: USO,age_years: 45.4,er_status_ihc: NA,pr_status_ihc: NA,her2_status: NA,er_status_ihc: NA,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 1,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.51745379876797,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615647/suppl/GSM615647_U133A_FL51_US55_07_13_05.CEL.gz,22283,45.4,Rx Insensitive,IIA,N0,T2,RD,0,4.51745379876797,NA,NA,N,P,Low,1,NA,LumA,RD,NA,NA,RCB-0/I,51,SET-Low,USO,breast cancer tumor,Taxotere
GSM615648,52,GSM615648,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-52",Homo sapiens,sample id: 52,source: USO,age_years: 59.2,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.42162902121834,type_taxane: Taxotere,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615648/suppl/GSM615648_U133A_FL10_03_16_05.CEL.gz,22283,59.2,Rx Insensitive,IIB,N0,T3,pCR,0,4.42162902121834,NA,P,N,N,High,3,N,Basal,RD,NA,N,RCB-0/I,52,SET-Low,USO,breast cancer tumor,Taxotere
GSM615649,67,GSM615649,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-67",Homo sapiens,sample id: 67,source: USO,age_years: 65.3,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N2,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 1,drfs_even_time_years: 0.449007529089665,type_taxane: Taxotere,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615649/suppl/GSM615649_U133A_FL52_US71_07_13_05.CEL.gz,22283,65.3,Rx Insensitive,IIIA,N2,T3,pCR,1,0.449007529089665,NA,N,N,N,High,3,N,Basal,RD,NA,N,RCB-II/III,67,SET-Low,USO,breast cancer tumor,Taxotere
GSM615650,68,GSM615650,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-68",Homo sapiens,sample id: 68,source: USO,age_years: 60.1,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N0,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.76933607118412,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615650/suppl/GSM615650_U133A_FL33-US67_06_10_05.CEL.gz,22283,60.1,Rx Sensitive,IIB,N0,T3,pCR,0,4.76933607118412,NA,N,N,P,High,3,N,Basal,RD,NA,N,RCB-0/I,68,SET-Low,USO,breast cancer tumor,Taxotere
GSM615651,70,GSM615651,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-70",Homo sapiens,sample id: 70,source: USO,age_years: 60.9,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 1,drfs_even_time_years: 0.791238877481177,type_taxane: Taxotere,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615651/suppl/GSM615651_U133A_FL124_US74_10_27_05.CEL.gz,22283,60.9,Rx Insensitive,IIB,N1,T2,pCR,1,0.791238877481177,NA,N,N,N,High,2,N,Basal,RD,NA,N,RCB-0/I,70,SET-Low,USO,breast cancer tumor,Taxotere
GSM615652,76,GSM615652,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-76",Homo sapiens,sample id: 76,source: USO,age_years: 41.3,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.44626967830253,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Her2,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615652/suppl/GSM615652_U133A_FL53_US72_07_13_05.CEL.gz,22283,41.3,Rx Insensitive,IIIA,N1,T3,RD,0,4.44626967830253,NA,P,N,P,High,3,N,Her2,RD,NA,P,RCB-0/I,76,SET-Low,USO,breast cancer tumor,Taxotere
GSM615653,77,GSM615653,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-77",Homo sapiens,sample id: 77,source: USO,age_years: 55.9,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.53388090349076,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615653/suppl/GSM615653_U133A_FL54_US80_07_20_05.CEL.gz,22283,55.9,Rx Insensitive,IIIA,N1,T3,RD,0,4.53388090349076,NA,P,N,P,High,2,N,LumB,RD,NA,P,RCB-II/III,77,SET-Low,USO,breast cancer tumor,Taxotere
GSM615654,80,GSM615654,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-80",Homo sapiens,sample id: 80,source: USO,age_years: 45.1,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 1,drfs_even_time_years: 3.43052703627652,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615654/suppl/GSM615654_U133A_FL64-US82_08_04_05.CEL.gz,22283,45.1,Rx Insensitive,IIIA,N1,T3,RD,1,3.43052703627652,NA,P,N,P,High,3,N,LumA,RD,NA,P,RCB-II/III,80,SET-Low,USO,breast cancer tumor,Taxotere
GSM615655,85,GSM615655,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-85",Homo sapiens,sample id: 85,source: USO,age_years: 26.1,er_status_ihc: N,pr_status_ihc: N,her2_status: NA,er_status_ihc: N,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: NA,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.24298425735797,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615655/suppl/GSM615655_U133A_FL75_US87_08_25_05.CEL.gz,22283,26.1,Rx Sensitive,IIIA,N1,T3,RD,0,1.24298425735797,NA,N,N,P,High,NA,NA,LumB,RD,NA,N,RCB-0/I,85,SET-Low,USO,breast cancer tumor,Taxotere
GSM615656,86,GSM615656,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-86",Homo sapiens,sample id: 86,source: USO,age_years: 49.3,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: pCR,pathologic_response_pcr_rd: pCR,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.58658453114305,type_taxane: Taxotere,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Normal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615656/suppl/GSM615656_U133A_FL68_US89_08_24_05.CEL.gz,22283,49.3,Rx Insensitive,IIB,N0,T3,pCR,0,3.58658453114305,NA,P,N,N,High,2,N,Normal,pCR,NA,N,RCB-II/III,86,SET-Low,USO,breast cancer tumor,Taxotere
GSM615657,87,GSM615657,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-87",Homo sapiens,sample id: 87,source: USO,age_years: 43.9,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N2,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 1,drfs_even_time_years: 0.424366872005476,type_taxane: Taxotere,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615657/suppl/GSM615657_U133A_FL77_US90_08_26_05.CEL.gz,22283,43.9,Rx Insensitive,IIIA,N2,T3,pCR,1,0.424366872005476,NA,N,N,N,High,3,N,Basal,RD,NA,N,RCB-II/III,87,SET-Low,USO,breast cancer tumor,Taxotere
GSM615658,88,GSM615658,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-88",Homo sapiens,sample id: 88,source: USO,age_years: 50.3,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_pcr_rd: pCR,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.48459958932238,type_taxane: Taxotere,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615658/suppl/GSM615658_U133A_FL76_US88_08_26_05.CEL.gz,22283,50.3,Rx Insensitive,IIB,N1,T2,pCR,0,4.48459958932238,NA,N,N,N,High,3,N,Basal,pCR,NA,N,RCB-II/III,88,SET-Low,USO,breast cancer tumor,Taxotere
GSM615659,94,GSM615659,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-94",Homo sapiens,sample id: 94,source: USO,age_years: 59.5,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.41889117043121,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615659/suppl/GSM615659_U133A_FL79_US96_08_26_05.CEL.gz,22283,59.5,Rx Insensitive,IIIA,N1,T3,RD,0,4.41889117043121,NA,P,N,P,Low,2,N,LumA,RD,NA,P,RCB-II/III,94,SET-Low,USO,breast cancer tumor,Taxotere
GSM615660,95,GSM615660,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-95",Homo sapiens,sample id: 95,source: USO,age_years: 40.7,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N3,clinical_ajcc_stage: IIIC,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_pcr_rd: pCR,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.04996577686516,type_taxane: Taxotere,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615660/suppl/GSM615660_U133A_FL72_US100_08_25_05.CEL.gz,22283,40.7,Rx Insensitive,IIIC,N3,T2,pCR,0,3.04996577686516,NA,N,N,N,High,3,N,Basal,pCR,NA,N,RCB-0/I,95,SET-Low,USO,breast cancer tumor,Taxotere
GSM615661,96,GSM615661,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-96",Homo sapiens,sample id: 96,source: USO,age_years: 62.3,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.42710472279261,type_taxane: Taxotere,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615661/suppl/GSM615661_U133A_FL81_US99_09_01_05.CEL.gz,22283,62.3,Rx Insensitive,IIB,N1,T2,pCR,0,4.42710472279261,NA,N,N,N,High,3,N,Basal,RD,NA,N,RCB-0/I,96,SET-Low,USO,breast cancer tumor,Taxotere
GSM615662,97,GSM615662,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-97",Homo sapiens,sample id: 97,source: USO,age_years: 43.4,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 1,drfs_even_time_years: 1.89733059548255,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615662/suppl/GSM615662_U133A_FL69_US93_08_24_05.CEL.gz,22283,43.4,Rx Insensitive,IIIA,N1,T3,RD,1,1.89733059548255,NA,P,N,P,High,3,N,LumB,RD,NA,P,RCB-II/III,97,SET-Low,USO,breast cancer tumor,Taxotere
GSM615663,100,GSM615663,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-100",Homo sapiens,sample id: 100,source: USO,age_years: 52.8,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_pcr_rd: pCR,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.435318275154,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615663/suppl/GSM615663_U133A_FL73_US103_08_25_05.CEL.gz,22283,52.8,Rx Insensitive,IIIA,N1,T3,RD,0,4.435318275154,NA,P,N,P,High,3,N,LumB,pCR,NA,P,RCB-0/I,100,SET-Low,USO,breast cancer tumor,Taxotere
GSM615664,101,GSM615664,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-101",Homo sapiens,sample id: 101,source: USO,age_years: 44.4,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.03764544832307,type_taxane: Taxotere,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: Normal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615664/suppl/GSM615664_U133A_FL107_US104_10_12_05.CEL.gz,22283,44.4,Rx Insensitive,IIIA,N1,T3,pCR,0,1.03764544832307,NA,P,N,N,Low,3,N,Normal,RD,NA,P,RCB-II/III,101,SET-Low,USO,breast cancer tumor,Taxotere
GSM615665,103,GSM615665,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-103",Homo sapiens,sample id: 103,source: USO,age_years: 50.1,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: pCR,pathologic_response_pcr_rd: pCR,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.48186173853525,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615665/suppl/GSM615665_U133A_FL149_US108_12_08_05.CEL.gz,22283,50.1,Rx Insensitive,IIB,N1,T2,RD,0,4.48186173853525,NA,P,N,P,High,2,N,LumA,pCR,NA,P,RCB-0/I,103,SET-Low,USO,breast cancer tumor,Taxotere
GSM615666,104,GSM615666,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-104",Homo sapiens,sample id: 104,source: USO,age_years: 66.7,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.56673511293635,type_taxane: Taxotere,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615666/suppl/GSM615666_U133A_FL110_US110_10_12_05.CEL.gz,22283,66.7,Rx Insensitive,IIIA,N1,T3,pCR,0,4.56673511293635,NA,N,N,N,High,3,N,Basal,RD,NA,N,RCB-0/I,104,SET-Low,USO,breast cancer tumor,Taxotere
GSM615667,106,GSM615667,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-106",Homo sapiens,sample id: 106,source: USO,age_years: 55.7,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.22313483915127,type_taxane: Taxotere,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615667/suppl/GSM615667_U133A_FL121_US111_10_27_05.CEL.gz,22283,55.7,Rx Insensitive,IIIA,N1,T3,pCR,0,2.22313483915127,NA,N,N,N,High,3,N,Basal,RD,NA,N,RCB-II/III,106,SET-Low,USO,breast cancer tumor,Taxotere
GSM615668,110,GSM615668,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-110",Homo sapiens,sample id: 110,source: USO,age_years: 40.3,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N2,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_pcr_rd: pCR,drfs_1_event_0_censored: 1,drfs_even_time_years: 1.50855578370979,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615668/suppl/GSM615668_U133A_FL105_US116_10_06_05.CEL.gz,22283,40.3,Rx Insensitive,IIIA,N2,T2,pCR,1,1.50855578370979,NA,N,N,P,High,3,N,Basal,pCR,NA,N,RCB-II/III,110,SET-Low,USO,breast cancer tumor,Taxotere
GSM615669,111,GSM615669,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-111",Homo sapiens,sample id: 111,source: USO,age_years: 47.4,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_pcr_rd: pCR,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.46817248459959,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615669/suppl/GSM615669_U133A_FL120_US112_10_20_05.CEL.gz,22283,47.4,Rx Sensitive,IIB,N0,T3,RD,0,4.46817248459959,NA,P,N,P,High,3,N,LumB,pCR,NA,N,RCB-0/I,111,SET-Low,USO,breast cancer tumor,Taxotere
GSM615670,112,GSM615670,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-112",Homo sapiens,sample id: 112,source: USO,age_years: 52.5,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.01916495550992,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615670/suppl/GSM615670_U133A_FL123_US117_10_27_05.CEL.gz,22283,52.5,Rx Insensitive,IIB,N0,T3,RD,0,4.01916495550992,NA,P,N,P,High,2,N,LumB,RD,NA,P,RCB-II/III,112,SET-Low,USO,breast cancer tumor,Taxotere
GSM615671,113,GSM615671,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-113",Homo sapiens,sample id: 113,source: USO,age_years: 38.6,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N0,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.95893223819302,type_taxane: Taxotere,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615671/suppl/GSM615671_U133A_FL118_US118_10_14_05.CEL.gz,22283,38.6,Rx Insensitive,IIB,N0,T3,pCR,0,3.95893223819302,NA,N,N,N,High,2,N,Basal,RD,NA,N,RCB-0/I,113,SET-Low,USO,breast cancer tumor,Taxotere
GSM615672,118,GSM615672,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-118",Homo sapiens,sample id: 118,source: USO,age_years: 49.6,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N0,clinical_ajcc_stage: IIB,grade: NA,pathologic_response_pcr_rd: pCR,pathologic_response_pcr_rd: pCR,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.86105407255305,type_taxane: Taxotere,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615672/suppl/GSM615672_U133A_FL147_US122_12_07_05.CEL.gz,22283,49.6,Rx Insensitive,IIB,N0,T3,pCR,0,2.86105407255305,NA,N,N,N,High,NA,N,Basal,pCR,NA,N,RCB-II/III,118,SET-Low,USO,breast cancer tumor,Taxotere
GSM615673,124,GSM615673,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-124",Homo sapiens,sample id: 124,source: USO,age_years: 34.1,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 1,drfs_even_time_years: 0.136892539356605,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615673/suppl/GSM615673_U133A_80-FL-002_01_20_06.CEL.gz,22283,34.1,Rx Insensitive,IIB,N0,T3,RD,1,0.136892539356605,NA,P,N,P,High,2,N,LumB,RD,NA,P,RCB-0/I,124,SET-Low,USO,breast cancer tumor,Taxotere
GSM615674,125,GSM615674,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-125",Homo sapiens,sample id: 125,source: USO,age_years: 32.6,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N1,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 1,drfs_even_time_years: 0.468172484599589,type_taxane: Taxotere,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615674/suppl/GSM615674_U133A_FL150_US128_12_08_05.CEL.gz,22283,32.6,Rx Insensitive,IIA,N1,T1,pCR,1,0.468172484599589,NA,N,N,N,High,3,N,Basal,RD,NA,N,RCB-0/I,125,SET-Low,USO,breast cancer tumor,Taxotere
GSM615675,130,GSM615675,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-130",Homo sapiens,sample id: 130,source: USO,age_years: 45.2,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.09582477754962,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615675/suppl/GSM615675_U133A_80-FL-003_01_20_06.CEL.gz,22283,45.2,Rx Insensitive,IIB,N0,T3,RD,0,4.09582477754962,NA,P,N,P,High,3,N,LumA,RD,NA,P,RCB-0/I,130,SET-Low,USO,breast cancer tumor,Taxotere
GSM615676,133,GSM615676,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-133",Homo sapiens,sample id: 133,source: USO,age_years: 46.8,er_status_ihc: N,pr_status_ihc: P,her2_status: N,er_status_ihc: N,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_pcr_rd: pCR,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.18891170431212,type_taxane: Taxotere,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615676/suppl/GSM615676_U133A_FL152_US135_12_08_05.CEL.gz,22283,46.8,Rx Sensitive,IIB,N1,T2,pCR,0,4.18891170431212,NA,N,N,N,High,3,N,Basal,pCR,NA,P,RCB-0/I,133,SET-Low,USO,breast cancer tumor,Taxotere
GSM615677,145,GSM615677,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-145",Homo sapiens,sample id: 145,source: USO,age_years: 46.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N3,clinical_ajcc_stage: IIIC,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_pcr_rd: pCR,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.06297056810404,type_taxane: Taxotere,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615677/suppl/GSM615677_U133A_FL178_US154_01_19_06.CEL.gz,22283,46,Rx Sensitive,IIIC,N3,T3,pCR,0,4.06297056810404,NA,N,N,N,High,3,N,Basal,pCR,NA,N,RCB-0/I,145,SET-Low,USO,breast cancer tumor,Taxotere
GSM615678,148,GSM615678,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-148",Homo sapiens,sample id: 148,source: USO,age_years: 54.6,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.97262149212868,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Her2,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615678/suppl/GSM615678_U133A_FL163_US144_01_10_06.CEL.gz,22283,54.6,Rx Insensitive,IIA,N0,T2,RD,0,3.97262149212868,NA,P,N,P,High,3,N,Her2,RD,NA,P,RCB-II/III,148,SET-Low,USO,breast cancer tumor,Taxotere
GSM615679,149,GSM615679,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-149",Homo sapiens,sample id: 149,source: USO,age_years: 42.6,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.92470910335387,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615679/suppl/GSM615679_U133A_FL173_US143_01_13_06_3.CEL.gz,22283,42.6,Rx Sensitive,IIIA,N1,T3,RD,0,1.92470910335387,NA,P,N,P,High,2,N,LumA,RD,NA,P,RCB-0/I,149,SET-Low,USO,breast cancer tumor,Taxotere
GSM615680,150,GSM615680,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-150",Homo sapiens,sample id: 150,source: USO,age_years: 48.4,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N0,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_pcr_rd: pCR,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.93429158110883,type_taxane: Taxotere,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615680/suppl/GSM615680_U133A_FL162_US141_01_10_06.CEL.gz,22283,48.4,Rx Sensitive,IIB,N0,T3,pCR,0,3.93429158110883,NA,N,N,N,High,3,N,Basal,pCR,NA,N,RCB-0/I,150,SET-Low,USO,breast cancer tumor,Taxotere
GSM615681,154,GSM615681,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-154",Homo sapiens,sample id: 154,source: USO,age_years: 52.8,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: NA,pathologic_response_pcr_rd: pCR,pathologic_response_pcr_rd: pCR,drfs_1_event_0_censored: 1,drfs_even_time_years: 1.23477070499658,type_taxane: Taxotere,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615681/suppl/GSM615681_U133A_80_FL_006_01_25_06.CEL.gz,22283,52.8,Rx Insensitive,IIA,N0,T2,pCR,1,1.23477070499658,NA,N,N,N,High,NA,N,Basal,pCR,NA,N,RCB-0/I,154,SET-Low,USO,breast cancer tumor,Taxotere
GSM615682,155,GSM615682,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-155",Homo sapiens,sample id: 155,source: USO,age_years: 46.0,er_status_ihc: N,pr_status_ihc: P,her2_status: N,er_status_ihc: N,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.69609856262834,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615682/suppl/GSM615682_U133A_80_FL_005_01_25_06.CEL.gz,22283,46,Rx Sensitive,IIB,N1,T2,RD,0,3.69609856262834,NA,N,N,P,High,2,N,LumA,RD,NA,P,RCB-0/I,155,SET-Low,USO,breast cancer tumor,Taxotere
GSM615683,159,GSM615683,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-159",Homo sapiens,sample id: 159,source: USO,age_years: 57.7,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.98904859685147,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615683/suppl/GSM615683_U133A_80_FL_008_01_25_06.CEL.gz,22283,57.7,Rx Insensitive,IIB,N1,T2,RD,0,3.98904859685147,NA,P,N,P,Low,2,N,LumA,RD,NA,P,RCB-0/I,159,SET-Low,USO,breast cancer tumor,Taxotere
GSM615684,161,GSM615684,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample USO-161",Homo sapiens,sample id: 161,source: USO,age_years: 61.1,er_status_ihc: N,pr_status_ihc: P,her2_status: N,er_status_ihc: N,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.12046543463381,type_taxane: Taxotere,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: Normal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615684/suppl/GSM615684_U133A_80_FL_009_01_26_06.CEL.gz,22283,61.1,Rx Insensitive,IIA,N0,T2,RD,0,4.12046543463381,NA,N,N,N,Low,3,N,Normal,RD,NA,P,RCB-II/III,161,SET-Low,USO,breast cancer tumor,Taxotere
GSM615685,223,GSM615685,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-223",Homo sapiens,sample id: 223,source: MDACC,age_years: 62.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 7.35934291581109,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615685/suppl/GSM615685_FL2042_223_0409.CEL.gz,22283,62,Rx Insensitive,IIB,N1,T2,RD,0,7.35934291581109,NA,P,N,P,High,3,N,LumA,RD,RCB-II,P,RCB-II/III,223,SET-Low,MDACC,breast cancer tumor,Taxotere
GSM615686,225,GSM615686,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-225",Homo sapiens,sample id: 225,source: MDACC,age_years: 37.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 1,drfs_even_time_years: 1.3388090349076,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615686/suppl/GSM615686_FL2043_225_0409.CEL.gz,22283,37,Rx Insensitive,IIA,N0,T2,RD,1,1.3388090349076,NA,P,N,P,Low,2,N,LumA,RD,RCB-II,P,RCB-II/III,225,SET-Low,MDACC,breast cancer tumor,Taxotere
GSM615687,249,GSM615687,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-249",Homo sapiens,sample id: 249,source: MDACC,age_years: 39.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N0,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 1,drfs_even_time_years: 1.25941136208077,type_taxane: Taxotere,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615687/suppl/GSM615687_FL2045_249_0409.CEL.gz,22283,39,Rx Sensitive,IIB,N0,T3,pCR,1,1.25941136208077,NA,N,N,N,High,3,N,Basal,RD,NA,N,RCB-0/I,249,SET-Low,MDACC,breast cancer tumor,Taxotere
GSM615688,268,GSM615688,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-268",Homo sapiens,sample id: 268,source: MDACC,age_years: 38.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 6.60917180013689,type_taxane: Taxotere,esr1_status: P,erbb2_status: P,set_class: SET-Int,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615688/suppl/GSM615688_FL2046_268_0409.CEL.gz,22283,38,Rx Sensitive,IIA,N0,T2,RD,0,6.60917180013689,NA,P,P,P,Low,2,N,LumA,RD,RCB-II,N,RCB-0/I,268,SET-Int,MDACC,breast cancer tumor,Taxotere
GSM615689,272,GSM615689,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-272",Homo sapiens,sample id: 272,source: MDACC,age_years: 40.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N0,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 1,drfs_even_time_years: 2.02600958247776,type_taxane: Taxotere,esr1_status: N,erbb2_status: P,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615689/suppl/GSM615689_FL2047_272_0409.CEL.gz,22283,40,Rx Insensitive,IIB,N0,T3,pCR,1,2.02600958247776,NA,N,P,N,High,3,N,Basal,RD,NA,N,RCB-0/I,272,SET-Low,MDACC,breast cancer tumor,Taxotere
GSM615690,290,GSM615690,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-290",Homo sapiens,sample id: 290,source: MDACC,age_years: 45.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 6.40657084188912,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615690/suppl/GSM615690_FL2048_290_0409.CEL.gz,22283,45,Rx Insensitive,IIA,N0,T2,RD,0,6.40657084188912,NA,P,N,P,Low,2,N,LumA,RD,RCB-II,P,RCB-II/III,290,SET-Low,MDACC,breast cancer tumor,Taxotere
GSM615691,293,GSM615691,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-293",Homo sapiens,sample id: 293,source: MDACC,age_years: 34.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 1,drfs_even_time_years: 2.09993155373032,type_taxane: Taxotere,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615691/suppl/GSM615691_FL2104_293_0509.CEL.gz,22283,34,Rx Insensitive,IIB,N1,T2,pCR,1,2.09993155373032,NA,N,N,N,High,3,N,Basal,RD,RCB-III,N,RCB-0/I,293,SET-Low,MDACC,breast cancer tumor,Taxotere
GSM615692,305,GSM615692,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-305",Homo sapiens,sample id: 305,source: MDACC,age_years: 59.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.14236824093087,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615692/suppl/GSM615692_FL2049_305_0409.CEL.gz,22283,59,Rx Sensitive,IIB,N1,T2,RD,0,4.14236824093087,NA,P,N,P,Low,2,N,LumA,RD,RCB-III,P,RCB-0/I,305,SET-Low,MDACC,breast cancer tumor,Taxotere
GSM615693,320,GSM615693,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-320",Homo sapiens,sample id: 320,source: MDACC,age_years: 36.0,er_status_ihc: N,pr_status_ihc: P,her2_status: N,er_status_ihc: N,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.72553045859001,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615693/suppl/GSM615693_FL2050_320_0409.CEL.gz,22283,36,Rx Insensitive,IIB,N1,T2,RD,0,4.72553045859001,NA,N,N,P,High,3,N,LumA,RD,NA,P,RCB-II/III,320,SET-Low,MDACC,breast cancer tumor,Taxotere
GSM615694,324,GSM615694,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-324",Homo sapiens,sample id: 324,source: MDACC,age_years: 40.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_pcr_rd: pCR,drfs_1_event_0_censored: 0,drfs_even_time_years: 5.4072553045859,type_taxane: Taxotere,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615694/suppl/GSM615694_FL2051_324_0409.CEL.gz,22283,40,Rx Insensitive,IIB,N1,T2,RD,0,5.4072553045859,NA,N,N,N,High,3,N,Basal,pCR,RCB-0/I,N,RCB-0/I,324,SET-Low,MDACC,breast cancer tumor,Taxotere
GSM615695,327,GSM615695,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-327",Homo sapiens,sample id: 327,source: MDACC,age_years: 72.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_pcr_rd: pCR,drfs_1_event_0_censored: 0,drfs_even_time_years: 5.37713894592745,type_taxane: Taxotere,esr1_status: N,erbb2_status: P,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615695/suppl/GSM615695_FL2027_327_0409.CEL.gz,22283,72,Rx Insensitive,IIIA,N1,T3,pCR,0,5.37713894592745,NA,P,P,N,High,3,N,Basal,pCR,RCB-0/I,P,RCB-0/I,327,SET-Low,MDACC,breast cancer tumor,Taxotere
GSM615696,336,GSM615696,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-336",Homo sapiens,sample id: 336,source: MDACC,age_years: 65.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 1,drfs_even_time_years: 2.95140314852841,type_taxane: Taxotere,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615696/suppl/GSM615696_FL2028_336_0409.CEL.gz,22283,65,Rx Insensitive,IIB,N1,T2,pCR,1,2.95140314852841,NA,N,N,N,High,3,N,Basal,RD,RCB-0/I,N,RCB-0/I,336,SET-Low,MDACC,breast cancer tumor,Taxotere
GSM615697,337,GSM615697,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-337",Homo sapiens,sample id: 337,source: MDACC,age_years: 52.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N2,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 6.07529089664613,type_taxane: Taxotere,esr1_status: P,erbb2_status: P,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615697/suppl/GSM615697_FL2029_337_0409.CEL.gz,22283,52,Rx Insensitive,IIIA,N2,T2,RD,0,6.07529089664613,NA,P,P,P,Low,3,N,LumA,RD,RCB-III,P,RCB-II/III,337,SET-Low,MDACC,breast cancer tumor,Taxotere
GSM615698,342,GSM615698,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-342",Homo sapiens,sample id: 342,source: MDACC,age_years: 56.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 5.75770020533881,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615698/suppl/GSM615698_FL2030_342_0409.CEL.gz,22283,56,Rx Sensitive,IIA,N0,T2,RD,0,5.75770020533881,NA,P,N,P,Low,3,N,LumA,RD,RCB-II,P,RCB-0/I,342,SET-Low,MDACC,breast cancer tumor,Taxotere
GSM615699,348,GSM615699,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-348",Homo sapiens,sample id: 348,source: MDACC,age_years: 47.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 5.85626283367557,type_taxane: Taxotere,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615699/suppl/GSM615699_FL2031_348_0409.CEL.gz,22283,47,Rx Sensitive,IIIA,N1,T3,pCR,0,5.85626283367557,NA,N,N,N,High,3,N,Basal,RD,RCB-II,N,RCB-0/I,348,SET-Low,MDACC,breast cancer tumor,Taxotere
GSM615700,364,GSM615700,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-364",Homo sapiens,sample id: 364,source: MDACC,age_years: 69.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIB,grade: 1,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 6.02053388090349,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615700/suppl/GSM615700_FL2105_364_0509.CEL.gz,22283,69,Rx Insensitive,IIB,N0,T3,RD,0,6.02053388090349,NA,P,N,P,Low,1,N,LumA,RD,RCB-II,P,RCB-II/III,364,SET-Low,MDACC,breast cancer tumor,Taxotere
GSM615701,437,GSM615701,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-437",Homo sapiens,sample id: 437,source: MDACC,age_years: 53.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 5.30047912388775,type_taxane: Taxotere,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615701/suppl/GSM615701_FL2033_437_0409.CEL.gz,22283,53,Rx Insensitive,IIB,N1,T2,pCR,0,5.30047912388775,NA,P,N,N,High,3,N,Basal,RD,RCB-III,N,RCB-0/I,437,SET-Low,MDACC,breast cancer tumor,Taxotere
GSM615702,440,GSM615702,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-440",Homo sapiens,sample id: 440,source: MDACC,age_years: 57.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 5.60164271047228,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615702/suppl/GSM615702_FL2034_440_0409.CEL.gz,22283,57,Rx Sensitive,IIA,N0,T2,RD,0,5.60164271047228,NA,P,N,P,High,3,N,LumB,RD,RCB-II,N,RCB-0/I,440,SET-Low,MDACC,breast cancer tumor,Taxotere
GSM615703,470,GSM615703,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-470",Homo sapiens,sample id: 470,source: MDACC,age_years: 58.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 5.13347022587269,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: Normal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615703/suppl/GSM615703_FL2035_470_0409.CEL.gz,22283,58,Rx Insensitive,IIA,N0,T2,RD,0,5.13347022587269,NA,P,N,P,Low,3,N,Normal,RD,RCB-0/I,N,RCB-II/III,470,SET-Low,MDACC,breast cancer tumor,Taxotere
GSM615704,480,GSM615704,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-480",Homo sapiens,sample id: 480,source: MDACC,age_years: 58.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIA,grade: 1,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 5.46475017111567,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: Normal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615704/suppl/GSM615704_FL2106_480_0509.CEL.gz,22283,58,Rx Insensitive,IIA,N1,T1,RD,0,5.46475017111567,NA,P,N,P,Low,1,N,Normal,RD,RCB-II,P,RCB-II/III,480,SET-Low,MDACC,breast cancer tumor,Taxotere
GSM615705,496,GSM615705,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-496",Homo sapiens,sample id: 496,source: MDACC,age_years: 40.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 1,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 5.28952772073922,type_taxane: Taxotere,esr1_status: P,erbb2_status: P,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615705/suppl/GSM615705_FL2056_496_0509.CEL.gz,22283,40,Rx Sensitive,IIB,N1,T2,RD,0,5.28952772073922,NA,P,P,P,Low,1,N,LumA,RD,RCB-II,P,RCB-0/I,496,SET-Low,MDACC,breast cancer tumor,Taxotere
GSM615706,509,GSM615706,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-509",Homo sapiens,sample id: 509,source: MDACC,age_years: 43.0,er_status_ihc: N,pr_status_ihc: P,her2_status: N,er_status_ihc: N,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 2,pathologic_response_pcr_rd: pCR,pathologic_response_pcr_rd: pCR,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.6570841889117,type_taxane: Taxotere,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615706/suppl/GSM615706_FL2057_509_0509.CEL.gz,22283,43,Rx Sensitive,IIIA,N1,T3,pCR,0,4.6570841889117,NA,N,N,N,High,2,N,Basal,pCR,RCB-0/I,P,RCB-0/I,509,SET-Low,MDACC,breast cancer tumor,Taxotere
GSM615707,544,GSM615707,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-544",Homo sapiens,sample id: 544,source: MDACC,age_years: 63.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.79123887748118,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615707/suppl/GSM615707_FL2058_544_0509.CEL.gz,22283,63,Rx Sensitive,IIA,N0,T2,RD,0,4.79123887748118,NA,N,N,P,High,3,N,Basal,RD,RCB-0/I,N,RCB-0/I,544,SET-Low,MDACC,breast cancer tumor,Taxotere
GSM615708,551,GSM615708,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-551",Homo sapiens,sample id: 551,source: MDACC,age_years: 64.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.95824777549624,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615708/suppl/GSM615708_FL2059_551_0509.CEL.gz,22283,64,Rx Insensitive,IIB,N1,T2,RD,0,4.95824777549624,NA,P,N,P,High,2,N,LumB,RD,RCB-II,N,RCB-II/III,551,SET-Low,MDACC,breast cancer tumor,Taxotere
GSM615709,575,GSM615709,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-575",Homo sapiens,sample id: 575,source: MDACC,age_years: 27.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc: P,clinical_nodal_status: N2,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.80219028062971,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615709/suppl/GSM615709_U133A_80-FL-109_FL285-575_05_19_06.CEL.gz,22283,27,Rx Insensitive,IIIA,N2,T3,RD,0,4.80219028062971,NA,P,N,P,High,3,N,LumB,RD,NA,N,RCB-0/I,575,SET-Low,MDACC,breast cancer tumor,Taxol
GSM615710,645,GSM615710,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-645",Homo sapiens,sample id: 645,source: MDACC,age_years: 42.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.06297056810404,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615710/suppl/GSM615710_FL2061_645_0509.CEL.gz,22283,42,Rx Insensitive,IIB,N0,T3,RD,0,4.06297056810404,NA,P,N,P,Low,2,N,LumA,RD,RCB-0/I,P,RCB-II/III,645,SET-Low,MDACC,breast cancer tumor,Taxotere
GSM615711,660,GSM615711,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-660",Homo sapiens,sample id: 660,source: MDACC,age_years: 34.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.1533196440794,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615711/suppl/GSM615711_FL2064_660_0509.CEL.gz,22283,34,Rx Insensitive,IIA,N0,T2,RD,0,4.1533196440794,NA,P,N,P,Low,2,N,LumA,RD,RCB-II,P,RCB-II/III,660,SET-Low,MDACC,breast cancer tumor,Taxotere
GSM615712,699,GSM615712,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-699",Homo sapiens,sample id: 699,source: MDACC,age_years: 57.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 1,drfs_even_time_years: 1.23750855578371,type_taxane: Taxotere,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615712/suppl/GSM615712_FL2065_699_0509.CEL.gz,22283,57,Rx Insensitive,IIB,N1,T2,pCR,1,1.23750855578371,NA,N,N,N,High,3,N,Basal,RD,RCB-III,N,RCB-0/I,699,SET-Low,MDACC,breast cancer tumor,Taxotere
GSM615713,748,GSM615713,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-748",Homo sapiens,sample id: 748,source: MDACC,age_years: 45.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 1,drfs_even_time_years: 3.09103353867214,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615713/suppl/GSM615713_FL2015_748_0409.CEL.gz,22283,45,Rx Insensitive,IIA,N1,T1,RD,1,3.09103353867214,NA,P,N,P,Low,2,N,LumA,RD,NA,P,RCB-II/III,748,SET-Low,MDACC,breast cancer tumor,Taxol
GSM615714,787,GSM615714,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-787",Homo sapiens,sample id: 787,source: MDACC,age_years: 54.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.84736481861739,type_taxane: Taxotere,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615714/suppl/GSM615714_FL828-787.CEL.gz,22283,54,Rx Insensitive,IIB,N1,T2,pCR,0,2.84736481861739,NA,N,N,N,High,3,N,Basal,RD,RCB-0/I,N,RCB-0/I,787,SET-Low,MDACC,breast cancer tumor,Taxotere
GSM615715,798,GSM615715,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-798",Homo sapiens,sample id: 798,source: MDACC,age_years: 50.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.8227241615332,type_taxane: Taxotere,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615715/suppl/GSM615715_FL832-798.CEL.gz,22283,50,Rx Insensitive,IIA,N0,T2,pCR,0,2.8227241615332,NA,N,N,N,High,3,N,Basal,RD,RCB-II,N,RCB-0/I,798,SET-Low,MDACC,breast cancer tumor,Taxotere
GSM615716,811,GSM615716,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-811",Homo sapiens,sample id: 811,source: MDACC,age_years: 33.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N2,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.48870636550308,type_taxane: Taxol,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615716/suppl/GSM615716_FL1452_811.CEL.gz,22283,33,Rx Insensitive,IIIA,N2,T3,pCR,0,2.48870636550308,NA,N,N,N,High,3,N,Basal,RD,RCB-II,N,RCB-0/I,811,SET-Low,MDACC,breast cancer tumor,Taxol
GSM615717,813,GSM615717,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-813",Homo sapiens,sample id: 813,source: MDACC,age_years: 45.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.66392881587953,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: Normal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615717/suppl/GSM615717_FL1126-813.CEL.gz,22283,45,Rx Insensitive,IIIA,N1,T3,RD,0,2.66392881587953,NA,P,N,P,Low,3,N,Normal,RD,RCB-II,P,RCB-0/I,813,SET-Low,MDACC,breast cancer tumor,Taxol
GSM615718,814,GSM615718,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-814",Homo sapiens,sample id: 814,source: MDACC,age_years: 54.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.83709787816564,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615718/suppl/GSM615718_FL1901-814rehyb.CEL.gz,22283,54,Rx Insensitive,IIB,N1,T2,RD,0,1.83709787816564,NA,P,N,P,Low,2,N,LumA,RD,RCB-0/I,N,RCB-0/I,814,SET-Low,MDACC,breast cancer tumor,Taxol
GSM615719,815,GSM615719,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-815",Homo sapiens,sample id: 815,source: MDACC,age_years: 49.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIB,grade: 1,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.1047227926078,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Int,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615719/suppl/GSM615719_FL1127-815.CEL.gz,22283,49,Rx Sensitive,IIB,N0,T3,RD,0,3.1047227926078,NA,P,N,P,Low,1,N,LumA,RD,RCB-II,P,RCB-II/III,815,SET-Int,MDACC,breast cancer tumor,Taxol
GSM615720,817,GSM615720,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-817",Homo sapiens,sample id: 817,source: MDACC,age_years: 35.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.59548254620123,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615720/suppl/GSM615720_FL1996_817_0409.CEL.gz,22283,35,Rx Insensitive,IIIB,N1,T4,RD,0,2.59548254620123,NA,P,N,P,High,3,N,LumB,RD,RCB-III,P,RCB-II/III,817,SET-Low,MDACC,breast cancer tumor,Taxol
GSM615721,821,GSM615721,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-821",Homo sapiens,sample id: 821,source: MDACC,age_years: 60.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.93497604380561,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615721/suppl/GSM615721_FL804-821.CEL.gz,22283,60,Rx Insensitive,IIA,N0,T2,RD,0,2.93497604380561,NA,P,N,P,Low,2,N,LumA,RD,RCB-III,P,RCB-0/I,821,SET-Low,MDACC,breast cancer tumor,Taxol
GSM615722,822,GSM615722,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-822",Homo sapiens,sample id: 822,source: MDACC,age_years: 43.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.01711156741958,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615722/suppl/GSM615722_FL1454_822.CEL.gz,22283,43,Rx Insensitive,IIB,N1,T2,RD,0,3.01711156741958,NA,P,N,P,Low,2,N,LumA,RD,RCB-II,P,RCB-0/I,822,SET-Low,MDACC,breast cancer tumor,Taxol
GSM615723,824,GSM615723,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-824",Homo sapiens,sample id: 824,source: MDACC,age_years: 41.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIIB,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_pcr_rd: pCR,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.97330595482546,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615723/suppl/GSM615723_FL1655_824.CEL.gz,22283,41,Rx Insensitive,IIIB,N1,T4,RD,0,2.97330595482546,NA,P,N,P,High,3,N,LumB,pCR,RCB-0/I,P,RCB-0/I,824,SET-Low,MDACC,breast cancer tumor,Taxol
GSM615724,825,GSM615724,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-825",Homo sapiens,sample id: 825,source: MDACC,age_years: 59.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_pcr_rd: pCR,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.85284052019165,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615724/suppl/GSM615724_FL1665_825.CEL.gz,22283,59,Rx Sensitive,IIA,N0,T2,RD,0,2.85284052019165,NA,P,N,P,High,3,N,LumA,pCR,RCB-0/I,P,RCB-0/I,825,SET-Low,MDACC,breast cancer tumor,Taxol
GSM615725,826,GSM615725,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-826",Homo sapiens,sample id: 826,source: MDACC,age_years: 33.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.03353867214237,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615725/suppl/GSM615725_FL1666_826.CEL.gz,22283,33,Rx Insensitive,IIA,N0,T2,RD,0,3.03353867214237,NA,P,N,P,High,3,N,LumA,RD,RCB-III,N,RCB-II/III,826,SET-Low,MDACC,breast cancer tumor,Taxol
GSM615726,828,GSM615726,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-828",Homo sapiens,sample id: 828,source: MDACC,age_years: 58.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N2,clinical_ajcc_stage: IIIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.95687885010267,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615726/suppl/GSM615726_FL1997_828_0409.CEL.gz,22283,58,Rx Insensitive,IIIB,N2,T4,RD,0,2.95687885010267,NA,P,N,P,High,3,N,LumB,RD,RCB-III,P,RCB-0/I,828,SET-Low,MDACC,breast cancer tumor,Taxol
GSM615727,829,GSM615727,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-829",Homo sapiens,sample id: 829,source: MDACC,age_years: 24.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N2,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_pcr_rd: pCR,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.77891854893908,type_taxane: Taxol,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615727/suppl/GSM615727_FL1457_829.CEL.gz,22283,24,Rx Sensitive,IIIA,N2,T2,pCR,0,2.77891854893908,NA,N,N,N,High,3,N,Basal,pCR,RCB-0/I,N,RCB-0/I,829,SET-Low,MDACC,breast cancer tumor,Taxol
GSM615728,831,GSM615728,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-831",Homo sapiens,sample id: 831,source: MDACC,age_years: 45.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc: P,clinical_nodal_status: N3,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.81724845995893,type_taxane: Taxol,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615728/suppl/GSM615728_FL1652_831.CEL.gz,22283,45,Rx Insensitive,IIB,N3,T2,pCR,0,2.81724845995893,NA,P,N,N,High,3,N,Basal,RD,RCB-II,N,RCB-II/III,831,SET-Low,MDACC,breast cancer tumor,Taxol
GSM615729,835,GSM615729,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-835",Homo sapiens,sample id: 835,source: MDACC,age_years: 53.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 1,drfs_even_time_years: 1.94387405886379,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Int,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615729/suppl/GSM615729_FL1976_835_0309.CEL.gz,22283,53,Rx Sensitive,IIIB,N1,T4,RD,1,1.94387405886379,NA,P,N,P,Low,3,N,LumA,RD,RCB-III,P,RCB-II/III,835,SET-Int,MDACC,breast cancer tumor,Taxol
GSM615730,837,GSM615730,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-837",Homo sapiens,sample id: 837,source: MDACC,age_years: 47.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 1,drfs_even_time_years: 1.27310061601643,type_taxane: Taxol,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615730/suppl/GSM615730_FL1662_837.CEL.gz,22283,47,Rx Insensitive,IIIB,N0,T4,pCR,1,1.27310061601643,NA,P,N,N,High,3,N,Basal,RD,RCB-II,N,RCB-0/I,837,SET-Low,MDACC,breast cancer tumor,Taxol
GSM615731,838,GSM615731,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-838",Homo sapiens,sample id: 838,source: MDACC,age_years: 43.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.4558521560575,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615731/suppl/GSM615731_FL1902-838rehyb.CEL.gz,22283,43,Rx Insensitive,IIA,N0,T2,RD,0,2.4558521560575,NA,P,N,P,High,2,N,LumB,RD,RCB-II,P,RCB-II/III,838,SET-Low,MDACC,breast cancer tumor,Taxol
GSM615732,839,GSM615732,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-839",Homo sapiens,sample id: 839,source: MDACC,age_years: 24.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 1,drfs_even_time_years: 1.63175906913073,type_taxane: Taxol,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615732/suppl/GSM615732_FL1903-839rehyb.CEL.gz,22283,24,Rx Insensitive,IIIA,N1,T3,pCR,1,1.63175906913073,NA,P,N,N,High,3,N,Basal,RD,RCB-II,N,RCB-0/I,839,SET-Low,MDACC,breast cancer tumor,Taxol
GSM615733,840,GSM615733,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-840",Homo sapiens,sample id: 840,source: MDACC,age_years: 64.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_pcr_rd: pCR,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.18754277891855,type_taxane: Taxol,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615733/suppl/GSM615733_FL2000_840_0409.CEL.gz,22283,64,Rx Insensitive,IIA,N0,T2,pCR,0,2.18754277891855,NA,N,N,N,High,3,N,Basal,pCR,RCB-0/I,N,RCB-0/I,840,SET-Low,MDACC,breast cancer tumor,Taxol
GSM615734,842,GSM615734,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-842",Homo sapiens,sample id: 842,source: MDACC,age_years: 61.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.80903490759754,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615734/suppl/GSM615734_FL1904-842rehyb.CEL.gz,22283,61,Rx Sensitive,IIA,N0,T2,RD,0,2.80903490759754,NA,P,N,P,Low,2,N,LumA,RD,RCB-II,P,RCB-0/I,842,SET-Low,MDACC,breast cancer tumor,Taxol
GSM615735,845,GSM615735,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-845",Homo sapiens,sample id: 845,source: MDACC,age_years: 51.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.6009582477755,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615735/suppl/GSM615735_FL1661_845.CEL.gz,22283,51,Rx Sensitive,IIB,N1,T2,RD,0,2.6009582477755,NA,P,N,P,High,3,N,LumB,RD,RCB-0/I,P,RCB-0/I,845,SET-Low,MDACC,breast cancer tumor,Taxol
GSM615736,854,GSM615736,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-854",Homo sapiens,sample id: 854,source: MDACC,age_years: 52.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_pcr_rd: pCR,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.32169746748802,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615736/suppl/GSM615736_FL1909-854rehyb.CEL.gz,22283,52,Rx Sensitive,IIA,N1,T0,RD,0,2.32169746748802,NA,P,N,P,High,3,N,LumB,pCR,RCB-0/I,N,RCB-0/I,854,SET-Low,MDACC,breast cancer tumor,Taxol
GSM615737,857,GSM615737,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-857",Homo sapiens,sample id: 857,source: MDACC,age_years: 50.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_pcr_rd: pCR,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.57357973990418,type_taxane: Taxol,esr1_status: N,erbb2_status: P,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615737/suppl/GSM615737_FL1910-857rehyb.CEL.gz,22283,50,Rx Sensitive,IIA,N0,T2,pCR,0,2.57357973990418,NA,P,P,N,High,3,N,Basal,pCR,RCB-0/I,N,RCB-0/I,857,SET-Low,MDACC,breast cancer tumor,Taxol
GSM615738,860,GSM615738,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-860",Homo sapiens,sample id: 860,source: MDACC,age_years: 61.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.37645448323066,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Int,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615738/suppl/GSM615738_FL1653_860.CEL.gz,22283,61,Rx Sensitive,IIIB,N0,T4,RD,0,2.37645448323066,NA,P,N,P,Low,2,N,LumA,RD,RCB-II,P,RCB-II/III,860,SET-Int,MDACC,breast cancer tumor,Taxol
GSM615739,865,GSM615739,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-865",Homo sapiens,sample id: 865,source: MDACC,age_years: 53.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N0,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 1,drfs_even_time_years: 1.65092402464066,type_taxane: Taxol,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615739/suppl/GSM615739_FL1632_865.CEL.gz,22283,53,Rx Insensitive,IIB,N0,T3,pCR,1,1.65092402464066,NA,N,N,N,High,3,N,Basal,RD,RCB-II,N,RCB-II/III,865,SET-Low,MDACC,breast cancer tumor,Taxol
GSM615740,867,GSM615740,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-867",Homo sapiens,sample id: 867,source: MDACC,age_years: 42.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.31895961670089,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Int,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615740/suppl/GSM615740_FL1663_867.CEL.gz,22283,42,Rx Sensitive,IIA,N0,T2,RD,0,2.31895961670089,NA,P,N,P,Low,2,N,LumA,RD,RCB-II,P,RCB-II/III,867,SET-Int,MDACC,breast cancer tumor,Taxol
GSM615741,868,GSM615741,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-868",Homo sapiens,sample id: 868,source: MDACC,age_years: 44.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.63175906913073,type_taxane: Taxol,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615741/suppl/GSM615741_FL1664_868.CEL.gz,22283,44,Rx Sensitive,IIA,N0,T2,pCR,0,1.63175906913073,NA,P,N,N,High,3,N,Basal,RD,RCB-0/I,N,RCB-0/I,868,SET-Low,MDACC,breast cancer tumor,Taxol
GSM615742,879,GSM615742,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-879",Homo sapiens,sample id: 879,source: MDACC,age_years: 38.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N3,clinical_ajcc_stage: IIIC,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_pcr_rd: pCR,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.08624229979466,type_taxane: Taxol,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615742/suppl/GSM615742_FL1542_879_2.CEL.gz,22283,38,Rx Insensitive,IIIC,N3,T2,pCR,0,2.08624229979466,NA,N,N,N,High,3,N,Basal,pCR,RCB-0/I,N,RCB-0/I,879,SET-Low,MDACC,breast cancer tumor,Taxol
GSM615743,880,GSM615743,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-880",Homo sapiens,sample id: 880,source: MDACC,age_years: 43.4,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N2,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.10540725530459,type_taxane: Taxotere,esr1_status: P,erbb2_status: P,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615743/suppl/GSM615743_FL2079_880_0509.CEL.gz,22283,43.4,Rx Insensitive,IIA,N2,T2,RD,0,2.10540725530459,NA,P,P,P,Low,2,N,LumA,RD,RCB-II,P,RCB-0/I,880,SET-Low,MDACC,breast cancer tumor,Taxotere
GSM615744,881,GSM615744,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-881",Homo sapiens,sample id: 881,source: MDACC,age_years: 48.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_pcr_rd: pCR,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.78507871321013,type_taxane: Taxotere,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: Normal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615744/suppl/GSM615744_FL2080_881_0509.CEL.gz,22283,48,Rx Sensitive,IIA,N0,T2,RD,0,1.78507871321013,NA,N,N,N,Low,3,N,Normal,pCR,RCB-0/I,N,RCB-0/I,881,SET-Low,MDACC,breast cancer tumor,Taxotere
GSM615745,883,GSM615745,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-883",Homo sapiens,sample id: 883,source: MDACC,age_years: 46.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: I,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.94934976043806,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615745/suppl/GSM615745_FL2078_883_0509.CEL.gz,22283,46,Rx Insensitive,I,N0,T1,RD,0,1.94934976043806,NA,P,N,P,Low,2,N,LumA,RD,RCB-II,P,RCB-0/I,883,SET-Low,MDACC,breast cancer tumor,Taxotere
GSM615746,885,GSM615746,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-885",Homo sapiens,sample id: 885,source: MDACC,age_years: 56.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N3,clinical_ajcc_stage: IIIC,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 1,drfs_even_time_years: 1.19917864476386,type_taxane: Taxol,esr1_status: N,erbb2_status: P,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Normal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615746/suppl/GSM615746_FL2007_885_0409.CEL.gz,22283,56,Rx Insensitive,IIIC,N3,T2,pCR,1,1.19917864476386,NA,N,P,N,High,2,N,Normal,RD,RCB-III,N,RCB-II/III,885,SET-Low,MDACC,breast cancer tumor,Taxol
GSM615747,886,GSM615747,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-886",Homo sapiens,sample id: 886,source: MDACC,age_years: 42.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.04791238877481,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-High,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615747/suppl/GSM615747_FL1607_886.CEL.gz,22283,42,Rx Sensitive,IIA,N0,T2,RD,0,2.04791238877481,NA,P,N,P,Low,2,N,LumA,RD,RCB-II,P,RCB-II/III,886,SET-High,MDACC,breast cancer tumor,Taxol
GSM615748,892,GSM615748,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-892",Homo sapiens,sample id: 892,source: MDACC,age_years: 60.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_pcr_rd: pCR,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.82067077344285,type_taxane: Taxol,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615748/suppl/GSM615748_FL1961-892.CEL.gz,22283,60,Rx Insensitive,IIA,N0,T2,pCR,0,1.82067077344285,NA,P,N,N,High,3,N,Basal,pCR,RCB-0/I,N,RCB-II/III,892,SET-Low,MDACC,breast cancer tumor,Taxol
GSM615749,893,GSM615749,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-893",Homo sapiens,sample id: 893,source: MDACC,age_years: 47.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.70841889117043,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615749/suppl/GSM615749_FL2081_893_0509.CEL.gz,22283,47,Rx Sensitive,IIA,N1,T1,RD,0,1.70841889117043,NA,P,N,P,High,3,N,LumB,RD,NA,P,RCB-0/I,893,SET-Low,MDACC,breast cancer tumor,Taxotere
GSM615750,896,GSM615750,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-896",Homo sapiens,sample id: 896,source: MDACC,age_years: 27.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.68925393566051,type_taxane: Taxotere,esr1_status: P,erbb2_status: P,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615750/suppl/GSM615750_FL2082_896_0509.CEL.gz,22283,27,Rx Sensitive,IIIA,N1,T3,RD,0,1.68925393566051,NA,P,P,P,Low,3,N,LumA,RD,RCB-II,P,RCB-0/I,896,SET-Low,MDACC,breast cancer tumor,Taxotere
GSM615751,901,GSM615751,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-901",Homo sapiens,sample id: 901,source: MDACC,age_years: 38.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.73853524982888,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615751/suppl/GSM615751_FL1963-901.CEL.gz,22283,38,Rx Insensitive,IIB,N1,T2,RD,0,1.73853524982888,NA,N,N,P,Low,3,N,LumA,RD,RCB-II,N,RCB-0/I,901,SET-Low,MDACC,breast cancer tumor,Taxol
GSM615752,905,GSM615752,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-905",Homo sapiens,sample id: 905,source: MDACC,age_years: 64.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.34702258726899,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Int,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615752/suppl/GSM615752_FL2233_905_0809.CEL.gz,22283,64,Rx Sensitive,IIA,N0,T2,RD,0,1.34702258726899,NA,P,N,P,Low,2,N,LumA,RD,RCB-II,P,RCB-II/III,905,SET-Int,MDACC,breast cancer tumor,Taxol
GSM615753,910,GSM615753,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-910",Homo sapiens,sample id: 910,source: MDACC,age_years: 46.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N3,clinical_ajcc_stage: IIIC,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.44010951403149,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Her2,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615753/suppl/GSM615753_FL1973_910_0309.CEL.gz,22283,46,Rx Insensitive,IIIC,N3,T4,RD,0,1.44010951403149,NA,P,N,P,High,3,N,Her2,RD,RCB-III,P,RCB-0/I,910,SET-Low,MDACC,breast cancer tumor,Taxol
GSM615754,913,GSM615754,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-913",Homo sapiens,sample id: 913,source: MDACC,age_years: 59.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc: P,clinical_nodal_status: N3,clinical_ajcc_stage: IIIC,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.53045859000684,type_taxane: Taxol,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Her2,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615754/suppl/GSM615754_FL2236_913_0809.CEL.gz,22283,59,Rx Insensitive,IIIC,N3,T2,pCR,0,1.53045859000684,NA,P,N,N,High,3,N,Her2,RD,RCB-II,N,RCB-II/III,913,SET-Low,MDACC,breast cancer tumor,Taxol
GSM615755,916,GSM615755,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-916",Homo sapiens,sample id: 916,source: MDACC,age_years: 31.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N2,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 0.980150581793292,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615755/suppl/GSM615755_FL2237_916_0809.CEL.gz,22283,31,Rx Insensitive,IIIA,N2,T3,RD,0,0.980150581793292,NA,P,N,P,High,3,N,Basal,RD,NA,P,RCB-II/III,916,SET-Low,MDACC,breast cancer tumor,Taxol
GSM615756,MDA002,GSM615756,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-MDA002",Homo sapiens,sample id: MDA002,source: MDACC,age_years: 53.1,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N2,clinical_ajcc_stage: IIIA,grade: 1,pathologic_response_pcr_rd: NA,pathologic_response_pcr_rd: NA,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.4031485284052,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Int,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615756/suppl/GSM615756_FL2550_05_014.CEL.gz,22283,53.1,Rx Sensitive,IIIA,N2,T2,RD,0,3.4031485284052,NA,P,N,P,Low,1,N,LumA,NA,NA,P,RCB-II/III,MDA002,SET-Int,MDACC,breast cancer tumor,Taxol
GSM615757,MDA003,GSM615757,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-MDA003",Homo sapiens,sample id: MDA003,source: MDACC,age_years: 62.6,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N0,clinical_ajcc_stage: I,grade: 2,pathologic_response_pcr_rd: NA,pathologic_response_pcr_rd: NA,drfs_1_event_0_censored: 1,drfs_even_time_years: 0.763860369609856,type_taxane: Taxotere,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615757/suppl/GSM615757_FL2552_05_032.CEL.gz,22283,62.6,Rx Insensitive,I,N0,T1,pCR,1,0.763860369609856,NA,N,N,N,High,2,N,Basal,NA,NA,N,RCB-II/III,MDA003,SET-Low,MDACC,breast cancer tumor,Taxotere
GSM615758,MDA005,GSM615758,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-MDA005",Homo sapiens,sample id: MDA005,source: MDACC,age_years: 49.1,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: NA,pathologic_response_pcr_rd: NA,drfs_1_event_0_censored: 1,drfs_even_time_years: 4.17248459958932,type_taxane: Taxotere,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615758/suppl/GSM615758_FL2554_06_001.CEL.gz,22283,49.1,Rx Insensitive,IIA,N1,T1,RD,1,4.17248459958932,NA,P,N,P,Low,2,N,LumA,NA,NA,P,RCB-II/III,MDA005,SET-Low,MDACC,breast cancer tumor,Taxotere
GSM615759,MDA006,GSM615759,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-MDA006",Homo sapiens,sample id: MDA006,source: MDACC,age_years: 66.7,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: NA,pathologic_response_pcr_rd: NA,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.93702943189596,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Int,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615759/suppl/GSM615759_FL2555_06_010.CEL.gz,22283,66.7,Rx Sensitive,IIB,N1,T2,RD,0,3.93702943189596,NA,P,N,P,Low,2,N,LumA,NA,NA,P,RCB-II/III,MDA006,SET-Int,MDACC,breast cancer tumor,Taxol
GSM615760,MDA007,GSM615760,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-MDA007",Homo sapiens,sample id: MDA007,source: MDACC,age_years: 67.4,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc: P,clinical_nodal_status: N2,clinical_ajcc_stage: IIIA,grade: 2,pathologic_response_pcr_rd: NA,pathologic_response_pcr_rd: NA,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.81382614647502,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615760/suppl/GSM615760_FL2556_06_011.CEL.gz,22283,67.4,Rx Sensitive,IIIA,N2,T2,RD,0,3.81382614647502,NA,P,N,P,Low,2,N,LumB,NA,NA,N,RCB-0/I,MDA007,SET-Low,MDACC,breast cancer tumor,Taxol
GSM615761,MDA008,GSM615761,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-MDA008",Homo sapiens,sample id: MDA008,source: MDACC,age_years: 60.9,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 1,pathologic_response_pcr_rd: NA,pathologic_response_pcr_rd: NA,drfs_1_event_0_censored: 0,drfs_even_time_years: 5.01574264202601,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615761/suppl/GSM615761_FL2593MDA008.CEL.gz,22283,60.9,Rx Sensitive,IIIA,N1,T3,RD,0,5.01574264202601,NA,P,N,P,Low,1,N,LumA,NA,NA,N,RCB-0/I,MDA008,SET-Low,MDACC,breast cancer tumor,Taxol
GSM615762,MDA009,GSM615762,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-MDA009",Homo sapiens,sample id: MDA009,source: MDACC,age_years: 32.8,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: NA,pathologic_response_pcr_rd: NA,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.18685831622177,type_taxane: Taxol,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Her2,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615762/suppl/GSM615762_FL2594MDA009.CEL.gz,22283,32.8,Rx Sensitive,IIIA,N1,T3,pCR,0,3.18685831622177,NA,N,N,N,High,3,N,Her2,NA,NA,N,RCB-0/I,MDA009,SET-Low,MDACC,breast cancer tumor,Taxol
GSM615763,MDA010,GSM615763,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-MDA010",Homo sapiens,sample id: MDA010,source: MDACC,age_years: 45.2,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: NA,pathologic_response_pcr_rd: NA,drfs_1_event_0_censored: 0,drfs_even_time_years: 6.08624229979466,type_taxane: Taxol,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615763/suppl/GSM615763_FL2595MDA010.CEL.gz,22283,45.2,Rx Insensitive,IIA,N0,T2,pCR,0,6.08624229979466,NA,N,N,N,High,3,N,Basal,NA,NA,N,RCB-0/I,MDA010,SET-Low,MDACC,breast cancer tumor,Taxol
GSM615764,MDA011,GSM615764,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-MDA011",Homo sapiens,sample id: MDA011,source: MDACC,age_years: 61.8,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: NA,pathologic_response_pcr_rd: NA,drfs_1_event_0_censored: 0,drfs_even_time_years: 5.59342915811088,type_taxane: Taxol,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615764/suppl/GSM615764_FL2596MDA011.CEL.gz,22283,61.8,Rx Insensitive,IIA,N0,T2,pCR,0,5.59342915811088,NA,N,N,N,High,3,N,Basal,NA,NA,N,RCB-0/I,MDA011,SET-Low,MDACC,breast cancer tumor,Taxol
GSM615765,MDA012,GSM615765,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-MDA012",Homo sapiens,sample id: MDA012,source: MDACC,age_years: 44.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 1,pathologic_response_pcr_rd: NA,pathologic_response_pcr_rd: NA,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.58042436687201,type_taxane: Taxol,esr1_status: N,erbb2_status: N,set_class: SET-High,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: Normal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615765/suppl/GSM615765_FL2597MDA012.CEL.gz,22283,44,Rx Sensitive,IIIA,N1,T3,RD,0,4.58042436687201,NA,P,N,N,Low,1,N,Normal,NA,NA,P,RCB-II/III,MDA012,SET-High,MDACC,breast cancer tumor,Taxol
GSM615766,MDA013,GSM615766,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-MDA013",Homo sapiens,sample id: MDA013,source: MDACC,age_years: 61.2,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: NA,pathologic_response_pcr_rd: NA,drfs_1_event_0_censored: 0,drfs_even_time_years: 5.06502395619439,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: Normal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615766/suppl/GSM615766_FL2598MDA013.CEL.gz,22283,61.2,Rx Insensitive,IIB,N1,T2,RD,0,5.06502395619439,NA,N,N,P,Low,3,N,Normal,NA,NA,N,RCB-II/III,MDA013,SET-Low,MDACC,breast cancer tumor,Taxol
GSM615767,MDA014,GSM615767,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-MDA014",Homo sapiens,sample id: MDA014,source: MDACC,age_years: 31.9,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: NA,pathologic_response_pcr_rd: NA,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.56125941136208,type_taxane: Taxol,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: Normal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615767/suppl/GSM615767_FL2599MDA014.CEL.gz,22283,31.9,Rx Sensitive,IIA,N1,T1,RD,0,4.56125941136208,NA,P,N,N,Low,2,N,Normal,NA,NA,N,RCB-0/I,MDA014,SET-Low,MDACC,breast cancer tumor,Taxol
GSM615768,MDA015,GSM615768,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-MDA015",Homo sapiens,sample id: MDA015,source: MDACC,age_years: 57.5,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: NA,pathologic_response_pcr_rd: NA,drfs_1_event_0_censored: 0,drfs_even_time_years: 5.1772758384668,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Int,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615768/suppl/GSM615768_FL2600MDA015.CEL.gz,22283,57.5,Rx Sensitive,IIA,N1,T1,RD,0,5.1772758384668,NA,P,N,P,Low,2,N,LumA,NA,NA,P,RCB-II/III,MDA015,SET-Int,MDACC,breast cancer tumor,Taxol
GSM615769,MDA016,GSM615769,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-MDA016",Homo sapiens,sample id: MDA016,source: MDACC,age_years: 43.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: NA,pathologic_response_pcr_rd: NA,drfs_1_event_0_censored: 1,drfs_even_time_years: 1.70294318959617,type_taxane: Taxol,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615769/suppl/GSM615769_FL2601MDA016.CEL.gz,22283,43,Rx Insensitive,IIB,N1,T2,pCR,1,1.70294318959617,NA,N,N,N,High,3,N,Basal,NA,NA,N,RCB-0/I,MDA016,SET-Low,MDACC,breast cancer tumor,Taxol
GSM615770,MDA018,GSM615770,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample MDACC-MDA018",Homo sapiens,sample id: MDA018,source: MDACC,age_years: 48.7,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N3,clinical_ajcc_stage: IIIC,grade: 2,pathologic_response_pcr_rd: NA,pathologic_response_pcr_rd: NA,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.69472963723477,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615770/suppl/GSM615770_FL2603MDA018.CEL.gz,22283,48.7,Rx Sensitive,IIIC,N3,T2,RD,0,1.69472963723477,NA,P,N,P,Low,2,N,LumA,NA,NA,P,RCB-0/I,MDA018,SET-Low,MDACC,breast cancer tumor,Taxol
GSM615771,LBJ016,GSM615771,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-LBJ016",Homo sapiens,sample id: LBJ016,source: LBJ/IN/GEI,age_years: 39.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N2,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 1,drfs_even_time_years: 3.92607802874743,type_taxane: Taxol,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Her2,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615771/suppl/GSM615771_U133A_FL66-LBJ16_08_04_05.CEL.gz,22283,39,Rx Insensitive,IIIA,N2,T3,pCR,1,3.92607802874743,NA,N,N,N,High,3,N,Her2,RD,RCB-II,N,RCB-II/III,LBJ016,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615772,LBJ032,GSM615772,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-LBJ032",Homo sapiens,sample id: LBJ032,source: LBJ/IN/GEI,age_years: 53.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.81587953456537,type_taxane: Taxotere,esr1_status: P,erbb2_status: P,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615772/suppl/GSM615772_FL734-LBJ32.CEL.gz,22283,53,Rx Insensitive,IIIA,N1,T3,RD,0,4.81587953456537,NA,P,P,P,Low,3,N,LumA,RD,RCB-II,P,RCB-II/III,LBJ032,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxotere
GSM615773,LBJ038,GSM615773,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-LBJ038",Homo sapiens,sample id: LBJ038,source: LBJ/IN/GEI,age_years: 58.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: pCR,pathologic_response_pcr_rd: pCR,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.94455852156057,type_taxane: Taxol,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615773/suppl/GSM615773_FL432-LBJ38.CEL.gz,22283,58,Rx Insensitive,IIB,N1,T2,pCR,0,4.94455852156057,NA,N,N,N,High,2,N,Basal,pCR,RCB-0/I,N,RCB-II/III,LBJ038,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615774,LBJ046,GSM615774,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-LBJ046",Homo sapiens,sample id: LBJ046,source: LBJ/IN/GEI,age_years: 59.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc: P,clinical_nodal_status: N2,clinical_ajcc_stage: IIIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 1,drfs_even_time_years: 0.492813141683778,type_taxane: Taxol,esr1_status: N,erbb2_status: P,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Her2,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615774/suppl/GSM615774_FL693-LBJ46.CEL.gz,22283,59,Rx Insensitive,IIIB,N2,T4,pCR,1,0.492813141683778,NA,P,P,N,High,2,N,Her2,RD,RCB-III,N,RCB-II/III,LBJ046,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615775,LBJ047,GSM615775,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-LBJ047",Homo sapiens,sample id: LBJ047,source: LBJ/IN/GEI,age_years: 46.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_pcr_rd: pCR,drfs_1_event_0_censored: 0,drfs_even_time_years: 5.02121834360027,type_taxane: Taxol,esr1_status: P,erbb2_status: P,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Her2,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615775/suppl/GSM615775_U133A_80-FL-104_FL280-LBJ47_05_17_06.CEL.gz,22283,46,Rx Insensitive,IIA,N0,T2,RD,0,5.02121834360027,NA,P,P,P,High,3,N,Her2,pCR,RCB-0/I,P,RCB-II/III,LBJ047,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615776,LBJ053,GSM615776,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-LBJ053",Homo sapiens,sample id: LBJ053,source: LBJ/IN/GEI,age_years: 45.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N2,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 1,drfs_even_time_years: 1.05407255304586,type_taxane: Taxotere,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615776/suppl/GSM615776_FL735-LBJ53.CEL.gz,22283,45,Rx Insensitive,IIIA,N2,T3,pCR,1,1.05407255304586,NA,N,N,N,High,3,N,Basal,RD,RCB-II,N,RCB-II/III,LBJ053,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxotere
GSM615777,LBJ054,GSM615777,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-LBJ054",Homo sapiens,sample id: LBJ054,source: LBJ/IN/GEI,age_years: 35.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.02464065708419,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615777/suppl/GSM615777_U133A_80-FL-098_FL274-LBJ54_05_11_06.CEL.gz,22283,35,Rx Insensitive,IIA,N1,T1,RD,0,4.02464065708419,NA,P,N,P,Low,2,N,LumA,RD,RCB-II,P,RCB-II/III,LBJ054,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615778,LBJ070,GSM615778,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-LBJ070",Homo sapiens,sample id: LBJ070,source: LBJ/IN/GEI,age_years: 38.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.02190280629706,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Her2,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615778/suppl/GSM615778_U133A_80-FL-105_FL281-LBJ70_05_17_06.CEL.gz,22283,38,Rx Sensitive,IIB,N0,T3,RD,0,4.02190280629706,NA,P,N,P,High,3,N,Her2,RD,RCB-II,P,RCB-0/I,LBJ070,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615779,LBJ071,GSM615779,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-LBJ071",Homo sapiens,sample id: LBJ071,source: LBJ/IN/GEI,age_years: 56.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: pCR,pathologic_response_pcr_rd: pCR,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.00273785078713,type_taxane: Taxol,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Normal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615779/suppl/GSM615779_FL736-LBJ71.CEL.gz,22283,56,Rx Insensitive,IIA,N0,T2,RD,0,4.00273785078713,NA,P,N,N,High,2,N,Normal,pCR,RCB-0/I,P,RCB-II/III,LBJ071,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615780,LBJ082,GSM615780,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-LBJ082",Homo sapiens,sample id: LBJ082,source: LBJ/IN/GEI,age_years: 39.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_pcr_rd: pCR,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.36755646817248,type_taxane: Taxol,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: Normal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615780/suppl/GSM615780_FL842-LBJ82.CEL.gz,22283,39,Rx Insensitive,IIIA,N1,T3,RD,0,3.36755646817248,NA,N,N,N,Low,3,N,Normal,pCR,RCB-0/I,N,RCB-II/III,LBJ082,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615781,LBJ103,GSM615781,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-LBJ103",Homo sapiens,sample id: LBJ103,source: LBJ/IN/GEI,age_years: 63.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.08555783709788,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615781/suppl/GSM615781_FL1413_LBJ130.CEL.gz,22283,63,Rx Insensitive,IIB,N0,T3,RD,0,3.08555783709788,NA,P,N,P,High,2,N,LumB,RD,RCB-II,P,RCB-II/III,LBJ103,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615782,LBJ105,GSM615782,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-LBJ105",Homo sapiens,sample id: LBJ105,source: LBJ/IN/GEI,age_years: 59.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc: P,clinical_nodal_status: N2,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_pcr_rd: pCR,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.87268993839836,type_taxane: Taxol,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: Normal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615782/suppl/GSM615782_FL1300_LBJ105.CEL.gz,22283,59,Rx Insensitive,IIIA,N2,T3,RD,0,1.87268993839836,NA,P,N,N,Low,3,N,Normal,pCR,RCB-0/I,N,RCB-II/III,LBJ105,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615783,LBJ131,GSM615783,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-LBJ131",Homo sapiens,sample id: LBJ131,source: LBJ/IN/GEI,age_years: 47.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.95482546201232,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Normal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615783/suppl/GSM615783_FL1414_LBJ131.CEL.gz,22283,47,Rx Insensitive,IIIA,N0,T4,RD,0,1.95482546201232,NA,P,N,P,High,2,N,Normal,RD,NA,N,RCB-II/III,LBJ131,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615784,LBJ143,GSM615784,Public on May 11 2011,Nov 01 2010,Feb 28 2013,RNA,1,"breast cancer, sample LBJ/IN/GEI-LBJ143",Homo sapiens,sample id: LBJ143,source: LBJ/IN/GEI,age_years: 63.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.7741273100616,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: Normal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615784/suppl/GSM615784_FL1417_LBJ143.CEL.gz,22283,63,Rx Insensitive,IIB,N1,T2,RD,0,1.7741273100616,NA,N,N,P,Low,3,N,Normal,RD,RCB-II,N,RCB-II/III,LBJ143,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615785,LBJ158,GSM615785,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-LBJ158",Homo sapiens,sample id: LBJ158,source: LBJ/IN/GEI,age_years: 51.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N2,clinical_ajcc_stage: IIIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 1,drfs_even_time_years: 0.783025325119781,type_taxane: Taxol,esr1_status: N,erbb2_status: P,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Her2,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615785/suppl/GSM615785_FL1418_LBJ158.CEL.gz,22283,51,Rx Insensitive,IIIB,N2,T4,RD,1,0.783025325119781,NA,N,P,N,High,2,N,Her2,RD,RCB-III,N,RCB-II/III,LBJ158,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615786,LBJ170,GSM615786,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-LBJ170",Homo sapiens,sample id: LBJ170,source: LBJ/IN/GEI,age_years: 55.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 1.60438056125941,type_taxane: Taxol,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615786/suppl/GSM615786_FL1915_LBJ170.CEL.gz,22283,55,Rx Insensitive,IIIB,N1,T4,pCR,0,1.60438056125941,NA,P,N,N,High,3,N,Basal,RD,RCB-0/I,P,RCB-0/I,LBJ170,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615787,LBJ171,GSM615787,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-LBJ171",Homo sapiens,sample id: LBJ171,source: LBJ/IN/GEI,age_years: 46.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 1,drfs_even_time_years: 0.722792607802875,type_taxane: Taxol,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615787/suppl/GSM615787_FL1916_LBJ171.CEL.gz,22283,46,Rx Insensitive,IIIA,N1,T3,pCR,1,0.722792607802875,NA,N,N,N,High,3,N,Basal,RD,RCB-III,N,RCB-0/I,LBJ171,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615788,PERU02,GSM615788,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-PERU02",Homo sapiens,sample id: PERU02,source: LBJ/IN/GEI,age_years: 71.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.17796030116359,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615788/suppl/GSM615788_29539_AB01833512_35703.CEL.gz,22283,71,Rx Insensitive,IIIA,N1,T4,RD,0,4.17796030116359,NA,P,N,P,High,3,N,LumB,RD,RCB-II,P,RCB-0/I,PERU02,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615789,PERU05,GSM615789,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-PERU05",Homo sapiens,sample id: PERU05,source: LBJ/IN/GEI,age_years: 38.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.75290896646133,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615789/suppl/GSM615789_29539_AB01723010_35704.CEL.gz,22283,38,Rx Insensitive,IIB,N1,T2,RD,0,4.75290896646133,NA,P,N,P,High,2,N,LumB,RD,RCB-II,P,RCB-0/I,PERU05,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615790,PERU06,GSM615790,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-PERU06",Homo sapiens,sample id: PERU06,source: LBJ/IN/GEI,age_years: 72.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIIB,grade: NA,pathologic_response_pcr_rd: NA,pathologic_response_pcr_rd: NA,drfs_1_event_0_censored: 0,drfs_even_time_years: 0.511978097193703,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615790/suppl/GSM615790_U133A_80_FL_085_FL261-PERU6_04_20_06.CEL.gz,22283,72,Rx Insensitive,IIIB,N1,T3,RD,0,0.511978097193703,NA,P,N,P,High,NA,N,LumB,NA,NA,P,RCB-II/III,PERU06,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615791,PERU16-18,GSM615791,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-PERU16-18",Homo sapiens,sample id: PERU16-18,source: LBJ/IN/GEI,age_years: 46.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIIB,grade: NA,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 4.12320328542094,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615791/suppl/GSM615791_29539_AB01723007_35647.CEL.gz,22283,46,Rx Insensitive,IIIB,N1,T4,RD,0,4.12320328542094,NA,P,N,P,Low,NA,N,LumA,RD,RCB-III,P,RCB-0/I,PERU16-18,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615792,PERU21,GSM615792,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-PERU21",Homo sapiens,sample id: PERU21,source: LBJ/IN/GEI,age_years: 36.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIIA,grade: NA,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.90965092402464,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615792/suppl/GSM615792_FL431-PERU21.CEL.gz,22283,36,Rx Sensitive,IIIA,N0,T3,RD,0,3.90965092402464,NA,P,N,P,High,NA,N,LumB,RD,RCB-III,P,RCB-0/I,PERU21,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615793,PERU23,GSM615793,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-PERU23",Homo sapiens,sample id: PERU23,source: LBJ/IN/GEI,age_years: 53.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N0,clinical_ajcc_stage: IIIB,grade: NA,pathologic_response_pcr_rd: pCR,pathologic_response_pcr_rd: pCR,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.97878165639973,type_taxane: Taxol,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Her2,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615793/suppl/GSM615793_U133A_80_FL_087_FL263-PERU23_04_27_06.CEL.gz,22283,53,Rx Insensitive,IIIB,N0,T4,pCR,0,2.97878165639973,NA,N,N,N,High,NA,N,Her2,pCR,RCB-0/I,N,RCB-II/III,PERU23,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615794,PERU26,GSM615794,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-PERU26",Homo sapiens,sample id: PERU26,source: LBJ/IN/GEI,age_years: 66.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N2,clinical_ajcc_stage: IIIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 1,drfs_even_time_years: 3.35386721423682,type_taxane: Taxol,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615794/suppl/GSM615794_FL694-Peru26.CEL.gz,22283,66,Rx Insensitive,IIIB,N2,T2,pCR,1,3.35386721423682,NA,P,N,N,Low,2,N,Basal,RD,RCB-III,P,RCB-II/III,PERU26,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615795,PERU28,GSM615795,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-PERU28",Homo sapiens,sample id: PERU28,source: LBJ/IN/GEI,age_years: 39.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 1,drfs_even_time_years: 0.818617385352498,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615795/suppl/GSM615795_U133A_80-FL-091_FL267-Peru28_05_09_06.CEL.gz,22283,39,Rx Insensitive,IIIB,N1,T2,RD,1,0.818617385352498,NA,P,N,P,Low,2,N,LumB,RD,RCB-III,P,RCB-II/III,PERU28,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615796,PERU37,GSM615796,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-PERU37",Homo sapiens,sample id: PERU37,source: LBJ/IN/GEI,age_years: 48.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc: P,clinical_nodal_status: N2,clinical_ajcc_stage: IIIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 1,drfs_even_time_years: 2.90759753593429,type_taxane: Taxol,esr1_status: P,erbb2_status: P,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Her2,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615796/suppl/GSM615796_FL695-Peru37.CEL.gz,22283,48,Rx Insensitive,IIIB,N2,T4,RD,1,2.90759753593429,NA,P,P,P,High,2,N,Her2,RD,RCB-III,N,RCB-0/I,PERU37,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615797,PERU38,GSM615797,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-PERU38",Homo sapiens,sample id: PERU38,source: LBJ/IN/GEI,age_years: 52.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.4798083504449,type_taxane: Taxol,esr1_status: P,erbb2_status: P,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615797/suppl/GSM615797_FL415-PERU38.CEL.gz,22283,52,Rx Sensitive,IIIB,N1,T4,RD,0,3.4798083504449,NA,P,P,P,High,2,N,LumA,RD,RCB-III,P,RCB-0/I,PERU38,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615798,PERU40,GSM615798,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-PERU40",Homo sapiens,sample id: PERU40,source: LBJ/IN/GEI,age_years: 40.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_pcr_rd: pCR,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.40862422997947,type_taxane: Taxol,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615798/suppl/GSM615798_U133A_80-FL-226-FL390-PERU49_09_22_06.CEL.gz,22283,40,Rx Insensitive,IIIA,N1,T3,pCR,0,3.40862422997947,NA,P,N,N,High,3,N,Basal,pCR,RCB-0/I,P,RCB-II/III,PERU40,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615799,PERU42,GSM615799,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-PERU42",Homo sapiens,sample id: PERU42,source: LBJ/IN/GEI,age_years: 42.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N2,clinical_ajcc_stage: IIIB,grade: NA,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.4798083504449,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615799/suppl/GSM615799_FL699-PERU42.CEL.gz,22283,42,Rx Insensitive,IIIB,N2,T4,RD,0,3.4798083504449,NA,P,N,P,High,NA,N,LumA,RD,NA,P,RCB-II/III,PERU42,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615800,PERU44,GSM615800,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-PERU44",Homo sapiens,sample id: PERU44,source: LBJ/IN/GEI,age_years: 40.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N0,clinical_ajcc_stage: IIIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 1,drfs_even_time_years: 0.876112251882272,type_taxane: Taxol,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615800/suppl/GSM615800_U133A_80-FL-228-FL392-PERU44_09_29_06.CEL.gz,22283,40,Rx Sensitive,IIIB,N0,T4,pCR,1,0.876112251882272,NA,N,N,N,High,3,N,Basal,RD,RCB-III,N,RCB-0/I,PERU44,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615801,PERU48,GSM615801,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-PERU48",Homo sapiens,sample id: PERU48,source: LBJ/IN/GEI,age_years: 59.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N3,clinical_ajcc_stage: IIIC,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 1,drfs_even_time_years: 2.6694045174538,type_taxane: Taxol,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615801/suppl/GSM615801_FL697-Peru48.CEL.gz,22283,59,Rx Insensitive,IIIC,N3,T4,pCR,1,2.6694045174538,NA,N,N,N,High,2,N,Basal,RD,RCB-III,N,RCB-II/III,PERU48,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615802,PERU50,GSM615802,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-PERU50",Homo sapiens,sample id: PERU50,source: LBJ/IN/GEI,age_years: 44.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N2,clinical_ajcc_stage: IIIA,grade: NA,pathologic_response_pcr_rd: pCR,pathologic_response_pcr_rd: pCR,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.31006160164271,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615802/suppl/GSM615802_U133A_80-FL-232-FL418-PERU50_11_17_06.CEL.gz,22283,44,Rx Insensitive,IIIA,N2,T2,RD,0,3.31006160164271,NA,P,N,P,High,NA,N,LumB,pCR,RCB-0/I,P,RCB-II/III,PERU50,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615803,PERU52,GSM615803,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-PERU52",Homo sapiens,sample id: PERU52,source: LBJ/IN/GEI,age_years: 58.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N1,clinical_ajcc_stage: IIIB,grade: NA,pathologic_response_pcr_rd: pCR,pathologic_response_pcr_rd: pCR,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.24709103353867,type_taxane: Taxol,esr1_status: N,erbb2_status: P,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Her2,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615803/suppl/GSM615803_FL727-peru52.CEL.gz,22283,58,Rx Sensitive,IIIB,N1,T4,pCR,0,3.24709103353867,NA,N,P,N,High,NA,N,Her2,pCR,RCB-0/I,N,RCB-0/I,PERU52,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615804,PERU53,GSM615804,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-PERU53",Homo sapiens,sample id: PERU53,source: LBJ/IN/GEI,age_years: 35.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.12662559890486,type_taxane: Taxol,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615804/suppl/GSM615804_FL471-PERU53.CEL.gz,22283,35,Rx Insensitive,IIIA,N1,T3,pCR,0,3.12662559890486,NA,N,N,N,Low,3,N,Basal,RD,RCB-II,N,RCB-0/I,PERU53,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615805,PERU54,GSM615805,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-PERU54",Homo sapiens,sample id: PERU54,source: LBJ/IN/GEI,age_years: 63.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N1,clinical_ajcc_stage: IIIB,grade: NA,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 1,drfs_even_time_years: 0.824093086926763,type_taxane: Taxol,esr1_status: N,erbb2_status: P,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Her2,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615805/suppl/GSM615805_FL728-peru54.CEL.gz,22283,63,Rx Insensitive,IIIB,N1,T2,pCR,1,0.824093086926763,NA,N,P,N,High,NA,N,Her2,RD,NA,N,RCB-II/III,PERU54,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615806,PERU56,GSM615806,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-PERU56",Homo sapiens,sample id: PERU56,source: LBJ/IN/GEI,age_years: 44.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N2,clinical_ajcc_stage: IIIB,grade: NA,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 1,drfs_even_time_years: 0.531143052703628,type_taxane: Taxol,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615806/suppl/GSM615806_FL729-peru56.CEL.gz,22283,44,Rx Insensitive,IIIB,N2,T4,pCR,1,0.531143052703628,NA,N,N,N,Low,NA,N,Basal,RD,RCB-III,N,RCB-II/III,PERU56,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615807,PERU57,GSM615807,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-PERU57",Homo sapiens,sample id: PERU57,source: LBJ/IN/GEI,age_years: 41.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIIB,grade: 1,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.90965092402464,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Int,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615807/suppl/GSM615807_FL425-PERU57.CEL.gz,22283,41,Rx Sensitive,IIIB,N1,T2,RD,0,3.90965092402464,NA,P,N,P,Low,1,N,LumA,RD,RCB-III,P,RCB-II/III,PERU57,SET-Int,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615808,PERU61,GSM615808,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-PERU61",Homo sapiens,sample id: PERU61,source: LBJ/IN/GEI,age_years: 69.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.13757700205339,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615808/suppl/GSM615808_FL426-PERU61.CEL.gz,22283,69,Rx Insensitive,IIIB,N1,T4,RD,0,3.13757700205339,NA,P,N,P,Low,3,N,LumB,RD,RCB-II,P,RCB-II/III,PERU61,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615809,PERU69,GSM615809,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-PERU69",Homo sapiens,sample id: PERU69,source: LBJ/IN/GEI,age_years: 53.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc: P,clinical_nodal_status: N2,clinical_ajcc_stage: IIIB,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.1813826146475,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615809/suppl/GSM615809_FL427-PERU69.CEL.gz,22283,53,Rx Insensitive,IIIB,N2,T4,RD,0,3.1813826146475,NA,P,N,P,High,2,N,LumB,RD,RCB-III,N,RCB-II/III,PERU69,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615810,PERU72,GSM615810,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-PERU72",Homo sapiens,sample id: PERU72,source: LBJ/IN/GEI,age_years: 37.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N2,clinical_ajcc_stage: IIIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 1,drfs_even_time_years: 2.13552361396304,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615810/suppl/GSM615810_FL465-PERU72.CEL.gz,22283,37,Rx Insensitive,IIIB,N2,T4,RD,1,2.13552361396304,NA,P,N,P,High,3,N,LumA,RD,RCB-III,P,RCB-0/I,PERU72,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615811,PERU73,GSM615811,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-PERU73",Homo sapiens,sample id: PERU73,source: LBJ/IN/GEI,age_years: 61.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N2,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.41957563312799,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615811/suppl/GSM615811_FL466-PERU73.CEL.gz,22283,61,Rx Insensitive,IIIA,N2,T3,RD,0,3.41957563312799,NA,P,N,P,Low,3,N,LumA,RD,RCB-III,P,RCB-0/I,PERU73,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615812,PERU76,GSM615812,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-PERU76",Homo sapiens,sample id: PERU76,source: LBJ/IN/GEI,age_years: 51.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N2,clinical_ajcc_stage: IIIB,grade: NA,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 1,drfs_even_time_years: 2.17932922655715,type_taxane: Taxol,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Her2,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615812/suppl/GSM615812_FL698-PERU76.CEL.gz,22283,51,Rx Insensitive,IIIB,N2,T4,pCR,1,2.17932922655715,NA,N,N,N,High,NA,N,Her2,RD,RCB-III,N,RCB-II/III,PERU76,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615813,Spain04,GSM615813,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-Spain04",Homo sapiens,sample id: Spain04,source: LBJ/IN/GEI,age_years: 68.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N0,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.7015742642026,type_taxane: Taxol,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Basal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615813/suppl/GSM615813_FL844-Spain4.CEL.gz,22283,68,Rx Insensitive,IIB,N0,T3,pCR,0,3.7015742642026,NA,N,N,N,High,3,N,Basal,RD,RCB-II,N,RCB-0/I,Spain04,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615814,Spain06,GSM615814,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-Spain06",Homo sapiens,sample id: Spain06,source: LBJ/IN/GEI,age_years: 67.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.66872005475702,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615814/suppl/GSM615814_FL1994_Spain6_0409.CEL.gz,22283,67,Rx Insensitive,IIA,N0,T2,RD,0,3.66872005475702,NA,P,N,P,Low,2,N,LumB,RD,RCB-II,P,RCB-II/III,Spain06,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615815,Spain07,GSM615815,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-Spain07",Homo sapiens,sample id: Spain07,source: LBJ/IN/GEI,age_years: 37.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.81382614647502,type_taxane: Taxol,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: Basal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615815/suppl/GSM615815_FL718-Spain7.CEL.gz,22283,37,Rx Insensitive,IIA,N0,T2,RD,0,3.81382614647502,NA,P,N,N,Low,2,N,Basal,RD,RCB-II,P,RCB-0/I,Spain07,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615816,Spain12,GSM615816,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-Spain12",Homo sapiens,sample id: Spain12,source: LBJ/IN/GEI,age_years: 60.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 1,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.38124572210815,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615816/suppl/GSM615816_FL846-Spain12.CEL.gz,22283,60,Rx Insensitive,IIA,N0,T2,RD,0,3.38124572210815,NA,P,N,P,Low,1,N,LumA,RD,RCB-II,P,RCB-II/III,Spain12,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615817,Spain13,GSM615817,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-Spain13",Homo sapiens,sample id: Spain13,source: LBJ/IN/GEI,age_years: 42.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIB,grade: 1,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.63039014373717,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Int,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: Normal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615817/suppl/GSM615817_FL847-Spain13.CEL.gz,22283,42,Rx Sensitive,IIB,N0,T3,RD,0,3.63039014373717,NA,P,N,P,Low,1,N,Normal,RD,RCB-II,P,RCB-II/III,Spain13,SET-Int,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615818,Spain27,GSM615818,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-Spain27",Homo sapiens,sample id: Spain27,source: LBJ/IN/GEI,age_years: 61.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.93223819301848,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615818/suppl/GSM615818_FL849-Spain27.CEL.gz,22283,61,Rx Insensitive,IIA,N0,T2,RD,0,2.93223819301848,NA,P,N,P,Low,2,N,LumA,RD,NA,P,RCB-II/III,Spain27,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615819,Spain30,GSM615819,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-Spain30",Homo sapiens,sample id: Spain30,source: LBJ/IN/GEI,age_years: 39.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc: P,clinical_nodal_status: N2,clinical_ajcc_stage: IIIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.00616016427105,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615819/suppl/GSM615819_FL739-Spain30.CEL.gz,22283,39,Rx Insensitive,IIIA,N2,T2,RD,0,3.00616016427105,NA,P,N,P,Low,2,N,LumA,RD,NA,N,RCB-II/III,Spain30,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615820,Spain32,GSM615820,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-Spain32",Homo sapiens,sample id: Spain32,source: LBJ/IN/GEI,age_years: 42.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 2,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 1,drfs_even_time_years: 1.21286789869952,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615820/suppl/GSM615820_FL1287_GM32.CEL.gz,22283,42,Rx Insensitive,IIIA,N1,T3,RD,1,1.21286789869952,NA,P,N,P,Low,2,N,LumA,RD,RCB-II,P,RCB-II/III,Spain32,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615821,Spain41,GSM615821,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-Spain41",Homo sapiens,sample id: Spain41,source: LBJ/IN/GEI,age_years: 64.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 1,drfs_even_time_years: 2.76522929500342,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumB,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615821/suppl/GSM615821_FL852-Spain41.CEL.gz,22283,64,Rx Insensitive,IIIA,N1,T3,RD,1,2.76522929500342,NA,P,N,P,High,3,N,LumB,RD,RCB-II,P,RCB-II/III,Spain41,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615822,Spain45,GSM615822,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-Spain45",Homo sapiens,sample id: Spain45,source: LBJ/IN/GEI,age_years: 56.0,er_status_ihc: P,pr_status_ihc: N,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIIB,grade: NA,pathologic_response_pcr_rd: pCR,pathologic_response_pcr_rd: pCR,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.74332648870637,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: Her2,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615822/suppl/GSM615822_FL721-spain45.CEL.gz,22283,56,Rx Insensitive,IIIB,N1,T4,RD,0,2.74332648870637,NA,P,N,P,High,NA,N,Her2,pCR,RCB-0/I,N,RCB-0/I,Spain45,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615823,Spain46,GSM615823,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-Spain46",Homo sapiens,sample id: Spain46,source: LBJ/IN/GEI,age_years: 45.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 1,drfs_even_time_years: 2.29979466119096,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Int,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: Her2,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615823/suppl/GSM615823_FL853-Spain46.CEL.gz,22283,45,Rx Sensitive,IIIA,N1,T3,RD,1,2.29979466119096,NA,N,N,P,High,3,N,Her2,RD,RCB-III,N,RCB-II/III,Spain46,SET-Int,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615824,Spain48,GSM615824,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-Spain48",Homo sapiens,sample id: Spain48,source: LBJ/IN/GEI,age_years: 46.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 3,pathologic_response_pcr_rd: pCR,pathologic_response_pcr_rd: pCR,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.17590691307324,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: Normal,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615824/suppl/GSM615824_FL723-spain48.CEL.gz,22283,46,Rx Insensitive,IIA,N0,T2,RD,0,3.17590691307324,NA,N,N,P,Low,3,N,Normal,pCR,RCB-0/I,N,RCB-II/III,Spain48,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615825,Spain49,GSM615825,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-Spain49",Homo sapiens,sample id: Spain49,source: LBJ/IN/GEI,age_years: 42.0,er_status_ihc: P,pr_status_ihc: P,her2_status: N,er_status_ihc: P,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 2.45037645448323,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Sensitive,ggi_class: High,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-0/I,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615825/suppl/GSM615825_FL741-Spain49.CEL.gz,22283,42,Rx Sensitive,IIB,N1,T2,RD,0,2.45037645448323,NA,P,N,P,High,3,N,LumA,RD,RCB-III,P,RCB-0/I,Spain49,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615826,Spain51,GSM615826,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-Spain51",Homo sapiens,sample id: Spain51,source: LBJ/IN/GEI,age_years: 44.0,er_status_ihc: N,pr_status_ihc: P,her2_status: N,er_status_ihc: N,clinical_nodal_status: N1,clinical_ajcc_stage: IIIA,grade: 1,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.1813826146475,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Int,chemosensitivity_prediction: Rx Sensitive,ggi_class: Low,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615826/suppl/GSM615826_FL854-Spain51.CEL.gz,22283,44,Rx Sensitive,IIIA,N1,T3,RD,0,3.1813826146475,NA,N,N,P,Low,1,N,LumA,RD,RCB-II,P,RCB-II/III,Spain51,SET-Int,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615827,Spain53,GSM615827,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-Spain53",Homo sapiens,sample id: Spain53,source: LBJ/IN/GEI,age_years: 71.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N1,clinical_ajcc_stage: IIB,grade: 3,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.19507186858316,type_taxane: Taxol,esr1_status: N,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: Low,pam50_class: Normal,dlda30_prediction: pCR,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615827/suppl/GSM615827_FL724-spain53.CEL.gz,22283,71,Rx Insensitive,IIB,N1,T2,pCR,0,3.19507186858316,NA,N,N,N,Low,3,N,Normal,RD,RCB-II,N,RCB-II/III,Spain53,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
GSM615828,Spain57,GSM615828,Public on May 11 2011,Nov 01 2010,Oct 26 2011,RNA,1,"breast cancer, sample LBJ/IN/GEI-Spain57",Homo sapiens,sample id: Spain57,source: LBJ/IN/GEI,age_years: 45.0,er_status_ihc: N,pr_status_ihc: N,her2_status: N,er_status_ihc: N,clinical_nodal_status: N0,clinical_ajcc_stage: IIA,grade: 1,pathologic_response_pcr_rd: RD,pathologic_response_pcr_rd: RD,drfs_1_event_0_censored: 0,drfs_even_time_years: 3.08281998631075,type_taxane: Taxol,esr1_status: P,erbb2_status: N,set_class: SET-Low,chemosensitivity_prediction: Rx Insensitive,ggi_class: High,pam50_class: LumA,dlda30_prediction: RD,rcb_0_i_prediction: RCB-II/III,tissue: breast cancer tumor,"Patients prospectively consented to a research biopsy by fine needle aspiration (FNA) or  core biopsy (CBX) prior to any systemic therapy, and to the future assessment of pathologic  response and/or survival endpoints",total RNA,Total RNA was extracted from tissue using Qiagen Rneasy columns,biotin,A single-round T7 amplification was used to generate biotin-labeled cRNA for hybridization.  At least 1 ug of RNA is required for cRNA synthesis.,9606,"Following fragmentation, 10 ug of cRNA were hybridized overnight at 46C on Affymetrix U133A arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.",GeneChips were scanned using the diagnostic-grade Affymetrix scanner 3000DX,Probe intensities were quantified with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings.  CEL files were normalized using global scaling with a trimmed mean target intensity of each array arbitrarily set to 600 using the MAS5 algorithm from the simpleaffy package (http://bioconductor.org/packages/2.4/bioc/html/simpleaffy.html).,GPL96,"Christos,,Hatzis",christos@nuverabio.com,781-938-3830,Nuvera Biosciences,"400 West Cummings Park, Suite 5350",Woburn,MA,1801,USA,www.nuverabio.com,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM615nnn/GSM615828/suppl/GSM615828_FL742-Spain57.CEL.gz,22283,45,Rx Insensitive,IIA,N0,T2,RD,0,3.08281998631075,NA,N,N,P,High,1,N,LumA,RD,RCB-II,N,RCB-II/III,Spain57,SET-Low,LBJ/IN/GEI,breast cancer tumor,Taxol
